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Abstract 
Inflammatory diseases, namely arthritis, are prevalent worlwide, and pain is considered to be 
one of the most important determinants of life quality. Frequently, such conditions and the 
pain associated with them are managed simultaneously by the use of anti-inflammatory drugs 
– including both steroidal and non-steroidal – which, though readily available, have widely-
recognised adverse effects and variable efficacy between individuals. In order to minimize 
these side effects and simultaneously increase the therapeutic efficacy associated with the use 
of anti-inflammatory drugs, different attempts have been made, including the potential for 
site-specific drug delivery to the colon. Among the useful strategies to target the colon, 
prodrugs are presented as a very promising solution. Cyclodextrins can be used as a carrier to 
develop colon-targeted prodrugs through the synthesis of a suitable covalent linkage with a 
drug. These molecules are known as cyclodextrin conjugates. 
The work presented in this thesis was based on the knowledge aforementioned with the 
principal aim to successfully synthesize cyclodextrin ester prodrugs of diclofenac for colonic 
delivery. 
The first challenge was to find a synthetic way to produce a conjugate using the most 
common natural cyclodextrin, β-cyclodextrin. Various strategies were attemped to establish 
an ester linkage between the drug and β-cyclodextrin. However, only the nucleophile 
substitution of mono-6-tosyl-β-cyclodextrin under microwave irradiation allowed a successful 
synthesis.  
The application of this strategy in the synthesis of other conjugates, namely with γ- and α- 
cyclodextrin, was explored, but difficulties were encountered. This led us to focus our 
investigation on the study of diclofenac-β-cyclodextrin conjugate, which was characterized by 
several techniques: matrix-assisted laser desorption/ionization (MALDI) spectra, infrared (IR) 
spectroscopy, proton nuclear magnetic resonance (
1
H NMR) spectroscopy and two-
dimensional rotating frame nuclear overhauser effect (ROESY) spectroscopy. Its purity was 
confirmed by high pressure liquid chromatography (HPLC), and preliminary chemical 
hydrolysis assays were performed. 
In vitro and ex vivo studies were then made in order to investigate the stability of the 
diclofenac-β-cyclodextrin conjugate along the gastrointestinal tract. Firstly, studies were 
iv 
carried out in human faecal slurries in order to assess the ability of the conjugate to release 
diclofenac in the lower intestine. These stability studies were conducted by comparison with a 
well-known colonic prodrug, sulfasalazine. Sugar-degrading enzymes and ester-hydrolysing 
enzyme were used in order to find an enzymatic media able to mimic the colonic metabolism 
of this conjugate. Secondly, stability was studied at the level of the upper GI tract using 
simulated gastric and intestinal fluids as described in the Pharmacopeia. The conjugate 
released diclofenac at the level of the lower intestine, and exhibited good stability in the upper 
gastrointestinal tract. Consequently, ex vivo studies were conducted in fluids collected from 
different animal species (pig, rabbit and rat) in order to identify a suitable animal model to 
further perform in vivo studies. Rats were shown to be the animal that most closely resembled 
the behaviour of the conjugate in humans and therefore were used in these additional studies 
for modelling. 
The influence of the regimen of food intake on the physiological conditions (mass contents 
and pH) of the gastrointestinal tract and on degradation of the conjugate versus sulfasalazine 
in the large intestine was then performed in rats in order to choose the best regimen to assess 
the in vivo bioavailability. Results showed that the feeding regimen affects gut contents (mass 
and pH), more specifically in the stomach and lower intestine, and also affects the rate of 
metabolism of diclofenac-β-cyclodextrin but not that of sulfasalazine. Fasting was shown to 
result in the most rapid degradation of diclofenac-β-cyclodextrin, possibly due to lack of 
competition (absence of food) for microbial enzymatic activity. 
As a proof-of-concept, a comparative in vivo study in fasted rats was performed by oral 
administration of a suspension of diclofenac-β-cyclodextrin and sulfasalazine with parallel 
administration of sodium diclofenac and sulfapyridine, as a control group of rats. A lag time 
between oral intake of prodrugs and the appearance of the respective drugs in plasma was 
observed, contrarily to that observed with the oral administration of free drugs whose plasma 
concentrations were measurable immediately after intake. These results confirm the in vivo 
ability of this conjugate to target and release diclofenac in the colon. A reduction of 50% in 
bioavailability was observed for diclofenac when administered in the form of its cyclodextrin 
conjugate compared with the free drug. 
Overall, diclofenac-β-cyclodextrin is a promising prodrug to be explored as a suitable tactic 
for the management of arthritis with simultaneous circumvention of the adverse gastric effects 
associated with the free drug. 
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RESUMO  
As doenças inflamatórias, nomeadamente a artrite, são doenças que afectam a população po 
todo o mundo. A ausência de dor é considerada um factor determinante para a qualidade de 
vida. Os anti-inflamatórios, esteróides ou não esteróides são a classe de fármacos usada no 
controlo deste tipo de doenças. No entanto, estes estão associados a diversos efeitos adversos 
e a variabilidade inter-individual também afecta em termos eficácia. Diferentes estratégias 
foram exploradas com o objectivo de aumentar a eficácia dos anti-inflamatórios e, ao mesmo 
tempo, diminuir os seus efeitos adversos. Entre as várias estratégias, destaca-se a que envolve 
a libertação específica destes fármacos ao nível do cólon. Para este efeito, o desenvolvimento 
de profármacos constitui uma solução promissora. As ciclodextrinas podem ser usadas como 
transportadoras para o design de profármacos, denominados conjugados, para libertação 
específica no cólon, estabelecendo uma ligação covalente ao respectivo fármaco. Esta tese 
resulta de um trabalho desenvolvido com base neste conceito tendo como objectivo sintetisar 
um profármaco do diclofenac para libertação específica no colon, usando ciclodextrinas como 
transportadores.  
O primeiro desafio consistiu em explorar diferentes estratégias para a síntese do conjugado 
entre o diclofenac e a β-ciclodextrina. Das diversas tentativas, apenas a substituição 
nucleofílica do 6-mono-tosil-β-cyclodextrina sob radiação de microondas, permitiu a síntese 
com sucesso. A aplicação da mesma estratégia para a síntese de outros conjugados, 
nomeadamente com γ- e α ciclodextrina foi explorada, contudo, inúmeras dificuldades foram 
encontradas. Deste modo, a nossa investigação focou-se no estudo do conjugado diclofenac-
β-cyclodextrina. Este novo conjugado foi caracterizado por diversas técnicas: 
Ionização/Dessorção de Matriz Assistida por Laser (MALDI), espectroscopia de infra-
vermelho (IV), ressonância magnética nuclear de protão (
1
H-RMN) e espectroscopia 
bidimensional do efeito nuclear de Overhauser (ROESY). A sua pureza foi avaliada por 
cromatografia de alta pressão (HPLC) tendo-se posteriormente realizado ensaios de 
estabilidade química. 
Efectuaram-se estudos in vitro e ex vivo no sentido de investigar a estabilidade do diclofenac-
β-cyclodextrina ao longo do tracto gastrointestinal. Foram realizados ensaios num sistema de 
fermentação com fezes humanas, de forma a descobrir a capacidade do conjugado libertar o 
diclofenac no intestino grosso. Estes estudos de estabilidade foram executados em 
comparação com um profármaco conhecido, a sulfasalazina. De forma a encontrar um sistema 
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enzimático que mimetize o metabolismo deste conjugado ao nível do cólon, realizaram-se 
estudos com enzimas capazes de degradar açúcares e enzimas com capacidade de hidrolisar 
ligações ester. Posteriormente, foi estudada a estabilidade ao nível do tracto gastrointestinal 
superior, utilizando simulados gástricos e intestinais descritos na Farmacopeia. O conjugado 
permitiu a libertação do diclofenac ao nível do intestino grosso e exibiu uma boa estabilidade 
no tracto gastrointestinal superior. Consequentemente, foram realizados estudos ex vivo em 
fluídos recolhidos de diferentes espécies de animais (porco, coelho e rato), de forma a 
identificar o animal adequado para a realização dos estudos in vivo. Os resultados obtidos no 
rato foram os que mais se assemelharam ao comportamento do conjugado obtido no sistema 
de fezes humanas. Por este motivo, o rato foi o animal escolhido para realizar os estudos 
subsequentes. 
Com o objectivo de escolher o regime alimentar mais adequado para concretizar os estudos de 
biodisponibilidade, foi investigada a influência do regime de alimentação nas condições 
fisiológicas do tracto gastrointestinal e na degradação do conjugado versus sulfasalazina no 
intestino grosso. Os resultados mostraram que o regime de alimentação influencia os 
conteúdos (massa e pH), mais especificamente a nível do estomago e do intestino grosso, e 
também afecta a velocidade de metabolismo do diclofenac-β-cyclodextrina, mas não da 
sulfasalazina. O jejum permite uma libertação mais rápida do conjugado, possivelmente 
devido a falta de competição (ausência de alimento) para as enzimas microbianas. 
Como prova do conceito, realizaram-se estudos in vivo em ratos em jejum, através da 
administração oral de uma suspensão de conjugado com sulfasalazina a um grupo de animais. 
Em paralelo, foi efectuada a administração de diclofenac de sódio e sulfapiridina a um grupo 
controlo. Observou-se um atraso entre a administração oral dos profármaco e o aparecimento 
do respectivo fármaco, contrariamente ao que se verificou com a administração dos fármacos 
livres, cujo aparecimento no plasma foi imediato. Estes resultados confirmaram a capacidade 
do conjugado em libertar o diclofenac especificamente no cólon. Uma redução de 50% na 
biodisponibilidade do diclofenac ocorre aquando da administração do conjugado 
comparativamente à administração do fármaco livre. 
Poderemos concluir que o diclofenac-β-cyclodextrina constitui um profármaco promissor a 
ser explorado no combate a doenças inflamatórias, tais como a artrite, ultrapassando 
simultaneamente os efeitos adversos associados ao diclofenac.  
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1 GENERAL INTRODUCTION 
Prodrug  
“A therapeutic agent which is inactive per se but is transformed into one or more active 
metabolites” 
 (Ettmayer, Amidon et al., 2004; Stella, Borchardt et al., 2007) 
1.1 Overview 
The oral route represents the largest market on the overall drug delivery market, herein among 
84% of the 50 most-sold pharmaceutical products in the US and European are given orally 
(Lennernäs and Abrahamsson, 2005). Orally administered drugs are generally given in the 
form of immediate-release or modified-release dosage forms. In the case of immediate-release 
dosage forms, after oral administration, the drug is released immediately in the stomach, 
providing rapid absorption. Modified release dosage forms are designed to extend or delay the 
release of the drug in the gastrointestinal (GI) tract (Bechgaard and Nielsen, 1978; Basit, 
2005). These dosage forms can be formulated as a single unit (tablets, capsules) or multiple 
unit (pellets, granules or minitablets) (Varum, Merchant et al., 2010).  
In the area of oral delivery, targeted drug delivery specifically in the colon has been of great 
interest due to the importance of this region of the GI tract not only for local but also for 
systemic therapy (Mcconnell, Liu et al., 2009). Drug targeting to the colon is valuable in the 
treatment of colon diseases such as: inflammatory bowel disease (ulcerative colitis and 
Crohn’s disease), irritable bowel syndrome (Meissner and Lamprecht, 2008), carcinomas 
(Lamprecht, Yamamoto et al., 2003) and infections (Mundargi, Patil et al., 2007). Moreover, 
the delay in drug absorption may be preferred in the treatment of diseases sensitive to 
circadian rhythms such as nocturnal asthma, angina, gastric ulcer and arthritis (Mcconnell, 
Liu et al., 2009). This region of the GI tract is considered to be more suitable for delivery of 
molecules that are degraded and/or poorly absorbed in the upper gut, such as peptides and 
proteins, improving their bioavailability (Fix, 1996; Langguth, Bohner et al., 1997; Mackay, 
Phillips et al., 1997; Katsuma, Watanabe et al., 2006).  
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Numerous strategies have been exploited to allow specific drug release in the colon 
(Chourasia and Jain, 2003; Basit, 2005), herein one of the major strategies of drug delivery to 
this part of the GI tract is prodrug based systems. 
Prodrugs are designed by attachment of a specific carrier to the active molecule by a suitable 
covalent linkage. The prodrug should pass intact and unabsorbed in the upper GI tract and 
undergo biotransformation in the colon releasing the active drug molecule. This is an 
enzymatic process that is carried out by the inherent bacterial flora present in the colon. This 
enzyme-trigger mechanism in prodrugs confers a better colon-target ability (Sinha and 
Kumria, 2001; Sinha and Kumria, 2004; Jung and Kim, 2010) and the proof of this is the 
success of sulfasalazine, a azo-colonic prodrug of mesalamine (5-ASA) developed in the 
1930s for the treatment of rheumatoid arthritis (Svartz, 1948) and that is still a reference on 
the treatment of inflammatory bowel disease (IBD) and has the greatest efficacy in ulcerative 
colitis (Qureshi and Cohen, 2005; Cohen, Lichtenstein et al., 2008). 
However, given the toxicity associated to its carrier – sulfapyridine, other molecules have 
been explored as a carrier, not only for the transport of mesalamine, but also for the transport 
of other active molecules with potential interest to be delivery specifically on the colon. The 
design of an azo-prodrug requires the presence of an amine functional group on the dug 
molecule to establish the azo-bond linkage. However, this group is not always present on the 
molecules structure. Therefore, it has been explored the design of other types of linkages that 
allows colonic specific delivery (Jung and Kim, 2010).  
Cyclodextrins are cyclic oligosaccharides known for more than 100 years, that have been 
studied and used to improve drug delivery of different systems (Szejtli, 2004). More recently, 
cyclodextrins have been explored as a carrier on the design of prodrugs for site-specific 
delivery of drugs. In the case of oral delivery, conjugates of cyclodextrins are presented as a 
strategy for colonic specific delivery of drugs (Uekama, Hirayama et al., 1998).  
Diclofenac is a powerful anti-inflammatory that has been on the market for 40 years (Haas 
and Rossi, 1974). Due to the gastrointestinal side effects associated to it, research has been 
conducted in order to improve the performance of this drug. One of the approaches involves 
the exploration of strategies able to site-specific release of this drug into the colon (Gan, 
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2010). Additionally, as an anti-inflammatory it has preventive effect against colon cancer 
(Calatayud, Warner et al., 2001).  
This dissertation accesses the ability of cyclodextrins as carriers for colonic specific delivery 
of a non-steroidal anti-inflammatory drug (NSAID) diclofenac. 
1.2 The gastrointestinal tract: main considerations on the design of a colonic prodrug 
The human GI tract starts at the mouth and ends at the anus; its length is about 8.35 meters. It 
is divided into sections: mainly stomach, small intestine (the duodenum, jejunum, and ileum) 
and large intestine (caecum, colon and rectum), allowing digestion and nutrient absorption in 
the proximal region to be separate from the vast microbial populations in the large intestine, 
thereby reducing conflict between host and microbes (Walter and Ley, 2011).  
 
 
 
 
 
 
 
 
Figure 1.1 Gastrointestinal tract anatomy. 
On the development of a prodrug for colonic specific delivery, it is necessary to be aware 
about all the different environments from the cavity buccal until colon through which the 
prodrug contacts and that can influence its performance. The pH is variable along the 
gastrointestinal tract and a huge variability exists between people (Fallingborg, Christensen et 
al., 1989), but also a considerable intra-individual variability can be observed (Ibekwe, Fadda 
et al., 2008). In the particular case of colonic prodrugs, pH can be an obstacle to the delivery 
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of prodrugs as the pH changes affects the degree of ionization of weak acidic and basic 
produgs and, consequently, their chemical stability (Stella, Borchardt et al., 2007). 
Additionally, the intraluminal pH along the GI tract influences bacterial concentration in each 
section of the gut. This is particularly evident namely at the level of the stomach where the 
own pH tends to destroy most bacteria. Bacterial microbiota exist in most parts of the GI tract 
and become an important component of the luminal content (Hawksworth, Drasar et al., 1971; 
Cummings and Macfarlane, 1997a). The current total estimate number of prokaryotes that 
inhabits the human gut goes up to 100 trillion (10
14
) microbes. This number makes the human 
gastrointestinal tract one of the most populated microhabitats on earth (Ley, Peterson et al., 
2006; Sousa, Paterson et al., 2008). The main concentration site of microbiota in the GI tract 
is the lower intestine. At this level, microbiota is responsible for the activation of colonic 
prodrugs allowing the release of the drug at colonic level. However, the stability of the own 
drug against the colonic microbiota has also to be considered when we design a reliable 
prodrug as a colonic specific system.  
 
Figure 1.2 Schematic representation of the main factors to be considered on the 
development of a colonic specific prodrug. 
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Transit time through the GI tract varies depending on various factors like GI motility, quantity 
and quality of food ingested, feeding regimen, food timing, and also nature of the oral 
formulation (Yuen, 1986; Varum, Merchant et al., 2010). The average overall transit time 
from the mouth to the anus in humans is 24–72 hours (Stella, Borchardt et al., 2007). 
Considering colonic prodrugs, the time between intake of a prodrug and its arrival in the 
colon will affect not only the onset of the drug in the local of action and /or at the plasmatic 
level but also, consequently, its efficacy. 
Following is described the main characteristics and functions of each sections of the GI tract 
that can influence the success of a colonic prodrug, including aspects related to the enzymes, 
pH, microbiota and gastrointestinal tract transit time 
 Stomach 1.2.1
The stomach is divided into cardia, fundus, corpus and pyloric region (antrum) and has 
several functions: storage of the ingested food, processing the food into a fluid chimie, 
mechanically and biochemically; control the rate of delivery of chimie into the duodenum and 
production of acid (Washington, Washington et al., 2000).  
In the stomach, due to secretion of hydrogen ions by gastric mucosa (parietal cells) the pH 
ranges from 0.8 and 2.0 in the fasted state and the number of bacteria decreases comparably 
with saliva (10
7
 CFU/mL) due to the acidic conditions. After ingestion of food, due to 
buffering and dilution effects caused by that, the pH ranges from 4 to 5 and bacteria 
proliferate to 10
4
 -10
8
 CFU/mL. Bacteria can escape due to the substantial volumes of liquid 
that are moving into the duodenum. At this level, microbiota is predominantly gram-positive 
and aerobic (Evans, Pye et al., 1988 ; Fallingborg, Christensen et al., 1989) The low pH is 
essential to maintain the environment sterile and regulates the production of pepsin (3.4.4.1), 
an exopeptidase (Dressman, Amidon et al., 1998).  
Gastric emptying presents great variability, which can range from a few seconds to a number 
of hours and can depend on the feed status (Ibekwe, Liu et al., 2006). Solid, large and caloric 
meals increase gastric emptying time (Varum, Hatton et al., 2013). In general, the transit time 
from the mouth to the small intestine in healthy human adults is 0.5–2 hours, whereas it can 
be delayed to 3–6 hours and 5–8 hours after the intake of light meals and heavy meals, 
respectively (Stella, Borchardt et al., 2007). Digenis et al. verified with a multiple-unit 
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formulation that there is a faster gastric emptying in pre-feeding state when compared to the 
fasted state, due to the increase of gastric motility and gastric emptying in presence of food 
(Digenis, Sandefer et al., 1990). 
 Small intestine 1.2.2
Small intestine is the longest section of the digestive tube, representing 81% of the total 
length of the GI tract. It is divided into 3 regions: duodenum, jejunum and ileum (Desesso and 
Jacobson, 2001). In the proximal part of the duodenum occurs the neutralisation of the acidic 
contents of the stomach by the alkaline pancreatic secretions, which contains bicarbonate, 
lipases, amylases and proteases (Dressman, Amidon et al., 1998; Sarti, Barthelmes et al., 
2011). Consequently, it is observed a burst increase of pH to 5.5. At the level of duodenum, 
food does not affect the pH (Kalantzi, Goumas et al., 2006). Additionally, bicarbonate 
secretion results in a further gradual rise in the luminal pH to  
6.6 ± 0.5 at jejunum level, reaching a peak at the ileum caecal junction 7.5 ± 0.5, in health 
condition (Evans, Pye et al., 1988 ; Dressman, Berardi et al., 1990; Ibekwe, Fadda et al., 
2008). 
In the duodenum and jejunum, the relatively rapid flow of the digesta concomitantly with bile 
and pancreatic fluid secretions, does not allow the increase of microbial multiplication 
(Tannock, 1999; Sousa, Paterson et al., 2008). At this stage the predominant species are 
aerobic and gram positive. However, in the distal ileum gram negative bacteria outnumber the 
gram positive and the bacterial composition becomes higher (Sinha and Kumria, 2003). 
The intestinal area is greatly enhanced by presence of plicae circulares (or Kreking folds), 
villis (finger like projections) and microvillis. Together, these folds provide a huge surface 
area for absorption, 200 m
2
, whereas the area of the stomach is only about 1 m
2
 (Kararli, 
1995; Rowland, Tozer et al., 1995; Desesso and Jacobson, 2001). This big surface area 
associated with the good blood supply and the gut associated lymphoid tissue (GALT), makes 
the small intestine the main site of absorption (Edwards, 1993), particularly in duodenum and 
proximal jejunum. The material that is not absorbed suffers movement towards the large 
intestine. Separating the ileum from the caecum is a one-way valve, the ileocaecal junction 
(ICJ), which regulates the movement of material between the small intestine and the colon 
and prevents the reflux of colon contents, in particular, the spread of bacteria from the colon 
to the ileum. 
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Although, the mean time to cross the small intestine is of 3-4 hours (Davis, Hardy et al., 
1986), the actual transit has demonstrated a range between 1 and 9.5 hours (Davis, Hardy et 
al., 1986; Sugito, Ogata et al., 1990; Coupe, Davis et al., 1991a). Fadda et al. verified that 
there is an acceleration in small intestinal transit in pre-feed state when compared with fasted 
and fed state (Fadda, Mcconnell et al., 2009). 
 
Figure 1.3 Gastrointestinal intraluminal pH, redox potential (RP) and bacterial 
concentration (Sousa, Paterson et al., 2008) Mean pH values  (Evans, Pye et al., 1988 ), 
mean Redox potential (mV) (V Stirrup, S J Ledingham et al., 1990) and bacterial 
concentration (CFU/g of contents) (Simon and Gorbach, 1984; Macfarlane and 
Macfarlane, 2004; Sousa, Paterson et al., 2008). 
 Large intestine 1.2.3
The large intestine comprises the caecum, colon, rectum and the anal canal. It represents 19% 
of the total length of the GI tract, herein the caecum, forms only 5% of the length of the 
human large intestine (Desesso and Jacobson, 2001; El-Kattan and Varma, 2012). The colon 
is subdivided into the ascending (right), transverse, descending (left) and sigmoid colon (the 
proximal colon usually refers to the ascending colon and transverse colon). In the adult, it is 
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approximately 150 cm long, significantly shorter than the small intestine. The 'large' refers to 
the diameter which varies from approximately 9.0 cm in the caecum to 2.0 cm in the sigmoid 
colon (Mrsny, 1992). The large gut receives material from the ileum, which has already been 
digested and the contents are then mixed and retained for 6-12 hours in the caecum and right 
colon. After the hepatic flexure, the chimie is processed into faeces, pass through the 
transverse to the left colon for storage and eventual excretion concomitant with epithelial cell 
turnover and bacteria (Cummings and Macfarlane, 1991; Hastewell, Williamson et al., 1991; 
Basit, 2005). The ascending colon is the preferential region in the lower intestine regarding to 
action of drugs, since the substantial residence time in this part and also because has more free 
water when compared to the transverse colon (Diakidou, Vertzoni et al., 2009). 
As compared with the small intestine, the large intestine shows much reduced surface area for 
absorption. This is due to the presence of semilunar folds instead of circular Kerkring's valves 
and due to the lack of villi and less developed microvilli (Hastewell, Williamson et al., 1991; 
Kararli, 1995). Additionally, the narrow ‘tighter junctions’ between epithelial cell, restrain the 
paracellular permeability of hydrophilic compounds (Hastewell, Williamson et al., 1991). 
Colon participates in the maintenance of fluid and electrolyte balance through reabsorption of 
water, sodium cation, chloride and secretion of potassium and bicarbonate (Dawson, 1991). 
Additionally, colon contains lower levels of luminal and mucosal digestive enzymes than 
stomach and small intestine (Gibson, Mcfarlan et al., 1989).  
However, the human colon is the major site for growth and microbial digestion. The colonic 
microbial community is very complex due to the diversity of species and, moreover, due to 
the difficulty to distinguish between permanent and transient members (Yatsunenko, Rey et 
al., 2012). The studies surrounding gastrointestinal microbiota have been extended for over a 
century and nowadays, it is estimated that the total number of procaryotes that inhabit the 
human gut goes up to 10
14
, herein aerobic species outnumber (Savage, 2001; Ley, Peterson et 
al., 2006). It is estimated that the gut microbiome contain 150-fold more genes than the 
human genome (Qin, Li et al., 2010). 
Current knowledge allows to recognize that the lower gastrointestinal tract contains over 400 
distinct species of bacteria, which belongs to relatively few phyla (Yang, 2008; Jung and 
Kim, 2010). The predominant microbiota belong to the phylum Firmicutes (gram positive) 
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and Bacteroidetes (gram negative), which account for more than 90% of the overall 
phylogenetic types. Additionally, Actinobacteria (gram positive) has also been found in 
human gut, normally with lower abundances of Verrucomicrobia and Proteobacteria and 
Fusobacteria (Eckburg, Bik et al., 2005; Wu, Chen et al., 2011; Yatsunenko, Rey et al., 2012; 
Aziz, Doré et al., 2013; Scott, Gratz et al., 2013).  
In the ascending colon, microorganisms having plentiful supply of dietary nutrients, tend to 
grow rapidly, while in the transverse and descending colon substrate availability is lower and 
bacteria growth is slower (Sousa, Paterson et al., 2008). Nevertheless, aproximately 1/3 of the 
faecal dry weight consists of bacteria (Sinha and Kumria, 2003).  
The complete definition of microbiota requires further studies, which may attend the 
combination of conventional and molecular microflora analysis. Moreover, the impact of 
microbiota on host physiology is still unclear (Mai and Morris, 2004).  
It is known that microbiota exists in relative stable conditions that rely on nutrient availability 
(carbohydrates, proteins and fats), pH, temperature, redox potential, degree of anaerobiosis 
and healthy state (Cummings and Macfarlane, 1991; Ojetti, Gigante et al., 2009) (Scott, Gratz 
et al., 2013). 
Primarily, these colonic bacteria rely on carbohydrate dietary components that are undigested 
by human enzymes in the upper GI tract for energy and growth, including resistant starch 
(RS), non-starch polysaccharides (NSP), and oligosaccharides (including prebiotics and 
cyclodextrins). Anaerobic fermentation of these subtracts results in the production of volatile 
fatty acids called short-chain fatty acids (SCFA), CO2, H2, CH4 and H2S. (Scott, Duncan et al., 
2008; Scott, Duncan et al., 2011). Gram-negative anaerobes belonging to the genus 
Bacteroides are the principal polysaccharide-degrading bacteria (Cummings and Macfarlane, 
1991). When the carbohydrate sources are depleted, which occurs namely at the level of the 
distal colon, residual proteins are used as a source of energy. The fermentation of proteins 
results in the formation of SCFA but also of branched chain fatty acids (BCFA) and other 
metabolites (Scott, Gratz et al., 2013). 
Short chain fatty acids are the major products of fermentation, which accounts for up to 10% 
of the human energy source (Frank, St. Amand et al., 2007). Butyrate, in particular, is the 
major source of energy for the colonocytes (the epithelial cells that line the colon), propionate 
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is transported to the liver where it has a role in gluconeogenesis, whilst acetate enters 
systemic circulation and is used in lipogenesis (Cummings and Macfarlane, 1997b; Scott, 
Duncan et al., 2008).  
 
Figure 1.4 Summary of bacterial metabolites derived from non-digestible carbohydrate 
and from residual protein fermentation. RS – resistant starch, NSP – non-starch 
polysaccharide, OS – oligosaccharides (including cyclodextrin), SCFA – short chain 
fatty acids, BCFA – branched chain fatty acids (isobutyrate, 2-methylbutyrate and 
isovalerate). Adapted from (Scott, Gratz et al., 2013). 
Due to the acidification of the contents by short-chain fatty acids resulted from fermentation 
by colonic bacterial, in the passage from ileum to caecum, a drop in the pH is observed 
(Evans, Pye et al., 1988 ; Scott, Gratz et al., 2013) Therefore, values of pH in contents from 
ascending colon were 7.8 and 6.0 in fasted and fed state, respectively (Diakidou, Vertzoni et 
al., 2009). The pH increases along the colon due to the progressively lower carbohydrate 
fermentation by bacteria, continuous bicarbonate secretion and metabolism of protein and 
urea to ammonia, particularly in the distal colon (Nugent, Kumar et al., 2001). On the other 
hand, short chain fatty acids are electronically charged at the gastrointestinal pH, and 
therefore a lower redox potential is expected in the large intestine (V Stirrup, S J Ledingham 
et al., 1990; Sousa, Paterson et al., 2008). 
Residual Proteins
Non-digestible Carbohydrate 
(RS, NSP, OS)
Lactate Succinate
Acetate
Propionate
SFCA
Gases
(CO2, H2, CH4)
SFCA
Butyrate Propionate
colonocytes
gluconeogenesisLipogenesis
BCFA
Phenols
Indols
Sulfides
Ammonia
Liver
ureia p-cresol
Amines
Nitrosamines
Chapter I 
13 
  Colon as a site for drug delivery 1.2.4
The high viscosity of fluids and the lower availability of fluids, especially after the hepatic 
flexure, turn the dissolution, particularly of poorly soluble drugs, difficult and limit the 
diffusion of drugs from the lumen to the site of absorption. Additionally, the wider lumen 
diameter reduces the exposure of drug molecules to the site of absorption (Basit, 2005). 
However, a greater part of the gut transit time is spent in this part of the GI tract (almost 
80%), which makes this site of the gut favorable not only for absorption of some drugs but 
also favorable for activation of colonic prodrugs with release of the respective drug (Tuleu, 
Basit et al., 2002; Stella, Borchardt et al., 2007; Sousa, Paterson et al., 2008). Actually, some 
drugs that are considered to have good absorption at colonic level including, diclofenac, 5-
fluorouracil, glibenclamide, ibuprofen, lamirocoxib, metoprolol, nifedipine, salicylic acid, 
simvastatin between others listed by Emma et al. (Mcconnell, Liu et al., 2009). 
Moreover, the colon is a relatively inert site for the metabolism of drugs by cytochrome P450 
(Biechea, Narjozb et al., 2007), and therefore drugs that are substrates for this enzyme have 
higher absorption from the colon, as demonstrated for simvastatin (Tubic-Grozdanis, 
Hilfinger et al., 2008). Additionally, the levels of efflux transporters (e.g. P-glycoprotein) are 
lower in the colon, which may also contribute to improve oral drug bioavailability of drugs 
that are substrates for these transporters (Englund, Rorsman et al., 2006; Berggren, Gall et al., 
2007). 
The metabolic potential of colon is equal or greater than of the liver. In general, while 
oxidation and conjugation are the predominant reactions metabolism in the liver, reduction 
and hydrolyses are the preferred ones in the large intestinal lumen (Jung and Kim, 2010). 
Colonic microbiota is capable of metabolizing a wide variety of drug molecules; over 30 drug 
molecules have been identified as substrates for colonic bacteria (Sousa, Paterson et al., 
2008). The main reductive enzymes include nitroreductase, azoreductase, deaminase and urea 
dehydroxylase (Scheline, 1973). On the other hand, between hydrolytic enzymes, 
glycosidases are particularly important once they are involved in the activation of 
polyssacarides based systems. The prevalent glycosidases are amylase, pectinase, xylanase, 
α-L-arabinofuranosidase, β-D-xylosidase, β-D-galactosidase and β-D-glucosidase 
(Englyst, Hay et al., 1987). The presence and capacities of these enzymes produced by the 
microbiota at colonic level are the key to the design of colonic delivery systems activated by 
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microbiota and also colonic prodrugs (e.g. sulfasalazine) able to site-specific release of drugs 
into the colon (Mooter, 2006). Further description about colonic enzymes is present in 
Chapter III, namely related enzymes that are possibly involved on the degradation of 
cyclodextrins. 
The colon is a site of interest to delivery drugs that are medicated to colonic diseases, 
inflammatory bowel diseases (Chron’s diseases and ulcerative colitis), constipation/diarrhoea, 
colorectal cancer, irritable bowel disease and intestinal infections. Drug is released directly in 
the affected area, not only resulting in an increase of the therapeutic potency by reduction of 
the dose administered, but also decreasing the occurrence of adverse effects, which results 
from the release of drugs in the upper GI tract or unnecessary systemic absorption (Chourasia 
and Jain, 2003; Gupta, Bhandari et al., 2009). Glucocorticoids, mesalazine, antimicrobial 
agents (nalidix acid and sulfa drugs), antispastic agent (mentol), anti-constipation (naloxone 
and nalmefene), chemopreventive agents (ursodeoxycholic acid), anti-cancer agents (9-
aminocampothecin, 5-fluorouracil), immunosuppressive agents, vermicides (mebendazole), 
cyclooxygenase-2 (COX-2) selective inhibitors to prevent colon rectal cancer, peptides and 
proteins drugs have high potential to be delivered to the colon.  
Moreover, therapeutic agents for the management of arthritis, asthma and gastric ulcer, which 
commonly have a peak symptom at bedtime, are potential candidates for colonic release. The 
treatment according to the circadian rhythm is called chronopharmacology, which includes 
anti-inflammatory drugs, histamine receptor 2 blokers, proton pump inhibitors and 
antiasthmatic agents (Jung and Kim, 2010).  
1.2.4.1 Colonic delivery of non-steroidal anti-inflammatory drugs (NSAIDs) 
NSAIDs are the most commonly prescribed therapeutic agents (Jones, 2001) and are good 
candidates for the development of controlled release preparations, particularly through the 
oral route. Their anti-inflammatory action is mainly based in the inhibition of cyclo-
oxygenase (COX), which is an enzyme that converts arachidonic acid into inflammatory 
mediators such as prostaglandins, prostacyclins, and thromboxanes (Kim, Brar et al., 2009). 
Two important COX enzymes have been described: COX-1, which is constitutively expressed 
in all tissues is involved in the synthesis of prostaglandins that protect the stomach and kidney 
from damage, and COX-2 which is almost undetectable in most tissues under normal 
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physiological conditions, but is induced by inflammatory stimuli, such as cytokines, being 
responsible for prostaglandins that contribute to the pain and swelling of inflammation (Vane 
and Botting, 1998). These drugs are widely used as anti-pyretics, analgesics, and in the 
treatment of chronic inflammatory diseases, such as arthritis. 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 The main sites of action of the anti-inflammatory drugs, adapted from the 
reference (Ulrich, Bigler et al., 2006). 
Beyond these traditional therapeutic indications, nowadays NSAIDs are also used as agents 
able to protect against Alzheimer’s disease (Veld, Ruitenberg et al., 2001; Etminan, Gill et al., 
2003). Other new applications of these drugs are being pursued, particularly in the cure and 
prevention of adenomas and colon tumors. Inflammation is now considered a well-established 
cancer risk factor, and a number of inflammatory conditions predispose to cancer, including 
ulcerative colitis (which increases about 20-fold the risk of developing colon cancer) 
(Coussens and Werb, 2002). Cancer prevention studies suggest that there may be a 40–50% 
reduction in mortality from colorectal cancer in people who take aspirin or other NSAIDs on a 
regular basis (Smalley and Dubois, 1997). NSAIDs are effective chemopreventive agents 
against colorectal neoplasia and are considered effective as single agents because they work 
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early in carcinogenesis across multiple pathways (Ulrich, Bigler et al., 2006; Cuzick, Otto et 
al., 2009). Second, NSAIDs reduce the number and size of colon adenomas (Hanif, Pittas et 
al., 1996). However, the gastrointestinal toxicity associated with the conventional NSAIDs 
may limit their long-term use for cancer prevention Long-term NSAIDs therapy has been 
associated with an increased risk of gastric erosion, ulcers and bleeding (Go, 2006). NSAIDs 
disrupt the normal gastric mucosal barrier of bicarbonate and hydrophobic mucus by two 
mechanisms. The principal mechanism, independent of route of administration, results from 
disturbance of prostaglandin synthesis by inhibition of the constitutive cyclo-oxygenase 
(COX) isoenzyme, COX-1. In the stomach, prostaglandins maintain mucosal blood flow, 
stimulating secretion of bicarbonate and mucus and regulating mucosal cell turnover and 
repair. Loss of protection by inhibition of prostaglandins renders the stomach vulnerable to 
damage by gastric acid. The second mechanism arises from the fact that NSAIDs become 
lipid soluble at low pH. Taken orally, they can cross the lipid barrier into gastric mucosal 
cells. At intracellular pH, they lose lipid solubility and become trapped, disrupting cell 
function, perhaps by inhibiting mitochondrial oxidative phosphorylation. Damage to surface 
mucosal cells compromises the normal protective mechanisms, reducing resistance to acid 
damage (Hayllar and Bjarnason, 1995; Hawkins and Hanks, 2000). It has been estimated that 
about 60% of all patients chronically treated with NSAIDs present dyspeptic symptoms and 
around 30% have gastroduodenal ulcers (Silverstein, Graham et al., 1995; Laine, 2001). 
In order to decrease gastrointestinal effects associated with NSAIDs various approaches have 
been adapted to formulate systems to specifically release drugs in the colon (Luppi, Cerchiara 
et al., 2003; Akhgaria, Garekania et al., 2005; Orlu, Cevher et al., 2006; Maestrellia, Zerroukb 
et al., 2008; Piao, Lee et al., 2008).  
1.2.4.2 Diclofenac 
Diclofenac [2-(2, 6-dicloranilino) phenyl acetic acid] is a non-steroidal anti-inflammatory 
drug, usually found as sodium or potassium salt. As a representative of the phenylacetic acid 
derivatives group, diclofenac is widely used in the long-term treatment of inflammation and 
painful conditions of rheumatic and non-rheumatic origin (Sallmann, 1986). This molecule 
inhibits preferentially COX-2 (Warner, Giuliano et al., 1999; Hinz, Rau et al., 2003; 
Yamazaki, Muramoto et al., 2006), and also inhibits the lipoxygenase pathway, reducing the 
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formation of leucotriens (Elder, Halton et al., 1997 ). In addition, diclofenac can inhibit 
phospholipase A2 which may explain the high anti-inflammatory activity of this drug.  
Much interest involves the specific release of diclofenac in the colon, given that such an 
approach would allow for circumvention the adverse gastric effects notoriously associated 
with drugs of this class. It is also widely believed that the colonic delivery of diclofenac 
would provide a suitable way for the management of arthritis pain by chronotherapy (Lin and 
Kawashima, 2012). Furthermore, diclofenac is known to be well-absorbed in the colon 
(Gleiter, Antonin et al., 1985) and has demonstrated to have an effective chemopreventive 
action against colon cancer (Saini, J. Kaur et al., 2009; Jasmeet and Nath, 2010).  
Several strategies have been studied with the purpose to release diclofenac in the colon, 
namely a time-based system that consisted in a polymeric matrix tablet (González-Rodríguez, 
Maestrelli et al., 2003), a time- and pH-dependent colon-specific tablet (Cheng, An et al., 
2004), a combination of pH dependent polymer coating and a matrix able to release the drug 
by an ionic-exchange mechanism (Ambrogi, Perioli et al., 2008), Eudragit
®
 L 100-55 
nanofibers – a pH dependent system (Shen, Yu et al., 2011),  poly(methyl acrylates)-coated 
chitosan–diclofenac sodium nanoparticles (Huanbutta, Sriamornsak et al., 2013). Below is 
described the main systems for colonic delivery of drugs. 
1.3  Systems to colonic target delivery of drugs to the colon 
Because of the distal location of the colon in the GI tract, an ideal system for colonic delivery 
should prevent drug release in the stomach and small intestine, and provide an abrupt onset of 
the drug upon entry into the colon (Yang, 2008). Rectal administration offers the shortest 
route for targeting drugs to the colon. Rectal formulations such enemas, foams and 
suppositories seem to be a very simple way for local drug delivery. However, it allows only 
reaching the rectum and lower parts of the distal colon. Reach the proximal part of colon via 
rectal administration is difficult. Moreover, this route of administration can be uncomfortable 
for patients and compliance may be less than optimal (Mooter, 2006). Therefore, the oral 
delivery is presented as the most convenient and preferred way to target the colon. 
Many different colon-specific drug delivery systems have been investigated based on the 
exploration of selected physiological parameters that exhibit particular features only in the 
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colon. However, due to the similarity between distal small intestine and the proximal colon, 
there are not many options that allow drug release only in the colon (Basit, 2005). Systems 
have been developed considering the next aspects: variation of pH along the GI tract (pH-
based systems), transit time in the GI tract (time-based systems), intra-luminal pressure 
(pressure-based systems), composition of the microbiota (microbiota-based systems) or the 
combination of two of these anterior factors (Table 1.1). 
 pH-based systems 
pH-dependent systems are designed based on the difference in pH-levels along the GIT. 
These formulations use pH sensitive polymer-based coatings that are insoluble at low pH 
levels, preventing dissolution and drug release in the upper gut but dissolving in the elevated 
pH conditions of the distal gut (Mcconnell, Liu et al., 2009). The thickness of the coating is 
the determinant factor for the success of these systems. The most commonly used pH-
dependent polymers are methacrylic acid copolymers usually known as Eudragit®. The major 
drawback of these systems is associated with the fact that pH is not predictably stable and 
therefore the site-specificity of formulations can be poor. pH is influenced by diet, disease 
(e.g. pH is lower in inflammatory bowel disease and in ulcerative colitis) and intra and inter-
individual differences observed along the GI tract (Leopold and Eikeler, 2000; Mooter, 2006; 
Mcconnell, Fadda et al., 2008). It was reported that release of drug from these systems may 
start in the proximal small intestine (Singh, 2007) and, on the other hand, some of these 
formulations pass intact through the gut, due to failure of the coating to dissolve (Sinha and 
Kumria, 2003; Ibekwe, Fadda et al., 2006; Ibekwe, Liu et al., 2006; Mcconnell, Liu et al., 
2009).  
 Time-dependent systems 
Time-dependent systems are designed to release the drug after a predetermined lag time of 5 
or 6 hours, which is expected to be the time required for the dosage form to reach the colon 
(Basit, 2005). These systems use erodible or a swelling coating polymers (Table 1.1). 
These formulations are susceptible to variable gastrointestinal transit, in particular, variable 
gastric emptying due to the size, shape and density of the dosage form and/or state of feeding 
and health condition of the subject (accelerated transit time is observed in IBD, carcinoid 
syndrome, diarrhea and ulcerative colitis) (Coupe, Davis et al., 1991a; Coupe, Davis et al., 
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1991b; Vassallo, Camilleri et al., 1992; Ohe, Camilleri et al., 1993; Mcconnell, Liu et al., 
2009). Therefore, the colon arrival time of a dosage form cannot be accurately predicted and, 
consequently, it is considered that this time-based systems cannot afford a reliable drug 
release in the colon (Mcconnell, Fadda et al., 2008).  
 Pressure controlled systems 
Presssure controlled systems are designed to release the drug by rupture of the dosage form in 
response to the raised luminal pressure in the distal gut. This is caused by the increase of 
viscosity and quantity of luminal contents (Yang, Chu et al., 2002). The performance of this 
system appears to be dependent on thickness of the coating and the capsule size of the capsule 
(Yang, Chu et al., 2002; Meissner and Lamprecht, 2008). The data related to the pressure 
along the GI tract are limited. 
 Microbiota activated systems  
These systems are designed taking in account the abrupt increase of bacteria population and 
associated enzymatic activities in ascending colon. These systems can be divided into: 
coating/matrices systems, which use polymers susceptible to fermentation in the lower 
intestine and prodrugs activated by colonic enzymes. This approach seems to be more site-
specific since the biodegradable enzymes produced by the vast microbiota only exists in the 
colon and, therefore, this is the most promising strategy for colonic delivery of active agents. 
The coating/matrices systems can be formulated using natural polymers namely 
polysaccharides (plant (e.g., pectin, guar gum, inulin, amylose), animal (e.g. chitosan, 
chondroitin sulphate), algal (e.g., alginates) or microbial (e.g., dextran)), or synthetic or semi-
synthetic polymers. These natural polymers are found in abundance, are inexpensive, non-
toxic and biodegradable. However, some of them are hydrophilic leading to premature release 
of drugs. Hence, these natural polymers can be chemically modified to increase their 
hydrophobicity (semi-synthetic polymers). Additionally, these systems can exploit the use of 
synthetic polymers (Fadda, Mcconnell et al., 2009; Shukla and Tiwari, 2012). With respect to 
safety, natural polymers are more favourable. On the other hand, the derivatization of natural 
polymers can result in decrease of biodegradability (Mooter, 2006).  
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Prodrugs approach provides site-specificity delivery and has been intensively explored. In the 
market, produgs of 5-aminosalicilic acid are commercially available (Table 1.1). The 
reduction of the azo bond, with the aid of azoreductase enzymes produced by the large 
intestinal microbiota, has been the basis of the development of colonic prodrugs, including 
those available in the market. The first example of this is sulfasalazine, which consists of 
mesalazine (5-ASA) linked via an azo bond to a sulphonamide, sulfapyridine (Zoetendal, 
Akkermans et al., 1998). Due to the undesirable side effects caused by sulfapyridine, an effort 
has been made to replace sulfapyridine by carrier molecules thought unlikely to produce side 
effects (Sousa, Paterson et al., 2008). Therefore, olsalazine, which consists of 2 molecules of 
5-ASA linked by an azo-bond, was developed. However, this molecule did not demonstrate a 
proportionally greater effect. Other azo prodrug of mesalazine is balsalazide which uses an 
inert carrier to transport mesalazine into the colon (Basit, 2005). A drawback of azo prodrugs 
is that the reduction process might be too slow, especially when diarrhoea occurs and leads to 
fast elimination of the delivery system (Meissner and Lamprecht, 2008). Other carriers have 
been explored for site colonic delivery of prodrugs (section 1.3.1). 
 Combined systems 
Complementary strategies considering the combination of different mechanisms of colonic 
drug release have been developed in order to overcome the limitations associated with 
systems that take in account only one of the mechanisms to trigger the colon. 
 Prodrugs as a strategy for site colonic delivery of drugs 1.3.1
Currently, it is estimated that about 10% of worldwide marketed drugs can be classified as 
prodrugs (Zawilska, Wojcieszak et al., 2013). For a drug to become a prodrug, the drug 
should have an appropriate functional group able to conjugate by a covalent linkage with a 
colonic specific carrier. The prodrug should pass intact through the upper gastrointestinal 
tract, but once in the large intestine, the covalent link should be cleavable via a reduction or a 
hydrolysis process activated by the resident microbiota, releasing the active drug molecule 
from the carrier (Stella, Borchardt et al., 2007; Jung and Kim, 2010; Dhaneshwar and 
Vadnerkar, 2011) To pass intact the upper gastrointestinal tract without significant absorption, 
it should be hydrophilic or large, which prevents passive transport through the intestinal 
epithelial cell layer (Ungell, Nylander et al., 1998; Chae, Jang et al., 2005). Therefore, the 
choice of the carrier is critical. 
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Table 1.1 Oral formulations for colonic site-specific delivery in the market. 
Colon 
Delivery 
System 
Market Brand Description Reference 
p
H
 d
ep
en
d
en
t 
sy
st
em
s Asacol® (mesalazine) Coating polymer soluble at pH > 7 (Eudragit S) 
(Ibekwe, Liu et al., 
2006) 
Salofalk® (mesalazine) Eudragit®L-coated tablet (release at pH >6) (Singh, 2007) 
Budenofalk® (budenoside) 
Eudragit S and L - coated granules (slow release 
at pH>6.4) 
(Ibekwe, Fadda et al., 
2006; Ibekwe, Liu et 
al., 2006) 
Entocort® (budesonide) 
Eudragit® L100-55-coated ethylcellulose 
granules (slow release at pH >5.5) 
(Edsbäcker, 
Bengtsson et al., 
2003) 
T
im
e 
d
ep
en
d
en
t 
sy
st
em
s 
Pentasa®   
Ethylcellulose-coated granules in tablet or sache 
form (slow release of drug through membrane) 
(Wilding, Kenyon et 
al. 2000) 
M
ic
ro
b
ia
l 
tr
ig
g
er
ed
 
d
el
iv
er
y
 
Dipentum® (olsalazine) Azo prodrugs of 5-aminosalicic acid.  
(Roldo, Barbu et al., 
2007) 
Among hydrophilic small molecules, aminoacids, glycosides and sulphate have been explored 
as carriers to target drugs to the colon. Aminoacids have polar groups, like the −NH2− and 
−COOH− that reduce the membrane permeability, and are additionally free of adverse effects. 
Amide prodrugs can be hydrolyzed by the amidase originated from microbes in the colon 
(Scheline, 1973). Conjugation of a drug with a sugar moiety (glucose, galactose, cellulose, 
glucoronic acid) forms glycosides (glucoside, galactoside, cellobioside, glucoronides). 
Glycoside prodrugs are hydrophilic and poorly absorbed from the small intestine, but once 
they reach the colon, they can be effectively cleaved by bacterial glycosidases to release the 
free drug or to be absorbed by the colonic mucosa (Sinha and Kumria, 2001). Conjugation 
with sulphate is another approach that has been explored since these prodrugs are activated 
through the action of sulphatases at colonic level (Jung, Doh et al., 2003). 
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Table 1.2 Colonic prodrugs designed using small carrier and the in vitro/in vivo 
performance.  
 Carrier Drug Performance of the prodrug Reference 
A
m
in
o
ac
id
s 
co
n
ju
g
at
es
 
Tyrosine 
Methionine 
Alanine 
Glutamic acid 
Salicylic acid Amide prodrugs tested in rabbits: methionine 
prodrug absorved in the duodenum; tyrosine 
prodrug was hydrolyzed in the small intestinal 
mucosa; L-alanine and glutamic acid prodrugs 
were hydrolyzed only in the contents of the 
lower GI tracts such as caecum and colon; D-
alanine with negligible hydrolyses (tested in 
rabbits). 
(Nakamura, Shiota et al., 
1988; Nakamura, Kido et al., 
1992; Nakamura, Tagami et 
al., 1992) 
Glycine 
Aspartic acid 
Glutamic acid 
Taurine  
Cysteine 
5-aminosalicylic 
acid 
Amide prodrugs are stable in the upper 
intestinal; glycine prodrug releases 65% and 
27% of 5-ASA in caecal and colonic contents in 
8 hours of incubation, respectively; aspartic 
prodrug releases 37% of 5-ASA, while 
glutamic prodrug releases 8% of 5-ASA in 
caecal contents in 16 h of incubation; taurine 
prodrug release 45% and 20% of the drug in 
caecal and colonic produg in 8 hours; cysteine 
prodrug releases 92% of 5-ASA after 24 hours. 
(Jung, Lee et al., 2000; 2001; 
Jung, Kim et al., 2003; Jung, 
Kim et al., 2006) (Leopold 
and Friend, 1995a; Leopold 
and Friend, 1995b)  
 
 
G
lu
co
si
d
es
 c
o
n
ju
g
at
es
 
Glucose  
Galactose 
Cellobiose 
Dexamethasone  
Prednisolone 
Hydrocortisone 
Fludrocortisone 
 
Prodrug hydrolyses is low in the stomach and 
the proximal small intestinal contents and 
increases in the contents of distal small 
intestine, and is maximum in the caecal content 
homogenates. Galactoside prodrugs were found 
to be more rapidly hydrolyzed than the 
corresponding glucosides, which are 
hydrolyzed faster than the cellobioside. 
(Friend and Chang, 1985) 
Glucose Dexamethasone 
Prednisolone 
. 
 
Dexamethasone glucoside showed that nearly 
60% of the oral dose reached the caecum 
between 4–5 hours, while the free drug is 
absorbed from the small intestine. Contrarily, 
the prednisolone prodrug was not that site-
specific, with 15% of dose administered 
reaching the caecum in 4–5 h and only 11% 
recovered unabsorbed from the caecum. 
(Friend and Chang, 1984; 
Friend and Tozer, 1992) 
 
Glucoronic 
acid 
Dexamethasone 
budesonide 
A similar study conducted in normal and colitic 
rats showed a high level of drug delivery to the 
colon using glucuronide prodrugs of 
dexamethasone and budesonide. 
(Haeberlin, Rubas et al., 
1993) (Cui, Friend et al., 
1994; Nolen, Fedorak et al., 
1997) 
Naloxone and 
Nalmefene 
These prodrugs are activated in large intestine, 
followed by a resultant diarrhea. These 
prodrugs do not interfere with the central 
analgesic effects of narcotics. 
(Simpkins, Smulkowski et al., 
1988) 
S
u
lp
h
at
e 
co
n
ju
g
at
es
 
Sulphate Prednisolone 
Dexamethasone 
Sulfate ester can serve as a novel colon-specific 
pro-moiety which limits the absorption in the 
upper intestine and release the drug by action of 
microbial sulfatse. 
(Jung, Doh et al., 2003) 
(Kim, Kong et al., 2006) 
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The large molecules used as a carrier are natural or synthetic polymers which undergo 
metabolism by the colonic microbiota. Examples of biodegradable molecules are poly(L-
aspartic acid) (Leopold and Friend, 1995b), polyssacarides including dextran, starch, starch, 
alginates, glycogen, pullullan, agarose, cellulose, chitosan, chitin and carrageenan 
(Vandamme, Lenourry et al., 2002; Dhaneshwar and Vadnerkar, 2011) and oligossacarides 
namely cyclodextrins (section 1.2.2) (Kamada, Hirayama et al., 2002). In the case of large 
carriers used to design prodrugs, the respective drug should have high efficacy in order to 
provide effective dose on administration of a practical dose of prodrug. The setback of 
polymeric materials is the large quantity required to be taken orally, which is not suitable 
when the drug has low efficacy (e.g. 5-ASA whose dose is 0.5 to 3 g/day). The problem of the 
large quantity of polymeric prodrug can be circumvent increasing the degree of substitution of 
the polymer, this is, by increasing the number of active molecules linked to each unit of 
polymer (Mooter, 2006; Jung and Kim, 2010).  
Cyclodextrins (section 1.2.2) are cyclic oligosaccharides that revelead to be promising in 
targeting drugs to the colon and are explored in this thesis as carriers for colonic delivery 
(Kurkov and Loftsson, 2013). Following, it is presented a brief description of the use of 
cyclodextrins in the field of oral drug delivery, including their application on colonic drug 
delivery. 
 Cyclodextrins  1.3.2
The first written record on cyclodextrins was published in 1891 by the French scientist 
A.Villiers. He described the isolation of a bacterial digest from starch, which was stable 
towards acid hydrolysis and, like starch, did not display reducing properties. It is now 
believed that Villiers had isolated a mixture of α- and β-cyclodextrin (α-CD and β-CD).  
Later, an Austrian microbiologist, Franz Schardinger, described two compounds that he had 
isolated from bacterial digest of potato starch, which he designated α-dextrin and β-dextrin. It 
was not until the 1940s, however, that the structure and physicochemical properties of 
cyclodextrins (CDs) were described in detail. The first cyclodextrin-related patent was issued 
in Germany in 1953 (Loftsson and Duchêne, 2007; Loftsson and Brewster, 2010). 
Cyclodextrins, also named Schardinger dextrins, cycloglucans or cycloamyloses make up a 
family of oligosaccharides comprised of five or more D-glucose attached by α-1-4 glycosidic 
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linkages. Cyclodextrins are produced from starch by the action of an enzyme, cyclodextrin 
glycosyltransferase (CDTGase; ED 2.4.1.19), which can be produced by a variety of bacteria. 
The three most common cyclic oligosaccharides are α-, β- and γ-CD consisting of six, seven 
and eight glucose units, respectively (Szejtli, 1998). Cyclodextrins consisting of more glucose 
units also exist, but they are currently too expensive to be utilized in the development of 
practical applications.  
As can be seen in the Figure 1.6, glucose repeating unit of a cyclodextrin contains three 
different hydroxyl groups. The glucose repeating unit contains one primary hydroxyl group at 
position 6 and two secondary hydroxyl groups connected to C-2 and C-3 (Wenz and Höfler, 
1999). 
The whole molecule assumes a rigid structure because of the formation of a belt of 
intramolecular hydrogen bonds between hydroxyl groups at the 2- and 3-positions of adjacent 
glucose units. The rotation of the secondary hydroxyl groups is thus restricted, whereas 
rotation of the primary hydroxyl groups is free, thus reducing the effective diameter of the 
cavity on the primary side of the molecule (Khan, Forgo et al., 1998). 
 
 
 
 
 
 
Figure 1.6 Schematic representation of the cone-shaped structure of the cyclodextrin. 
Therefore, CDs possess doughnut-like annular structures with wide and narrow hydrophilic 
ends delineated by secondary 2-OH and 3-OH and primary 6-OH groups, respectively. The 
presence of the hydroxyl groups makes the upper and lower end of the molecule hydrophilic. 
Cavity 
Primary Hydroxyl 
Secondary Hydroxyl 
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The cavity of the cyclodextrin rings consists of a ring of C-H groups, a ring of glycosidic 
oxygen atoms and again a ring of C-H groups. This renders the interior of the cyclodextrin 
rings hydrophobic, providing a cavity for the inclusion of non-polar guest compounds. 
Encapsulation of a molecule within cyclodextrin depends upon the size of the cavity and the 
drug. α-Cyclodextrin is generally too small, γ-CD is not stable enough, and hence β-
cyclodextrin has been extensively used in this area (Khan, Forgo et al., 1998). However, β-
cyclodextrin has a solubility lower than the others cyclodextrins. The unusual low water 
solubility of β-cyclodextrin may be explained by the very rigid structure resulting from the H-
bonding of the C-2 hydroxyl of a glucopyranose unit with the C-3 hydroxyl of an adjacent 
unit. Interference with the hydrogen bonding of the hydroxyl groups increases the water 
solubility of the cyclodextrins. At high pH, ionization of hydroxyl groups increases water 
solubility; at pH 12.5 the solubility of β-cyclodextrin is 750 g/L (Coleman, Nicolis et al., 
1992). 
Chemically modified cyclodextrin derivatives have been synthetized with a view to extend the 
physiochemical properties and inclusion capacity of the parent CDs. In general, natural 
cyclodextrins have low aqueous solubility. Modifications of the natural cyclodextrins allow to 
overcome its low solubility and, therefore, improves its applicability. 
Table 1.3 Physical properties and molecular dimensions of the natural cyclodextrins 
(Valle, 2004). 
Cyclodextrin α β ϒ 
Structure 
 
 
 
 
 
 
 
 
  
Number of glucose 
Units 
6 7 8 
MW 
(g/mol) 
972 1135 1459 
Water Solubility 
(g/100ml) at 25oc 
14.5 1.85 23.2 
Cavity Diameter (Å) 4.7-5.3 6.0-6.5 7.5-8.3 
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Table 1.4 Structural and physiochemical properties of selected cyclodextrin of 
pharmaceutical interest (Marcus E. Brewster and Loftsson, 2007; Loftsson and 
Brewster, 2010). 
 
Cyclodextrin 
 
 
MS 
MW (Da) Solubility in water (mg/mL at 25ºC) 
2-Hydroxypropyl-α-cyclodextrin (HPαCD) 0.65 1199 >500 
2-Hydroxypropyl-β-cyclodextrin (HPβCD) 0.65 1400 >600 
Sulfobutylether-β-cyclodetrin sodium salt (SBEβCD) 0.9 2163 >500 
Randomly methylated β-cyclodextrin (RMβCD) 
1.8 
0.57 
1312 
1191 
>500 
200 
Maltosyl β-cyclodextrin (MβCD) 0.14 1459 >500 
2-hydroxypropyl-γ-cyclodextrin 0.6 1576 >600 
MS:molar degree of substitution; Mw:     
Chemically modified cyclodextrins of pharmaceutical interest are classified in hydrophilic, 
hydrophobic and ionizable cyclodextrin derivatives.  In the hydrophilic derivatives, the 
hydroxypropyl derivatives of β- and γ-cyclodextrin, the randomly methylated β-cyclodextrin, 
sulfobutylether β-cyclodetrin hydroxyalkylated and branched cyclodextrin derivatives are the 
most relevant ones (Loftsson, Brewster et al., 2004) The introduction of ionizable groups on 
the hydroxyl groups of cyclodextrins offers a pH-dependent hydrophilic activity on such 
derivatives. In this group, carboxymethyethyl cyclodextrins are the most important ionizable 
derivatives. 
The physicochemical properties of the CD derivatives, including their aqueous solubility and 
complexation capabilities, not only depend on the structure of the appended substituent but 
Chapter I 
27 
also on their location within the CD molecule and the number of substituents per CD 
molecule. The molar degree of substitution (MS) is defined as the average number of 
substituents that have reacted with one glucopyranose repeat unit (Loftsson and Brewster, 
2010). 
 Cyclodextrins in oral drug delivery 1.3.3
The lipophilic microenvironment of the central cavity of CDs gives the ability to form 
inclusion complexes by taking the whole molecule or rather some nonpolar parts in its 
hydrophobic cavity. Taking this in advantage, cyclodextrins can enhance the bioavailability of 
hydrophobic drugs by increasing drug solubility, dissolution and/or drug permeability.  
The inclusion complexes between poorly soluble drugs and hydrophilic cyclodextrins allow 
the increase of water solubility of the drug and consequently the dissolution rate. The increase 
in the dissolution performance can improve the oral bioavailability of class II and IV drugs of 
BCS (Biopharmaceutical Classification System), improving the pharmacological effect and 
allowing a reduction in the dose of the administered drug (Valle, 2004; Loftsson, Vogensen et 
al., 2007; Rebecca L. Carrier, Lee A. Miller et al., 2007; Vyas, Saraf et al., 2008). Otherwise, 
CDs increase bioavailability by increasing the permeability of hydrophobic drugs, by making 
the drug available at the surface of the biological barrier of the intestine. In case of water-
soluble drugs, CDs increase drug permeability by direct action on mucosal membranes 
(Rajeswari Challa, Alka Ahuja et al., 2005; Loftsson, Vogensen et al., 2007). 
In addition, CDs are mainly used to improve other desirable properties of drugs such as 
stability (Rajeswari Challa, Alka Ahuja et al., 2005), gastrointestinal tolerability (Loftsson, 
Brewster et al., 2004), and can be used to mask the undesirable taste of drugs (Rajeswari 
Challa, Alka Ahuja et al., 2005; Loftsson, Vogensen et al., 2007). 
This ability to form complexes makes CDs applicable as functional drug carriers controlling 
rate and/or time profile of oral drug release. The hydrophilic derivatives (methylated, 
hydroxyalkylated, branched 6-glucosyl and maltosyl) and ionizable derivatives (carboxyalkyl, 
carboxymethyl, sulfates, alkylsulfonates) of CDs can serve as potent drug carriers for 
immediate release and delay release formulations, respectively, while the release rate of water 
soluble drugs can be retarded by hydrophobic derivatives of CDs (ethylated and peracylated) 
(Hyrayama and Uekama, 1999; Uekama, 2002; Uekama, 2004). 
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Figure 1.7 Effect of cyclodextrin complexation on the drug bioavailability after non-
parental administration. (Loftsson, Jarho et al., 2005). 
 
Table 1.5 The biopharmaceutics classification system and the effect of drug/cyclodextrin 
complexation on the oral bioavailability of drugs (Loftsson, Brewster et al., 2004). 
FDA 
Class* 
Drug properties 
RDS to drug absorption3 
 
Effect of drug 
complexation Aqueous 
solubility1 
Permeability2 
I Highly soluble Highly permeable (good bioavailability) Can decrease absorption 
II Poorly soluble Highly permeable Aqueous diffusion Can enhance absorption 
III Highly soluble Poorly permeable  Membrane permeation Can decrease absorption 
IV Poorly soluble Highly permeable  
Aqueous difusion and 
membrane permeation 
Can enhance absorption 
*
FDA Biopharmaceutics Classification System of orally administered drugs. 
1
Intrinsic solubility of the drug in the 
aqueous membrane exterior. 
2
Passive drug permeation through lipophilic biomembrane such as the gastrointestinal 
mucosa. 
3
RDS of drug delivery from the aqueous exterior into the body. 
FDA: Food and Drug Administration; RDS: Rate determining step 
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1.3.3.1 Cyclodextrin conjugates for colonic drug delivery 
When administered orally, a CD complex is in equilibrium with the molecule and the empty 
CD. In GI tract fluids, the degree of dissociation is dependent on the magnitude of the 
stability constant of the complex (Hyrayama and Uekama, 1999). 
This form of drug carrying as an inclusion complex is not suitable to deliver the drug to the 
targeted site, since the drug complex can dissociate and the drug releases, by dilution process 
and/or competitive inclusion effects before reaching the colon.  To overcome this problem the 
drug can be conjugated with a cyclodextrin. In this conjugation the drug bonds covalently to 
cyclodextrin (Uekama, 2004). 
CDs are not absorbed through biological membranes such as the GI tract because of their 
bulky and hydrophilic nature. Natural α-CD, β-CD and γ-CD are more resistant towards non-
enzymatic hydrolysis than the linear oligosaccharides. They are chemically stable under 
neutral and basic conditions and the hydrolyse rate increases in the order α-CD < β-CD, γ-CD 
(Szejtli, 1998; Loftsson and Brewster, 2010) Moreover, natural α- and β-cyclodextrins, unlike 
γ-cyclodextrin, cannot be hydrolysed by human salivary and pancreatic α-amylases. However, 
the vast microbiota present in the colon, especially Bacteroides, breaks these into small 
saccharides that are absorbed in the large intestine (Flourié, Molis et al., 1993; Irie and 
Uekama, 1997; V. R. Sinha and Kumria, 2001; Chourasia and Jain, 2003).  
Therefore, CDs are useful as colon-targeting carriers, and various cyclodextrin prodrugs have 
been synthesized in order to obtain site-specific delivery of drugs to the colon. In addition, in 
the USA, natural CDs (α-, β-, γ-) are ‘Generally Regarded As Safe’ (GRAS) which allows 
safety assurance of these prodrugs as new entities (Astray, Gonzalez-Barreiro et al., 2009). 
Moreover, fermentation of cyclodextrins leads to production of short-chain fatty acids 
(SCFA) that can contribute to the maintenance of the health and integrity of the colonic 
epithelium, as described previously (Giardina and Inan, 1998).  
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Figure 1.8 Schematic comparison of the digestion of natural α-CD, β-CD and γ-CD after 
oral administration. Cyclodextrins are slowly hydrolysed by α-amylases but relatively 
rapidly digested by bacteria. Adapted from (Kurkov and Loftsson, 2013). 
Drug molecules were selectively conjugated using the primary or secondary hydroxyl groups 
of CDs through an ester or amide linkage. Therefore, a limited number of prodrugs can be 
formed due to the chemical linkage required in their formation.  
Several drugs have been combined with CDs to synthesize prodrugs enabling colonic specific 
release (Table 1.6). Cyclodextin conjugates of non-steroidal anti-inflammatory drugs include: 
byphenylacetic acid (Uekama, Minami et al., 1997a; Minami, Hirayama et al., 1998), 
ketoprofen  (Kamada, Hirayama et al., 2002), etodolac (Rizzarelli, Vecchio et al., 2007), 
mefenamic acid (Dev, Mhaske et al., 2007), naproxen, flurbiprofen, sulindac (El-Kamel, 
A.M.Abdel-Aziz et al., 2008), ibuprofen, indomethacin (Namazi, Bahrami et al., 2005); short-
chain fatty acids such as n- butyric acid (Hirayma, Ogata et al., 2000); steroidal drugs like 
prednisolone (Yano, Hirayama et al., 2001; Yano, Hirayama et al., 2002), budesonide 
(Prabhu, D.Satyanarayana et al., 2009); a drug for the treatment of inflammatory bowel 
disease, 5-aminosalicylic acid (Zou, Okamoto et al., 2005). There are also β-lactam antibiotics 
like ampicillin, amoxicillin, cephalexin (Namazi and Kanani, 2007); and recently anticancer 
drugs like 5-fluoracil (Udo, Hokonohara et al., 2010), and scuterallin, a flavonoid with 
anticancer activity (Yang, Zhao et al., 2013). All these examples have been designed 
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anticipating new candidates for colon-specific delivery prodrugs but, asfar as we know, there 
are no reports of cyclodextrin conjugate with diclofenac. In the case of prednisolone and 
budesonide a linker molecule, succinic acid, was used between drug and cyclodextrin, 
forming esters at both ends of the linker molecule (Yano, Hirayama et al., 2001; Prabhu, 
D.Satyanarayana et al., 2009). Modification of β-cyclodextrin with water soluble polymer 
poly(ethylene glycol) was used to produce conjugates of antibiotics (Namazi and Kanani, 
2007) and conjugates of indomethacin and ibuprofen (Namazi, Bahrami et al., 2005).  
In most of the drug-cyclodextrin conjugates, namely those with a ester linkage, the drug was 
released in the contents of large intestine, whereas only minor chemical hydrolysis occured in 
the upper GI tract (Uekama, 2004; Kurkov and Loftsson, 2013). These promising results 
highlight cyclodextrin-based prodrugs as an area for further research. 
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Table 1.6 Active molecules conjugated with cyclodextrins, including type of carrier, 
linkage and the presence/ absence of carrier. 
 Carrier Linkage Spacer/ 
intermediate 
Reference 
Drug cyclodextrins Ester amide 
biphenylacetic cid 
α √ √  
(Uekama, Minami 
et al., 1997b) 
β √ √  
ϒ √ √  
Dimethyl-β √   
(Ventura, Paolino 
et al., 2003a) 
etodolac β √   
(Rizzarelli, 
Vecchio et al., 
2007) 
ketoprofen α √   
(Kamada, 
Hirayama et al., 
2002) 
mefenamic acid β √   
(Dev, Mhaske et 
al., 2007) 
naproxen 
α √   
(El-Kamel, 
A.M.Abdel-Aziz et 
al., 2008) 
β √   
flurbiprofen 
α √   
β √   
sulindac 
β √   
α √   
ibuprofen β √  Poly(ethylene glycol) (Namazi, Bahrami 
et al., 2005) indomethacin β √  Poly(ethylene glycol) 
butyric acid β √   
(Hirayma, Ogata et 
al., 2000) 
prednisolone 
α √  
succinic acid 
hemiester 
(Yano, Hirayama 
et al., 2000; 2001) 
β √  
γ √  
budesonide β √  
succinic acid 
hemiester 
(Prabhu, 
D.Satyanarayana et 
al., 2009) 
5-Aminosalicylic 
acid  
α √   
(Zou, Okamoto et 
al., 2005) 
β √   
ϒ √   
5-fluoracil β √ √ 
5-fluorouracil-1- 
acteic acid 
(Udo, Hokonohara 
et al., 2010) 
scutellarin β  √ 
amino-cyclodextrin 
enamino- cyclodextrin 
dienamino- 
cyclodextrin 
(Yang, Zhao et al., 
2013) 
ampicillin β √  
Poly(ethylene glycol) 
(Namazi and 
Kanani, 2007) 
amoxicillin β √  
caphalexin β √  
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1
(Hirayama, Minami et al., 1996; Uekama, Minami et al., 1997b; Ventura, Paolino et al., 2003a)
 
, 
2(Kamada, 
Hirayama et al., 2002)
,
 3
(Rizzarelli, Vecchio et al., 2007), 
4(
Jilani, Pillai et al., 1997), 
5
(El-Kamel, A.M.Abdel-Aziz 
et al., 2008) 
6 
(Namazi, Bahrami et al., 2005)
7
(Hirayama, Ogata et al., 2000) 
8
(Yano, Hirayama et al., 2000; 
Yano, Hirayama et al., 2002) 
9
(Prabhu, D.Satyanarayana et al., 2009), 
10
(Zou, Okamoto et al., 2005) 
11
(Udo, 
Hokonohara et al., 2010) 
12
(Yang, Zhao et al., 2013)
 
 Figure 1.9 Structures of active molecules studied where cyclodextrins were used as a 
carrier to target the colon. 
1Biphenylacetic acid 
 
2Ketoprofen
 
3Etodolac 
 
4Mefenamic acid 
 
5Naproxen  
 
5Fluribuprofen 
5Sulindac 6Ibuprofen 
 
6Indomethacin 
 
7Butyric acid 
 
8Prednisolone 
 
9Budenoside
  
10 5-Aminosalicylic acid  
(mesalazine) 
11Fluorouracil 12Scuteralin 
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1.4 In vivo evaluation  
1.4.1.1 Animal models  
The ultimate investigation of any colon-specific drug delivery system must be performed in 
vivo, in humans. However, prior to the test in humans, it is common procedure to assess the 
performance of the delivery system in animal models. Different animal models such rabbit, rat 
and pig are used to evaluate the delivery of drugs to the colon because they resemble the 
conditions of the human GI tract (Figure 1.10). However, the choice of the animal model to 
perform in vivo studies is a very critical point, given the important anatomic, physiological, 
biochemical and metabolic differences that exist between human and the common laboratory 
animals (Kararli, 1995), which contributes to the noticeable differences on the behaviour of 
the drug delivery systems between species.  
 
Figure 1.10 Gastrointestinal tracts of small hindgut-fermenting mammalian herbivore 
(rabbit) and gastrointestinal tracts of mammalian omnivores (rat, pig). Adapted from 
references 1(Stevens, 1977) and  2(Argenzio and Southworth, 1975). 
In the case of colonic prodrugs different animal models have been used: rabbits, to evaluate 
aminoacids prodrugs (Nakamura, Kido et al., 1992; Nakamura, Tagami et al., 1992); pig, to 
evaluate dextran prodrugs (Harboe, Larsen et al., 1989); and rats, to study glucosides prodrugs 
(Simpkins, Smulkowski et al., 1988; Cui, Friend et al., 1994) and also cyclodextrin prodrugs 
(Kamada, Hirayama et al., 2002). 
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Below, it is described the main anatomic and physiological characteristics including 
differences on the pH (Table 1.7) and microbiota (Table 1.8) along the GI tract of each animal 
model considered thereafter in this dissertation. 
1.4.1.2 Stomach 
Like humans, pigs and rabbits have a glandular type stomach while the stomach of rats is 
divided in two main sections: glandular and non-glandular. The non-glandular section also 
called forestomach portion is an entry from esophagus and the site for storage and bacterial 
digestion (Kararli, 1995).  
In rabbits, stomach is the major site of digestion (Yu, Chiou et al., 2000). Its stomach is 
normally never empty, herein the gastric emptying time is highly variable. After 24 hour of 
fasting, it has been shown that the stomach of an adult rabbit is still 50% full (Harboe, Larsen 
et al., 1989; Davies, Certzoomed et al., 2003). 
The stomach of pigs is two to three times larger than the stomach of humans and the cardiac 
mucosa occupies a greater portion of the stomach compared to the human stomach (Kararli, 
1995).  
1.4.1.3 Small intestine, pancreas and gall bladder 
The small intestine is the major site of absorption, due to its enormous surface and due to 
existence of villi and microvilli in all animals (Peetersg, Charlier et al., 1985; Kararli, 1995). 
In rabbits, the end of the ileum is expanded into a thick walled called sacculus rotundus, 
which seems to have an immunological function and is only found in Lagomorphs (Davies, 
Certzoomed et al., 2003; Merchant, Mcconnell et al., 2011). Like humans, rabbits are poor 
biliary excreters (Toutain, Ferran et al., 2010). Otherwise, rats are good biliary excreters, they 
do not have a gall bladder, and thus the bile enters the dudodenum continuously as it is made 
(Toutain, Ferran et al., 2010). 
1.4.1.4 Caecum and colon 
The large intestine provides a chamber for the final phase of digestion, for both herbivores 
(rabbits) and omnivorous (rats and pigs). The pig, rabbit and rat have a well-defined caecum 
whereas in man the caecum is very small and is continuous with the colon.  
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The colon of pig consists on, ascending, transverse and a portion of the descending colon 
coiled tightly into a series of centripetal and centrifugal coils. Pig has an extensive sacculation 
(haustra) and elongation of the large intestine (Swindle, Makin et al., 2011). The length and 
the capacity of the large intestine of pigs are about 1.5 - 3 times larger than that of humans 
(Christensen, Knudsen et al., 1999).  
In rats, the caecum is the main site of fermentation and represents 26% of the length of the 
large intestine. The colon of rats is not sacculated nor long and it is mainly important for re-
absorption of water and formation of faecal pellets (Desesso and Jacobson, 2001). Rats pratice 
coprofagy, i.e. they ingest part of their faeces, which allows the digestion of faecal bacteria 
and the intestinal absorption of vitamins and microbial protein (Hawksworth, Drasar et al., 
1971).  
In rabbits, the thin-walled caecum is a large organ (40–60% of the total volume of the 
gastrointestinal tract) that ends in an appendix which secretes bicarbonate ions into the caecal 
lumen, which are thought to act as a buffer for the volatile fatty acids produced by caecal 
fermentation (Davies, Certzoomed et al., 2003). The colon of rabbits is sacullated, and 
consists of a proximal and distal colon separated by a short transverse colon, and it ends with 
the fusus coli, which is responsible for the peristaltic waves on the colon (Davies, Certzoomed 
et al., 2003). Rabbits practice caecotrophy that is considered more sophisticated than 
coprophagy (Hörnicke, 1981). Rabbits produce two types of faeces: soft faeces, also named 
caecotrophs that are rich in vitamins, protein and minerals and regular hard faeces. The 
process of excretion of caecotrophs and immediate re-ingesting directly from the anus gives a 
second opportunity to benefit from valuable nutrient substances. Such physiological recycling 
usually occurs twice each day (Toutain, Ferran et al., 2010). 
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Table 1.7 Comparison of gastrointestinal pH between animal species under fed (ad 
libitum) state.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from references
 1
(Mcconnell, Basit et al., 2008) 
2
(Marounek, Vovk et al., 1995; Merchant, Mcconnell et 
al., 2011). 
1.4.1.5 Gastrointestinal microbiota 
The large intestine has higher concentrations and larger numbers of bacteria than the stomach 
and small intestine in all species, including the human (Stella, Borchardt et al. 2007). 
Moreover, fermentation process occurs in the stomach of both rats and rabbits. In rats, it 
Species Gastrointestinal tract 
region 
Mean pH values 
Rats 
1
 stomach 3.2 ± 1.0 
small 
intestine 
duodenum 5.0 ± 0.3 
jejunum 5.10 ± 0.3 
ileum 5.94 ± 0.4 
caecum 5.9 ± 0.4 
large 
intestine 
proximal 5.51 ± 0.5 
distal 5.77 ± 0.5 
Rabbit
 2
 stomach fundus 3.0 
antrus 1.6 
small 
intestine 
proximal 
distal 6.4 -7.0 
medium 6.9 - 7.2 
distal 7.2 - 7.4 
ileo-caecal junction 6.6 
caecum 6.0 - 6.1  
appendix 6.4 
Colon proximal 6.2 - 6.4 
distal 6.5 
Pig 
3
 stomach fundus 4.6 
antrum 4.4 
small 
intestine 
proximal 6.1 - 6.5 
medium 6.3 - 6.6 
distal 6.4 - 6.7 
caecum 6.1 
colon 
 
proximal 6.1 - 6.4 
medium 6.3 - 6.5 
distal 6.5 - 6.6 
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occurs due to ingestion of coprophages and in rabbits due to ingestion of caecotrophes. In the 
stomach of rats bacteria are autochthonous, i.e. permanently attached to the epithelium, and 
the faeces ingested only provide the buffer necessary for fermentation process (Hörnicke, 
1981). The presence of bacteria in stomach of rats is explained by the existence of a non-
glandular compartment in the stomach which permits the bacteria to proliferate in this non-
acid producing region. Consequently, rats have a large number of bacteria along the whole 
length of the gastrointestinal tract. The main organisms in stomach and small intestine of rats 
are Lactobacilli (Firmicutes Phylum), Bacteroides (Bacteroidetes Phylum) and Bifidobacteria 
(Actinobacteria Phylum) (Hawksworth, Drasar et al., 1971; Tannock, 1999) These organisms 
outnumber the enterobacteria (Proteobacteria phylum), mainly Escherichia coli by a factor of 
more than 10
2
 (Hawksworth, Drasar et al., 1971). 
In rabbits, caecothrophs are responsible for the existence of bacteria at the level of the 
stomach (Griffiths and Davies, 1963). The gastric pH in rabbits is generally maintained 
between 1 and 2 and increase to 3 in presence of caecotrophs (Davies, Certzoomed et al., 
2003). This gastric pH avoids the occurrence of fermentation in the gastric luminal of rabbits. 
Fermentation takes place inside caecothrophs, which are unaffected by the luminal pH, given 
the fact that they are covered by a mucous membrane. This membrane remains 
morphologically intact once caecotrophs are swallowed without mastication (Griffiths and 
Davies, 1963; Davies, Certzoomed et al., 2003). The bacteria, maintained at high pH by 
phosphate buffer, produces amylase which, together with the salivary and food amylases, 
degrades food starch to maltose and glucose. Thus, in rabbits, the caecotrophes provide both 
the buffer and the active microbes in fermentation (Griffiths and Davies, 1963). Although 
caecotrophy, the flora of rabbits at the level of the upper gastrointestinal tract is very simple 
and similar to that in man and the number of bacteria is much lower than in rats (Table 1.8) 
(Hawksworth, Drasar et al., 1971). The prevalent organisms in the upper gastrointestinal tract 
of rabbits are Bacteroids (Bacteroidetes Phylum) and Bifidobacterias (Actinobacteria 
Phylum), like in human (Kararli, 1995).  
Wkswortbh et al. reported the principal bacteria present in the large intestine of rats, rabbits 
and human. Microbiota present in this part of the gut of these animals belong to the 
Firmicutes Phylum (Enterococcus, Lactobacillus spp), Bacteroidetes Phylum (Bacteroids 
spp), Proteobacteria Phylum (Enterobacteriaceae spp, mainly Escherichia coli) and 
Actinobacteria Phylum (Bifidobacterium spp). The strictly anaerobic bacteria (Bacteroides 
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and Bifidobacteria) greatly outnumber the aerobes (enterobacteria and enterococci). 
Lactobacilli are present in very large number in the rat and in smaller numbers in the rabbit 
and man (Hawksworth, Drasar et al., 1971). 
The main bacteria populations in the lower intestine of pig belong to Firmicutes Phylum 
(Lactobacillus spp, Eubacterium spp, Clostridium spp), Bacteroidetes Phylum (Bacteroids 
spp), Proteobacteria Phylum (Enterobacteriaceae spp/ Echerichia coli) and Actinobacteria 
Phylum (Bifidobacterium spp) (Mountzouris, Balaskas et al., 2006; Reilly, Sweeney et al., 
2010).  
Table 1.8 Microbiota in different regions of the GI tract of the most commonly used 
laboratory animal models.  
Species Stomach Proximal small 
intestine 
Distal small 
intestine 
Large intestine Rectum and 
feces 
Rats1 107-109 106-108 107-108 108-109 109-1010 
Rabbits1 100-106 100-105 106-107 108-109 109-1010 
Pigs2 107-108.6 106.5 – 107.0 107.6 – 108.0 108.6 (caecum) 108.8 
Adapted from references 
1
 (Kararli, 1995) and 
2
(Desesso and Jacobson, 2001) 
From the viewpoint of bacteria distribution in the GI tract, rabbits may be more suitable than 
rodents as models to evaluate prodrug approach for colon-specific delivery (Stella, Borchardt 
et al., 2007).  
Relative to microbiota in the lower intestine, a huge similarity in terms of bacteria Phylum 
between all animals and human exists. As described before, in human, the dominant bacterial 
Phyla are the Firmicutes (Clostridium, Roseburia, Faecalibacterium and Ruminococcus 
species), Bacteroidetes (Bacteroides and Prevotella) and Actinobacteria (Bifidobacterium), 
normally with lower abundances of Verrucomicrobia and Proteobacteria (Wu, Chen et al., 
2011; Aziz, Doré et al., 2013; Chassard and Lacroix, 2013; Scott, Gratz et al., 2013).  
1.5 Project aims 
The research work presented in this thesis aims to synthesize a cyclodextrin-based prodrug of 
diclofenac and investigate its ability to target the colon. 
Therefore, the research work was designed and organized to meet the following aims: 
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- Development of a method to prepare cyclodextrin conjugates of diclofenac in a short 
reaction time and physical-chemical characterization obtained molecules (Chapter II). 
This would provide a reliable method to produce efficiently and conveniently new 
cyclodextrin conjugates in adequate quantities to proceed for further studies. 
- In vitro assessment of the stability of diclofenac-cyclodextrin conjugates in the upper 
gastrointestinal tract using simulated gastrointestinal fluids and animal fluids to 
predict in vivo behaviour. Investigate the ability of the conjugate to site-specific 
release of diclofenac on the colon and compare the performance of this type of 
prodrug with the classic prodrug sulfasalazine. This would allow accessing the inter-
species variability on the metabolism of produgs and the establishment of the best 
animal model to perform the in vivo studies (Chapter III). 
- Investigate the influence of different feeding regimens on the distribution and pH 
contents along the gut and on the metabolism of cyclodextrin conjugates (Chapter IV). 
This would provide information necessary to understand the importance of the feeding 
state on the drug disposition. 
- Investigate the in vivo behaviour of the cyclodextrin conjugates versus sulfasalazine 
and determine the potential of cyclodextrin to be used as a carrier to colon specific 
delivery (Chapter V). 
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2 SYNTHESIS AND CHEMICAL CHARACTERIZATION OF DICLOFENAC-
CYCLODEXTRIN CONJUGATES 
2.1 Introduction 
Natural cyclodextrins (CDs), namely α-, β- and γ- have been studied as carriers for colonic 
drug delivery. Due to their size and hidrophilicity, they are not absorbed through the intestine. 
Cyclodextrins, α- and β- , contrarily to γ-cyclodextrin can pass intact through the upper 
gastrointestinal tract and only when reach the colon they are metabolized, as described in 
Chapter I. Thus, α- and β-cyclodextrins are the most interesting cyclodextrins to work as 
carriers.  
To develop a stable colonic specific prodrug, it is important to produce a linkage between 
CDs and a drug. The linkage should be sufficiently stable to survive the transit through the 
stomach and small intestine, but also susceptible to be broken only at the colon level where 
the drug is released. 
However, to generate this linkage between a cyclodextrin and a drug, several challenges 
related with the own CDs and the structure of the drug need to be addressed. Not all the drugs 
that are candidates to colon delivery can be modified to a prodrug. For a drug to become a 
colon-specific prodrug, it needs to have an appropriate functional group suitable for 
conjugation (Jung and Kim, 2010). Otherwise, synthesis of CDs conjugates is associated with 
a wide variety of physical-chemical processes that can succeed, owing to the presence of the 
hydrophobic cavity and a large number of hydroxyl groups that provides molecule 
nucleophilicity. 
For this reason, what follows is a description of the main physical-chemical characteristics of 
cyclodextrins as a molecule, as well as of diclofenac, with the purpose of link both in order to 
get specific delivery of the anti-inflammatory drug in the colon. 
 Cyclodextrin chemistry 2.1.1
The α-, β-, and γ-cyclodextrin contain 18, 21 and 24 hydroxyl groups, respectively. Thus, 
each cyclodextrin moiety potentially has several sites of modification. The available 
modifications of cyclodextrin will occur at the hydroxyl groups, taking advantage of their 
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nucleophilicity, which directs regioselectivity and the extent of modification (mono-, di-, etc) 
(Khan, Forgo et al., 1998). 
 
 
Figure 2.1 α-1,4 glycosidic bond and the three different types of hydroxyl groups of a 
cyclodextrin. 
The primary and secondary hydroxyl groups have different reactivities, but also the two 
secondary hydroxyl groups between them. This last difference is due to the fact that the 
hydroxyl groups at C-2 are closer to the hemi-acetal than the hydroxyl groups at C-3. This 
makes the hydroxyl groups attached at C-2 slightly more acidic, hence slightly more reactive 
and consequently more susceptible to deprotonation than the hydroxyl groups at C-3. These 
hydroxyl groups at position 3 are the most inaccessible because they are sterically hindered. 
On the other side, the hydroxyl groups at the C-6-position are the most basic (and often most 
nucleophilic) (Hybl, Rundle et al., 1965; Saenger, Noltemeyer et al., 1976). Thus, an 
electrophilic reagent attacks at the most reactive C-6 hydroxyl groups. Then, under anhydrous 
conditions, the C-2 hydroxyl groups are the most vulnerable to deprotonation (Saenger, 
Noltemeyer et al., 1976). Bulky reagents tend to react preferentially at the primary C-6 
hydroxyl groups of the macrocycle because these have easier access (Khan, Forgo et al., 
1998). It is important to recognize that more reactive reagents will attack the hydroxyl groups 
less selectively (Khan, Forgo et al., 1998).  
Synthesis of cyclodextrin conjugates at position 6 has been investigated by some authors 
(Uekama, Minami et al., 1997b; Udo K, Hokonohara K et al., 2010). This modification is 
easier since primary hydroxyl groups are more nucleophilic than their secondary counterparts. 
However, is not only the nucleophilicity of the hydroxyl groups that dictates the site of 
reaction. Other factors determine the nature of the product. If the electrophilic reagent forms a 
Primary hydroxyl 
Secondary hydroxyl 
α -1,4-glycosidic bond 
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complex with cyclodextrin, then the orientation of the reagent within the complex introduces 
an additional factor in determining the nature of the product (Ueno and Breslow, 1982). If the 
complex formed is very strong, then the predominant product formed will be directed by the 
orientation of the reagent within the complex. On the other hand, if the complex is weak, then 
the product formation will be directed by the relative nucleophilicities of the hydroxyl groups 
(Ueno and Breslow, 1982). 
It is also important to note that solvents play an important role in determining the strength and 
the orientation of the complex between the reagent and cyclodextrin. Thus, for example tosyl 
chloride reacts with α-cyclodextrin in pyridine to give the 6-tosylated product whereas, in 
aqueous base, it gives the 2-tosylated product (Fujita, Nagamura et al., 1984). 
The size of the cyclodextrin cavity also affects the strength and the orientation of the complex 
and affects the product of the reaction. For example, in aqueous solutions, tosyl chloride 
reacts with α-cyclodextrin to give the 2-substituted product; whereas with  
β-cyclodextrin, it gives the 6-substituted product (Takahashi, Hattori et al., 1984b). 
 Diclofenac chemistry 2.1.2
Diclofenac, 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid is a synthetic non-steroidal 
anti-inflammatory. It is a weak acid with a pKa of 4 and a partition coefficient  
(n-octanol:aqueous buffer, pH 7.4) of 13.4 (Palomo, Ballesteros et al., 1999).  
It is manufactured via a stable intermediate, 1-(2,6-dichlorophenyl) indolin-2-one (Figure 
2.2), which is commonly known as the indolinone derivative, by heating in the presence of 
sodium hydroxide (Yasumitsu Tamura, Jun-Ichi Uenish et al., 1984; Roy, Islam et al., 2001). 
The molecule of diclofenac, from a point of view of its structure, is a hybrid between a 
fenamic and an acetic acid class derivative; the characteristic feature is the presence of a 
secondary amino group (N-H) bridging two aromatic rings and representing the source of a 
series of intramolecular H-bonds towards a chlorine atom of one and the carboxyl group of 
the other aromatic ring of the diclofenac molecule. Other H-bonds exists between the 
carboxyl groups of two different molecules of diclofenac, which face together in a dimer. The 
dimer form represents a structural unit of the solid state of diclofenac, like that of most 
carboxylic acids. All the H-bonds involve the hydrophilic groups inside the dimer inter- and 
intra-molecularly and therefore make the diclofenac molecule less available to intermolecular 
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interaction with the environment, such as the water molecules of the solvent (Castellari and 
Ottani, 1997; Fini, Cavallari et al., 2010). 
                            
 
Figure 2.2 I- 1-(2,6-dichlorophenyl) indolin-2-one structure, precursor on the synthesis 
of diclofenac. II- Diclofenac: (2-(2,6-dichloranilino) phenylacetic acid) structure.  
 Design of diclofenac-cyclodextrin ester conjugate 2.1.3
Although an ester bond is not a suitable linkage for colon-specific drug delivery considering 
that esterases are abundant in the whole gastrointestinal tract without significant regional 
preference (Inoue, Morikawa et al., 1979), ester prodrugs of not only cyclodextrins but also 
dextrans have been developed with a good colon-targetibility (Jung and Kim, 2010). 
2.1.3.1 Strategies to synthesize ester cyclodextrin conjugates 
The literature describes the synthesis of ester conjugates of cyclodextrins using several 
methods, including: i) activation of drug carboxylic group using a carbodiimide derivative, 
following reaction with an hydroxyl group of the cyclodextrin (Yano, Hirayama et al., 2001; 
Namazi, Bahrami et al., 2005; Zou, Okamoto et al., 2005; Dev, Mhaske et al., 2007; Prabhu, 
D.Satyanarayana et al., 2009; Udo, Hokonohara et al., 2010) ii) formation of an acid chloride 
of the drug and posterior reaction with cyclodextrin (Ventura, Paolino et al., 2003b); iii) 
modification of CDs hydroxyl groups, by an electrophilic reagent, leading to the formation of 
one group more labile to nucleophilic substitution.  
i) Activation of drug carboxylic group using a carbodiimide derivative, following 
reaction with a hydroxyl group of the cyclodextrin. 
Carbodiimide derivatives are powerfull desidratant agents that react with the carboxylic group 
of the drug and allow the formation of an intermediate derivative sufficiently active to react 
with the hydroxyl groups of the cyclodextrin. The rate of this reaction also depends very 
I II 
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much on the nucleophilicity of their anions. Dicyclohexylcarbodiimide (DCC) has been the 
most commonly used carbodiimide and is regarded as a standard (Michael Smith, J.G. Moffatt 
et al., 1958). It is a non-aqueous carbodiimide that has been used to synthesize cyclodextrin 
conjugates of mefenamic acid (Dev, Mhaske et al., 2007), ibuprofen, indomethacin (Namazi, 
Bahrami et al., 2005) and β-lactam antibiotics (Namazi and Kanani, 2007). 
Carbonyldiimidazole (CDI) represents an alternative carbodiimide, but it is less frequently 
used, most probably due to cost and its sensitivity to moisture. This carbodiimide has been 
used to form cyclodextrin conjugates of 5-fluorouracil-1-acetic acid (Udo K, Hokonohara K et 
al., 2010), 5-aminosalicylic acid (Zou, Okamoto et al., 2005) and prednisolone (Yano, 
Hirayama et al., 2001).  
 
Figure 2.3 Synthetic scheme of synthesis of drug-cyclodextrin conjugate by a 
carboodimiide activation of the drug.  
A water soluble carbodiimide such as dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (EDAC) can be used to facilate the purification of the product (Albert and 
Hamilton, 2001).  
Based on the literature, reactions between acids and carbodiimides in general occurs rapidly 
(Khorana, 1953). 4-dimethylaminopyridine (DMAP) (pKa=9.70) can assist on the 
Drug Drug-intermediate 
O-acylisourea  intermediate Cyclodextrin 
Carbodiimide 
Drug-cyclodextrin conjugate 
Step 1 
Step 2  
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deprotonation of the nucleophile working as a nucleophilic acylation catalyst (Albert and 
Hamilton, 2001). 
ii) Formation of an acid chloride of the drug and posterior reaction with 
cyclodextrin. 
Formation of an acid chloride of anti-inflammatory drug and posterior reaction with 
cyclodextrin constitutes other method to synthetize cyclodextrin conjugates. This method was 
adopted to synthetize dimethyl-beta-cyclodextrin-4-biphenylylacetic acid conjugate (Ventura, 
Paolino et al., 2003a) 
 
Figure 2.4 Synthetic scheme of synthesis of drug-cyclodextrin conjugate by formation of 
an acid chloride of the drug and posterior reaction with cyclodextrin. 
iii) Modification of β-cyclodextrin hydroxyl groups, by an electrophilic reagent, 
leading to the formation of one group more labile to nucleophilic substitution. 
Another possibility to achieve the required conjugation is through transformation of the 
hydroxyl groups of cyclodextrin by an electrophilic agent, followed by nucleophylic attack by 
the diclofenac sodium salt. 
Drug Thionyl chloride Drug acid chloride 
Cyclodextrin Drug-cyclodextrin conjugate Drug acid chloride 
Step 1 
Step 2 
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Transformation of the hydroxyl group at 6-position into a 6-toluenesulfonylcyclodextrin was 
adopted by many authors. Since the tosyl group is a good leaving group, it may undergo 
displacement with a wide variety of nucleophiles to produce a series of monosubstituted 
cyclodextrins. 
 
Figure 2.5 Synthetic scheme of synthesis of drug-cyclodextrin conjugate by nucleophilic 
substitution at the cyclodextrin structure. 
This strategy was adopted particularly in the synthesis of the β-cyclodextrin ester of ibuprofen 
(Coates, Easton et al., 1991) fluribuprofen, 2-phenylpropanoic acid and N-acetylphenylalanine 
(Coates, Easton et al., 1994). Also for the synthesis of cyclodextrin conjugates with fenilacetic 
acid (Uekama, Minami et al., 1997b), etodolac (Rizzarelli, Vecchio et al., 2007), ketoprofen 
(Kamada, Hirayama et al., 2002),  
n-butyric acid (Hirayma, Ogata et al., 2000), naproxen, and flurbiprofen (El-Kamel, 
A.M.Abdel-Aziz et al., 2008).  
Step 2 
Cyclodextrin p-Toluenesulfonyl chloride Tosyl cyclodextrin derivative 
Tosyl cyclodextrin 
 
Drug Drug-cyclodextrin conjugate 
Step 1 
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2.2 Aims and Objectives 
The aim of this Chapter is to investigate a method to synthesize diclofenac-cyclodextrin 
conjugates. In order to pursue this, the following objectives were defined: 
- establishment of a reproducible method to synthesize diclofenac-β-cyclodextrin conjugate; 
- chemical characterization of the obtained conjugate;  
- evaluation of the ability of the chosen method used to synthesize diclofenac-β-cyclodextrin, 
and also to synthesize the other γ- and α- conjugates. 
2.3 Materials 
 Chemicals 2.3.1
β-cyclodextrin was purchased from Roquette. β-cyclodextrin hydrated (MW=1,134.98 g/mol), 
DCC, CDI EDAC, DMAP, p-toluenesulfonyl chloride, 2,4,6-triisopropylbenzenesulfonyl 
chloride, Diaion-HP-20 trifluroacetic acid and acetone were purchased from Sigma. Sodium 
diclofenac (MW=318.13 g/mol) was kindly provided by Labesfal Genéricos (Portugal). 
Dimethylformamide (DMF), sodium hydroxide, ethyl acetate, isopropanol, ethanol, 
ammonium chloride, methanol, acetonitrile, thionyl chloride, tetrahydrofuran (THF), 
triethylamine (TEA) ethanol, acetonitrile and water for HPLC, were purchased from Fisher 
Scientific. Deuterated dimethyl sulfoxide (DMSO-d6) was purchased from Euriso-top 
(Peypin, France). Ammonia, acetic acid, pyridine, sulfuric acid and p-anisaldehyde were 
purchase from Acros Organics. DC Silicagel 60 F254 was purchased from VWR. 
Pyridine was kept dry over potassium hydroxide and DMF over molecular sieves 4Å prior to 
use. 
Diclofenac free acid was obtained according to the method described by Fadda et al. Briefly, 
a saturated aqueous solution of diclofenac sodium salt was acidified with diluted hydrochloric 
acid until a white precipitate of diclofenac acid was observed. The precipitate was filtered, 
washed with bidistilled water and air dried (Lai, Sinico et al., 2009). 
Other chemicals and solvents were of analytical reagent grade and deionized water was used. 
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2.4 Methods 
 Synthesis of diclofenac-β-cyclodextrin conjugate. 2.4.1
Several methods were investigated to synthesize ester diclofenac-β-cyclodextrin conjugate 
including: 
2.4.1.1 Activation of diclofenac carboxylic group using a carbodiimide derivative, 
following reaction with a hydroxyl group of the cyclodextrin. 
Briefly, sodium diclofenac (1.57 mmol) was dissolved in DMF. DCC (1.57 mmol) was then 
added to the solution, and the mixture stirred at 0 
o
C for 2 hours, adapting the method 
reported previously (Dev, Mhaske et al., 2007). After the addition of the cyclodextrin in 
DMF, the mixture was stirred at room temperature. Different conditions were tested following 
this procedure, including the addition of DMAP as a catalyst (Albert and Hamilton, 2001). 
Replacement of sodium diclofenac by diclofenac free acid was also performed (Manfredini, 
Pavan et al., 2002). Other carbodiimides derivatives were tested, namely CDI (Udo, 
Hokonohara et al., 2010) and EDAC (Bakar, Oelgemöller et al., 2009).  
2.4.1.2 Formation of an acid chloride of the drug followed by reaction with 
cyclodextrin. 
For the synthesis of diclofenac chloride, diclofenac free acid (3.37 mmol) was refluxed with 
thionyl chloride (10 mL) for 5 hours. After this step, β-cyclodextrin was added to diclofenac 
chloride and the reaction proceeded until formation of the conjugate. This method was 
performed adapting those described by Puglisi et al.(Ventura, Paolino et al., 2003a) and by 
Picci et al. (Cassano, Trombino et al., 2010). 
2.4.1.3 Modification of β-cyclodextrin hydroxyl groups by an electrophilic reagent, 
leading to the formation of one group more labile to nucleophilic substitution. 
Diclofenac-β-cyclodextrin was synthesized through a 2-steps process involving tosylation of 
β-cyclodextrin (Step 1) and nucleophylic substitution of tosylated β-cyclodextrin by sodium 
diclofenac (Step 2). 
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2.4.1.3.1 Step 1: tosylation of β-cyclodextrin 
Tosylated β-cyclodextrin was synthesized adapting the procedure described by (Mcnaughton, 
Engman et al., 2004). Briefly, to a solution of 5 g of β-cyclodextrin (4.4 mmol) in water (110 
mL) 1.25 g of p-toluenesulfonyl chloride (6.55 mmol) was added and the resultant solution 
was stirred at room temperature for 2 hours under inert atmosphere. Aqueous sodium 
hydroxide (NaOH) (2.5 M, 20 mL) was added and the solution stirred for 10 minutes before 
unreacted p-toluenesulfonyl chloride was filtered off. 5.8 g of ammonium chloride (108 
mmol) was added to lower the pH to approximately pH 8. The solution was cooled overnight 
and the resultant white precipitated collected by filtration. The white powder was washed with 
acetone and water to remove the non-reacted cyclodextrin and then dried under vacuum. The 
product obtained was used directly in the next step. 
2.4.1.3.2 Step 2: nucleophilic reaction 
This step was performed following two different approaches - with and without the use of 
microwaves. 
Non-microwave reaction: 
In this method sodium diclofenac (0.7 mmol) was added to β-cyclodextrin tosylate (0.5 
mmol) in anhydrous DMF (5 mL) and the mixture stirred at 100 ºC for 24 hours (Hirayma, 
Ogata et al., 2000). 
Microwave reaction: 
Reactions were carried out in an appropriate 10 mL thick walled glass vials under closed 
vessel conditions using CEM Discover S-class single mode microwave reactor with 
temperature, pressure and microwave power monitoring. 
Sodium diclofenac (0.333 mmol) was dissolved in 3 mL of anhydrous DMF containing β-
cyclodextrin tosylate (0.327 mmol) in an appropriate thick-walled glass vial. The reaction 
vessel was then sealed with a teflon
®
 cap and the reaction mixture magnetically stirred and 
heated at 140 
o
C for 40 minutes under focused microwave irradiation with an initial power 
setting of 75 W. The product obtained was precipitated in acetone, filtered, washed several 
times with acetone and ethyl ether and dried. In order to obtain a purified sample, 300 mg of 
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the crude product was passed through DIAION HP-20 ion-exchange chromatography column 
eluting with water/methanol, and steadily increasing the methanol content. The conjugate was 
eluted with 80% methanol. Methanol in the eluate was removed under reduced pressure, the 
solution lyophilized in a freeze-dryer (Lyph-lock 6 apparatus, Labconco) for 72 hours and the 
diclofenac-β-cyclodextrin was obtained with a yield of 20%. 
1
H NMR (500 MHz, DMSO-d6) δ (ppm) 7.52 (d, H-5’, H-3’ of Diclofenac), 7.22 (d, H-4’’ of 
Diclofenac), 7.20 (t, H-4 of Diclofenac), 7.05 (t, H-6’’ of Diclofenac), 6.83 (t, H-5’’ of 
Diclofenac), 6.25 (d, H-7’’ of Diclofenac), 5.66–5.84 (m, OH-2 and OH-3 of β-cyclodextrin), 
4.83 (d, H-1 of β-cyclodextrin), 4.21–4.55 (m, OH-6, H-6 of β- cyclodextrin), 3.50–3.90 (m, 
H-6, H-3 and H-5 of β-cyclodextrin), 3.25–3.43 (m, H-2, H-4 of β-cyclodextrin), MS 
(MALDI) m/z for C56H79Cl2NNaO36, found 1434.308 [conjugate+Na]. 
 Applicability of the nucleophilic microwave approach on the synthesis of diclofenac-2.4.2
γ-cyclodextrin and diclofenac-α-cyclodextrin 
2.4.2.1 Diclofenac-γ-cyclodextrin 
2.4.2.1.1 Step 1: tosylation of γ-cyclodextrin 
Synthesis of 6-monotosyl-γ-cyclodextrin  
Tosylated γ-cyclodextrin was synthesized adapting the procedure described in the literature to 
produce γ-cyclodextrin ditosylated (Kahee Fujita, Hatsuo Yamamura et al., 1988). In this 
case, p-toluenesulfonyl chloride (2.02 g, 10.5 mmol) was added to a solution of γ-cyclodextrin 
(2.02 g, 1.55 mmol) in pyridine (20 mL) and stirred for 2 hours at room temperature under 
nitrogen atmosphere followed by addition of ethanol (20 mL). After addition of acetone, a 
solid precipitated was collected by filtration, washed with acetone, and dried under vacuum 
and at 100 ºC to afford 1-2 g of tosylate. This material can be re-crystallized by dissolving it 
in isopropanol at boiling temperature and then addition of water followed by cooling to room 
temperature, and storage in a refrigerator overnight. 
Synthesis of Mono-6-(O-2,4,6-triisopropylbenzenesulfonyl)-γ-cyclodextrin  
The synthesis was perfomed adapting the method described by Ronald Palin et al. (Palin, 
Grove et al., 2001). To a dry round-bottomed flask pyridine (10 mL) was added, followed by 
γ-cyclodextrin (1.0 g, 0.77 mmol) and 2,4,6-triisopropylbenzenesulfonyl chloride (0.7 g, 2.3 
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mmol) at room temperature under nitrogen. After 24 hours, 100 mL of acetone was added to 
the mixture. 
2.4.2.1.2 Step 2: Nucleophilic reaction - microwave approach 
Sodium diclofenac (79.5 mg, 0.25 mmol) was dissolved in 3 mL anhydrous DMF containing 
γ-cyclodextrin tosylated (376 mg) in an appropriate thick-walled glass vial. The reaction 
vessel was then sealed with a teflon® cap and the reaction mixture was magnetically stirred 
and heated at temperature varying between 130-160 ºC for 20-40 minutes under focused 
microwave irradiation with an initial power setting of 75 W.  
After cooling to room temperature, the product was precipitated in acetone. The precipitate 
was filtered and washed several times with acetone and diethyl ether, filtered off and then 
dried. Then the product was purified through by DIAION HP-20 ion-exchange 
chromatography eluting with water/methanol with increasing methanol content. The 
conjugate appeared with a composition of 80% methanol. Methanol in the eluate was 
removed under reduced pressure and the solution was lyophilized. Yield of isolated, pure 
product: 10-30%. 
2.4.2.2 Diclofenac-α-cyclodextrin 
2.4.2.2.1  Step 1: tosylation of α-cyclodextrin 
Tosylated α-cyclodextrin was synthesized adapting the procedures described in the literature 
(Melton and Slessor, 1971; Weihua Tang and Ng, 2008). Briefly, 1 g (1 mmol) of γ-
cyclodextrin was added to pyridine (10 mL) under stirring at room temperature under 
nitrogen. p-Toluenesulfonyl chloride was dissolved in 5 mL of pyridine and then added 
slowly during 30 minutes to the mixture of α-cyclodextrin in pyridine for 3 hours. After that, 
the reaction was stopped by the addition of acetone. The crude product was washed with 
methanol in order to eliminate pyridine. 
2.4.2.2.2 Step 2: nucleophilic reaction - microwave approach 
The protocol followed was the same used to prepare diclofenac-γ-cycldoextrin conjugate. 
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 Characterization 2.4.3
The control of reactions was perfomed using thin layer chromatography (TLC). TLC was also 
used to monitorize elutes from the chromatography and the purification of the end products. 
One or more of the following techniques confirmed the identification of the obtained 
compounds: proton nuclear magnetic resonance (
1
H NMR) spectroscopy; matrix-assisted laser 
desorption/ ionization (MALDI) spectroscopy; infrared (IR) spectroscopy; and high 
performance liquid chromatography (HPLC). 
Thin layer chromatography (TLC) was conducted on aluminum plates percoated with silica 
gel F254 (Merck & Co.) and eluted with a mixture of 2-propanol/ethyl acetate/water/ammonia 
(6:1:3:1) or acetonitrile/water/ammonia (6:3:1). 
For spot detection the plates were immersed in a mixture of p-anisaldehyde (2 mL)/ethanol 
(36 mL)/acetic acid (5–6 drops)/sulfuric acid (2 mL). The plate was heated to 150 °C for 5 
minutes in order to visualize the spots. 
MALDI-TOF mass spectra were obtained on an Autoflex III, Bruker using methanol and 
water as solvents and α-cyano-4-hydroxy-cinnamic acid (HCCA) as matrix. 
1
H NMR spectra were acquired on a Varian Unity-500MHz spectrometer, using DMSO-d6 as 
solvent and tetramethylsilane (TMS) as an internal reference. 
IR spectra were obtained using Thermo Scientific Nicolet 6700 FT-IR spectrometer by 
scanning KBr disks of the samples. 
An HPLC system (model HP1100 series, Hewlett Packard, Germany) equipped with an 
autosampler (Agilent 1100 series, Germany) was used. A reversed-phase X-Terra C-18 
column, 5 μm, 4.6 mm × 250 mm (Waters, USA), with a pre-column, was employed. Mobile 
phase consisted of acetonitrile (ACN) and 0.4% trifluoroacetic acid (TFA) in water, an 
injection volume of 20 μL and detection at 254 nm at 30 °C 
For analysis of the products of reactions, a gradient system of 0.4% TFA in water (A) and 
acetonitrile (B) was followed: 0-15 minutes 10-90% B; 15-22 minutes 90-10% B. The sample 
injection volume was 20 µl, the flow rate is 1.2 mL/min and detection wavelength was 254 
nm at 30 ºC. For the analysis of the products of the chemical stability assays, the gradient 
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system was: 0-15 minutes 25-60% B; 15-22 minutes 60-25% B, with a flow rate of 1.0 
mL/min. 
 Chemical stability of diclofenac-β-cyclodextrin in aqueous buffer solutions 2.4.4
Hydrolyses of conjugate was assessed in different buffer solutions namely: pH 1.2, acetate 
buffer 4.5, phosphate buffer pH 6.8, phosphate buffer 7.4. Preparation of the buffers is 
described in Appendix A. 
Solutions of conjugate were prepared by dissolving an accurately weighed amount of 
conjugate (4 mg) in 5 mL of each buffer containing 1% of DMF (Table 2.1). 
The samples were incubated at 37 ºC and shaken at 100 rpm. At fixed intervals, 100 µL were 
withdrawn, mixed with 400 µL of methanol and analyzed by HPLC to determine the 
percentage of conjugate under the aforementioned conditions. Each experiment was 
performed in triplicate. 
Table 2.1 Schematic representation of the stability tests of diclofenac-β-cyclodextrin in 
different buffers. 
Buffer solution 
(1% DMF) 
[Conjugate] 
buffer solution 
 Sampling 
volume  
 
Final volume 
(addition 
methanol) 
Final 
[conjugate] 
pH 1.2 
800 µg/mL 
 
100 µL 
 
500 µL 
 
160 µg/mL 
 
pH 4.5 
pH 6.8 
pH 7.4 
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2.5 Results and discussion 
 Synthesis and characterization of diclofenac-β-cyclodextrin conjugate 2.5.1
2.5.1.1 Activation of diclofenac carboxylic group using a carbodiimide derivative, 
following reaction with a hydroxyl group of the cyclodextrin 
The first approach was the carboxylic activation by  dicyclohexylcarbodiimide derivatives 
following a general procedure (Dev, Mhaske et al., 2007) with (DMAP) (Manfredini, Pavan et 
al., 2002; Li, Rossoni et al., 2007; Nemmani, Mali et al., 2009). This attempt failed to 
generate the required product. The substitution of DCC by other water insoluble carbodiimide 
derivative, CDI, or by EDAC, a water soluble carbodiimide also failed. Analysis of the NMR 
spectra did not show the expected product.  
Results suggest that the nucleophylic attack of the hydroxyl group of cyclodextrin cannot 
compete with the more favorable intramolecular acylation by the nearby amino group 
(Palomo, Ballesteros et al., 1999). 
 
 
Figure 2.6 Intramolecular cyclization reaction of diclofenac (Palomo, Ballesteros et al., 
1999).  
 
1-(2,6-dichlorophenyl)-indolin-2-one 
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Additionally, in order to clarify the reactivity of the two diiferent nucleophilic centers of 
diclofenac (NH, COOH) the reaction of diclofenac with benzyl bromide was performed in a 
mixture of DMF and acetonitrile. An ester of diclofenac was obtained in the form of crystals 
with considerable dimensions (see Appendix B). This result allows concluding that the 
carboxylic acid is more reactive than the amine and that carbodiimides are not reacting at the 
level of the amine group.  
2.5.1.2 Formation of an acid chloride of the drug followed by reaction with 
cyclodextrin 
Following the procedure described for the formation of an acid chloride of the drug, 
diclofenac was dissolved in thionyl chloride, but immediately the reaction solution became 
intensely red. The isolated product did not correspond to chloride acid of diclofenac. It is 
possible, therefore, that an intramolecular acylation of the diclofenac amino group had 
occured (Mcmaster and Ahmann, 1928). 
 
 
Figure 2.7 Preferential cyclization of the diclofenac molecule suggested by the lack of 
success on the attempt of synthesize an acid chloride. 
2.5.1.3 Modification of β-cyclodextrin hydroxyl groups, by an electrophilic reagent, 
leading to the formation of one group more labile to nucleophilic substitution 
This method involved two main steps: the transformation of the hydroxyl group at  
6-position into a 6-p-(toluenesulfonyl) cyclodextrin (Step 1) and nucleophylic substitution of 
tosylated cyclodextrin by sodium diclofenac (Step 2), as described previously. 
Diclofenac acid chloride  Cyclization of the acid chloride  
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2.5.1.3.1 Step 1: tosylation of β-cyclodextrin 
The major challenge of the first step was to achieve monotosylation of cyclodextrin 
specifically to the 6-position without considerable amounts of primary and secondary side 
multi-tosylated by-products. (Khan, Forgo et al., 1998; Brady, Lynam et al., 2000) This 
selective sulfonylation generally occurs in dry pyridine (Weihua Tang and Ng, 2008), or in 
water at alkaline pH (Brady, Lynam et al., 2000). 
Firstly, it was thought that the reaction between tolylsulfonyl chloride and β-cyclodextrin in 
water resulted in the introduction of the tosyl group on the secondary alcohol side of 
cyclodextrin (Onozuka, Kojima et al., 1980). This was later corrected (Takahashi, Hattori et 
al., 1984a), proving the formation of monotosylated cyclodextrin on the primary hydroxyl of 
cyclodextrin. This process is accompanied by host-guest complex formation between 
cyclodextrin and tosyl chloride in aqueous solution (Onozuka, Kojima et al., 1980; Takahashi, 
Hattori et al., 1984a). Both solvents, pyridine and alkaline solution allow substitution of 
primary hydroxyl of β-cyclodextrin (Keiko Takahashi, Kenjiro Hattori et al., 1984). However, 
pyridine is a non-user-friendly solvent and forms a pyridinium complex with the cyclodextrin 
cavity, complicating the process of purification (Khan, Forgo et al., 1998). Due to these facts, 
the method using water as solvent was the one selected to prepare the 6-p-toluenosulfonyl-β-
cyclodextrin derivative using p-tolylsulfonyl chloride (Brady, Lynam et al., 2000).  
 
Figure 2.8 Synthetic scheme of preparation of mono-6-tosyl-β-cyclodextrin. I- β-
cyclodextrin; II- Tosyl β-cyclodextrin. 
Following the procedure  using p-toluenesulfonyl chloride in water (Mcnaughton, Engman et 
al., 2004), gram amounts of the 6-p-toluenosulfonyl-β-cyclodextrin were obtained being then 
 
I II 
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characterized by NMR spectroscopy and MALDI-TOF spectrometry. For the substitution 
reaction, this product was used without purification, despite the presence of small amounts of 
di- and tri-tosilated derivatives as verified by MALDI analysis. 
Mono-6-sulfonylciclodextrins can also be prepared in alkaline solution using other sulfonyl 
derivatives namely p-toluenesulfonic anhydride (Zhong, Byun et al., 1998) or  
1-(p-toluenesulfonyl) imidazole (Brady, Lynam et al., 2000) accompanied by higher yields 
(61% and 40% respectively), rather than that obtained using of p-toluenesulfonyl chloride also 
in water: 34% (Jicsinszky and Iványi, 2001), 11% (Petter, Salek et al., 1990), 6.3% (Dragos 
Vizitiu, Caroline S. Walkinshaw et al., 1997) 25% (Brady, Lynam et al., 2000) and 32% 
(Mcnaughton, Engman et al., 2004). However, difficulties in preparing tosic acid free p-
tolunesulfonic anhydride frequently results in lower yield, 1-(p-toluenesulfonyl) imidazole 
also needs to be prepared previously, which implies a higher procedure to obtain sulfonated 
cyclodextrin (Brady, Lynam et al., 2000).  
2.5.1.3.2 Step 2: nucleophilic reaction 
The required following step was the nucleophylic substitution of the tosyl group by the 
diclofenac.  
i) Non-microwaves reaction  
Following the conventional strategies the reaction between tosylcyclodextrin and diclofenac 
in DMF does not result in an ester formation. The work of Jiben Roy et al. and also of Petar 
Tudja et al., showed that under heating conditions diclofenac can suffer dehydratation and an 
intramolecular cyclization (Roy, Islam et al., 2001; Tudja, Khan et al., 2001). 
Our efforts led us to the conclusion that with this strategy some different approach should be 
taken. 
ii) Microwaves reaction 
Our efforts led us to conclude that an alternative strategic approach should be taken.  
Microwave irradiation has long been viewed as an interesting alternative to the use of 
classical heating systems, and particularly in the field of organic synthesis, largely due to the 
Chapter II 
61 
increases in reaction rates, improved yields and selectivities associated with this technique 
(Richel, Laurent et al., 2011). 
Nucleophylic substitution of tosyl group by the sodium diclofenac was achieved in DMF 
under microwave irradiation. The diclofenac-β-cyclodextrin conjugate was obtained after a 
systematic study of temperature and microwave conditions.  
 
 
Figure 2.9 Synthetic scheme for the preparation of diclofenac-β-cyclodextrin conjugate.  
I - tosyl β-cyclodextrin, II - sodium diclofenac, III - diclofenac-β-cyclodextrin. 
An HPLC study of different samples prepared under different reaction temperatures showed 
that reactions undertaken at 140 
o
C produced the best yield. As temperature increases, it is 
also possible to observe a decrease in diclofenac-β-cyclodextrin yields. This is likely due to 
the degradation that diclofenac suffers at high temperatures (Tudja, Khan et al., 2001; 
Galmier, Bouchon et al., 2005 ). 
The use of microwave radiation additionally led to the conjugate formation, with a short 
reaction time and less solvent, comparatively to the conventional processes required for the 
preparation of cyclodextrin conjugates (Hirayama, Ogata et al., 2000). 
+
I I
I 
III 
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Figure 2.10 HPLC chromatograms of crude product of conjugates synthesized under 
microwave irradiation conditions for 40 minutes under different temperatures: A: 100 
ºC; B: 140 ºC; C: 160 ºC; D: 200 ºC. The numbers represent the area of the 
corresponding peak. Conjugate retention time: 8.0 minutes; diclofenac retention time 
11.9 minutes. Elution conditions are described in point 2.4.3. 
After chromatographic purification, about 20% yield of product was achieved, and the 
microwave approach to the synthesis of this conjugate proved to be consistently reproducible. 
It is reported that solvolysis of the tosylated cyclodextrins compete with the desired 
nucleophilic substitution when the reaction is carried out in water, producing cyclodextrins 
(Melton and Slessor 1971), which can contribute to the low yield of the reaction. Thus, it is 
important the use of dry DMF as well as the use of very well dry intermediate tosylated 
cyclodextrin. 
Moreover, it was observed that when diclofenac is dissolved in DMF in the absence of 
cyclodextrin tosylated reagent and submitted to the same conditions than that used to perform 
the nucleophilic reaction in microwaves, the solution presented a green dark colour. This 
proves that simultaneous decomposition of sodium diclofenac into other compounds occurs 
when nucleophilic reaction is carried out. Previously, it were found some changes of the 
colour of diclofenac, when heated. The same study reported that the colour of the cyclic 
derivative, 1-(2,6-dichlorophenyl)-indolin-2-one is white but black when heated (Tudja, Khan 
et al., 2001). 
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2.5.1.4 Characterization of 6-p-toluenosulfonyl-β-cyclodextrin 
2.5.1.4.1 Matrix-assisted laser desorption/ionization (MALDI) spectroscopy  
Mass spectrometry, demonstrated that the product of the tosylation reaction is mainly the 
mono-tosylated-cyclodextrin (1311.605 [M+Na] adduct) contaminated with some di-
tosylcyclodextrins (1465.667 [M+Na] adduct) (Figure 2.11). 
 
 
Figure 2.11 MALDI mass spectrum of tosylated β-cyclodextrin compound. A- β-
cyclodextrin, B- monotosylated β-cyclodextrin, C- ditosylated β-cyclodextrin 
A 
B 
C 
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2.5.1.4.2 Proton nuclear magnetic resonance (1H NMR) spectroscopy 
 
Figure 2.12 1H NMR spectrum of β-cyclodextrin (A); 1H NMR spectrum of β-
cyclodextrin tosylated (B); Structure of β-cyclodextrin (I); structure of β-cyclodextrin 
tosylated (II). 
NMR confirmed the substitution at the 6-position due to an upfield shift of protons of primary 
hydroxyl origin, and the existence of an AB system due to protons linked to the tosyl group 
(Figure 2.12).  
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Figure 2.13 A- 1H NMR spectrum of β-cyclodextrin tosylated without recristalization. B- 
1H NMR spectrum of β-cyclodextrin tosylated with one recristalization. C- 1H NMR 
spectrum of β-cycodextrin tosylated after two purifications. 
Re-crystallization of the tosylated product, as shown in Figure 2.13, only changes the kinetics 
of the intermolecular proton exchange, without modifying the product.  
 
2.5.1.5 Characterization of diclofenac-β-cyclodextrin conjugate 
2.5.1.5.1 High Performance Liquid Chromatography (HPLC) 
After purification by column chromatography the diclofenac-β-cyclodextrin conjugate was 
fully characterized and the purity by HPLC analysis was high. The retention time of the 
conjugate (8.1 minutes) is distinct from the retention time of the tosylated β-cyclodextrin (5.5 
minutes) as shown in Figure 2.14.  
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Figure 2.14 HPLC chromatogram of diclofenac-β-cyclodextrin conjugate (retention time 
of 7.9 minutes) after purification (A), and of tosylated β-cyclodextrin (retention time of 
5.5 minutes) (B). Matrix-assisted laser desorption/ionization (MALDI) spectroscopy. 
MALDI-TOF of the product shows only a signal m/z of 1434.308 corresponding to the 
[M+Na] adduct. No other relevant mass signal was observed as shown in Figure 2.15. 
 
Figure 2.15 MALDI mass spectrum of diclofenac-β-cyclodextrin conjugate. 
A 
B 
Chapter II 
67 
2.5.1.5.2 Proton nuclear magnetic resonance (1H NMR) spectroscopy 
The formation of the conjugate was proved by comparison of the 
1
H NMR spectrum of the 
free β-cyclodextrin (Figure 2.16 II-A) and of the sodium diclofenac (Figure 2.16 II-B) with   
the spectrum of the diclofenac-β-cyclodextrin conjugate (Figure 2.16 II-C).  
On the spectrum of sodium diclofenac, the H-2 protons appear at 3.38 ppm. Protons from the 
phenyl acetate ring protons are affected by the proximity of two chemical groups, the 
carboxylic group and the 2,6 – diclorophenyl ring. H-5’’ (6.83 ppm) and H-6’’ (7.05 ppm) 
appear as a triplet, and H-4’’ (7.07 ppm) as a duplet. H-7’’is the most shielded due to its 
proximity to the amine group. The signals of the 2, 6 diclorophenyl ring protons appear 
downfield. H-5’ and H-3’ are chemically and magnetically equivalent (7.43 ppm) and appear 
as a duplet, while H-4’ (7.06 ppm) appears as a triplet.  
In the diclofenac conjugate, all the signals related to diclofenac suffer downfield shifts, except 
for the H-2 protons. These modifications in the chemical shifts suggest that the diclofenac is 
not included in the cyclodextrin cavity when in the conjugate form. The upfield shift observed 
for H-2 protons of diclofenac is otherwise typical for the ones observed for an ester bond.  
On the 
1
H NMR analysis of the unmodified β-cyclodextrin (Figure 2.16 II-A), however, the 
secondary hydroxyl groups appear downfield (OH-2, singlet 5.76; OH-3, singlet 5.71), where 
these protons form intramolecular hydrogen bonds that contribute to a deshielding effect. The 
proton from the primary hydroxyl is a free-rotating proton and thus appears much more 
shielded at 4.61 ppm, as a triplet. A duplet due to H-1 protons appears at 4.81 ppm. The H-3 
(triplet, 3.61 ppm) and H-5 (duplet of triplets, 3.54 ppm) protons are located within the cavity, 
while H-4 (triplet, 3.33 ppm) and H-2 (duplet of duplets, 3.30 ppm) are on the exterior of the 
cavity. This AB system corresponds to 1/7th of the area of the β-cyclodextrin H-1 protons, 
indicating once again a 1:1 stoichiometric relationship. 
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Figure 2.16 I-Structure of the diclofenac-β-cyclodextrin; II-A-1H NMR spectrum of 
hydrated β-cyclodextrin hydrated. II-B-1H NMR spectrum of sodium diclofenac. III-C-
1H NMR spectrum of diclofenac-β-cyclodextrin conjugate. 
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Tabela 1 1H Chemical Shifts (ppm) for the protons of diclofenac and of cyclodextrin in 
the free state and in the conjugated form in DMSO-d6. 
 
  
Molecule Proton type 
δ (ppm) 
Free Conjugate 
Β-cyclodextrin 
OH-2 (singlet) 5.76 Multiplet 
(OH-2;OH-3) 
(5.66-5.84) OH-3 (singlet) 5.71 
OH-6 (triplet) 4.60 
Multiplet 
(OH-6, H6 (AB system)) 
4.21-4.55 
H6 (singlet) 3.66 
Multiplet  
(H6, H3,H5) 
3.5-3.9 
H3 (triplet) 3.61 
H5 (duplet) 3.50 
H2 (singlet) 3.38 Multiplet 
(H2,H3) 
3.25-3.43 H4 (triplet) 3.33 
H1 (douplet) 4.81 4.83 
Diclofenac H5’, H3’(duplet) 7.43 7.52 
H4’’(duplet) 7.07 7.22 
H4’(triplet) 7.06 7.20 
H6’’(triplet) 6.92 7.05 
H5’’(triplet) 6.74 6.83 
H7’’(duplet) 6.22 6.25 
H-2 (singlet) 3.38 3.30 
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2.5.1.5.3 ROESY experiments 
ROESY experiments shown in Figure 2.17 indicate that the only intermolecular correlations 
observed were between the H4’’ and H6’’ protons of the phenyl acetate ring and the H-6 
protons of the β-cyclodextrin, corroborating the hypothesis of non-penetration of diclofenac 
into the hydrophobic core of cyclodextrin. 
 
Figure 2.17 1H NMR ROESY spectra of the diclofenac-β-conjugate. 
2.5.1.5.4 Infrared (IR) spectroscopy 
IR spectroscopy also aided the identification of the diclofenac-β-cyclodextrin conjugate (see 
Figure 2.18) (Özkan, Atay et al., 2000; Wang, Han et al., 2006; Hamdi, Abderrahim et al., 
2010; Jing, Yanping et al., 2011). The spectrum of the conjugate (Figure 2.18-C) shows a 
pattern distinct from the spectrum of β-cyclodextrin (Figure 2.18-B) and of the diclofenac 
(Figure 2.18-A). The broad band at 3300-3500 cm
-1
, from the O-H stretching, is narrower and 
more closely resembles the corresponding β-cyclodextrin. Equally, the region at 1000-1200 
cm
-1
, from the C-O-C stretching, is similar in spectrum (Figure 2.18-B), but with a new 
prominent band located at 1028 cm
-1
. Near the H-O-H bending band of β-cyclodextrin at 1650 
cm
-1
, a new band appears at 1729 cm
-1
 due to the created ester bond. 
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Figure 2.18 IR spectra of diclofenac (A), β-cyclodextrin (B) and diclofenac-β-diclofenac 
conjugate (C). 
2.5.1.5.5 Chemical stability of diclofenac-β-cyclodextrin conjugate in aqueous buffer 
solutions 
One of the physiological factors affecting drug release from prodrugs is the pH of the 
medium. Therefore in a first approach our objective was to investigate the effect of pH on 
diclofenac liberation from the obtained conjugates. 
Results of in vitro hydrolysis studies, followed by HPLC, has shown in Figure 2.19, revealed 
that the conjugate is markedly stable to all selected pH values during the first 4 h. 
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After 24 hours, only for the pH of 1.2, the conjugate suffered degradation of about 25%. 
These results are very significant and showed that this conjugate can be chemically stable in 
the pH environment of the gastrointestinal tract. 
  
Figure 2.19 Stability studies of diclofenac-β-cyclodextrin in differents aqueous buffer 
solutions. Each value represents mean ± S.D (n=3). 
During these experiments, it was found out that in some samples rather than conjugate and 
diclofenac peaks, in HPLC chromatograms other peaks with a retention time closer to the 
retention time of diclofenac were observed, as it is shown in Figure 2.20-A. 
In order to understand the origin of these new peaks, sodium diclofenac and diclofenac free 
acid were incubated in pH 1.2 and the results were analyse by HPLC. Extra peaks were also 
observed in the samples of diclofenac free acid (Figure 2.20-B) and sodium diclofenac 
(Figure 2.20-C) incubated at pH 1.2, which allowed to conclude that the extra peaks were 
originated from the contact of the diclofenac with the acid solution. Further studies need to be 
done in order to investigate the precise structure of the derivative from diclofenac molecule. 
It has already been reported that diclofenac suffers an intramolecular cyclization under the 
acidic conditions, which can cause its inactivation. As a consequence of the intramolecular 
cyclization, Na
+
 is lost hence the solubility of the compound decreases (Palomo, Ballesteros et 
al., 1999). It is reported the formation of 1-(2,6-dichlorophenyl)-indolin- 2-one, which is an 
indol-cyclic amide and an intermediate product of the synthesis of diclofenac sodium. 
(Yasumitsu Tamura, Jun-Ichi Uenish et al., 1984). 
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Figure 2.20 HPLC chromatograms of diclofenac-β-cyclodextrin (A), diclofenac free acid 
(B) and sodium diclofenac (C) after incubation in buffer at pH 1.2 for 24 h in case of A 
and B and 5 h in case of C. Diclofenac-β-cyclodextrin conjugate retention time is 7.0 and 
retention time of diclofenac is 16.9 minutes. 
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 Applicability of the nucleophilic microwave approach on the synthesis of diclofenac-2.5.2
γ-cyclodextrin and diclofenac-α-cyclodextrin 
The synthesis of other diclofenac conjugates derived from the natural α- and  
γ- cyclodextrins was attempted by the method that successfully allowed the synthesis of 
diclofenac-β-cyclodextrin. 
The main goal is to assess if the reaction is possible using other cyclodextrins, once physical 
differences exist between them. Both, α- and β-cyclodextrins are much more soluble in water 
than β-cyclodextrin, and the molecular size is also different with consequently different 
reactivities. Thus, the ability of the nucleophilic reaction under microwaves was tested. 
Like observed for β-cyclodextrin, modification of the hydroxyl group by electrophilic reagent 
on α- and γ-cyclodextrins had to be produced first (Step 1) followed by the nucleophilic 
reaction (Step 2).  
Different problems were encountered on the synthesis of α- and γ-cyclodextrin conjugates as 
described below. 
2.5.2.1 Synthesis and characterization of diclofenac-γ-cyclodextrin conjugate 
2.5.2.1.1 Step 1: tosylation of γ-cyclodextrin 
Tosylation of γ-cyclodextrin was carry out according to the method described to prepare 
ditosylated cyclodextrin (Kahee Fujita, Hatsuo Yamamura et al., 1988). The synthesis of 
monotosilated γ-cyclodextrin is very difficult since γ-cyclodextrin does not form an inclusion 
complex with tosyl derivatives as described by Bruno Perly et al.. Consequently, its big cavity 
causes polysubstitution when it reacts with p-toluenesulfonyl chloride (Djedaini-Pilard, 
Azaroual-Bellanger et al., 1995). Tosylation occurs preferentially at hydroxyl groups at C-6. 
However, 8 primary hydroxyl groups are available and therefore the reaction needs to be 
controlled. 
As it is shown in Figure 2.21 (Section 2.5.2.1.3), the product of this reaction is a mixture of 
different tosylated products with multiple degrees of substitution even after recrystallization 
process. In order to get the monotosylated product, some changes were made in the reaction 
conditions namely the decrease of the ratio tosyl chloride/cyclodextrin, time of reaction, and 
temperature; however no significant differences in product distribution were observed. 
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Moreover, besides its toxicity, working with pyridine led to the formation of an unstable stick 
mass during isolation, which rendered stirring impossible during the course of the reactions 
and during the isolation of the product.  
The attempt of tosylation γ-cyclodextrin adopting the method in aqueous solution as used 
described to synthesized β-cyclodextrin tosylated (Brady, Lynam et al., 2000) failed. As 
described by Florence Djeda’ini-Pilard et al. the reaction of γ-cyclodextrin with 4-
toluenesulfonylchloride in aqueous solution results in polysubstitution at C-6 probably 
because of the larger γ-cyclodextrin annulus (Djedaini-Pilard, Azaroual-Bellanger et al., 
1995). Moreover, once γ-cyclodextrin presents higher water solubility when compared with β-
cyclodextrin, the final product in water is very difficult to isolate, once it did not precipitate 
by the addition of common organic solvents, such as acetone.  
In order to get mono-6-(O-2,4,6-triisopropylbenzenesulfonyl)-cyclodextrin, the method 
described by Palin et al. was adopted. This procedure resulted in less polisubstitution than that 
obtained using the 4-toluenosulphonyl chloride. In our case the mono but also dissubstituted 
product were obtained, as confirmed by the mass spectrum (Figure 2.22) (Palin, Grove et al., 
2001).  
Beyond, 2,4,6-triisopropylbenzenesulfonyl, other larger arenesulfonyl chlorides, such as 2-
naphthalenesulfonyl chloride (Djedaini-Pilard, Azaroual-Bellanger et al., 1995), have been 
explored by other authors in order to control the production of monosubstituted γ-
cyclodextrins (Djedaini-Pilard, Azaroual-Bellanger et al., 1995). For instance, the synthesis of 
mono-6-(2-naphthalenesulfonyl)-γ-cyclodextrin (Ueno, Tomito et al., 1983) was adopted by 
Kaneto Uekama et al. 1998 (Uekama, Minami et al., 1997b) to produce BPAA-γ-cyclodextrin 
conjugate. However, Palin et al. obtained di- and tri-adducts when preparing mono-6-(2-
naphthalenesulfonyl)-γ-cyclodextrin according to literature procedures, reporting the 
difficulty inherent to purification of the monosubstitued cyclodextrin. Additionally, the use of 
this alternative arenesulfonyl provides low yields with a more expensive (Palin, Grove et al., 
2001). 
2.5.2.1.2 Step 2: nucleophilic reaction  
This step is performed using the crude product poli-substitued derivative obtained on the 
former step. 
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Using the microwave approach to synthesize diclofenac-γ-cyclodextrin conjugate, di-
diclofenac-γ-cyclodextrin resulted as a contaminant. Purification of the product allowed 
isolation of diclofenac-γ-cyclodextrin as it can be observed in Figure 2.24. After purification, 
the monosubstituted product was obtained with 10% yield and characterized, according as 
described in point 1.4.2.1.2.   
However, the reaction revelead not to be reproducible and the yield depended on the batch of 
the tosylated γ-cyclodextrin that was formerly obtained. Although, all the tosylated 
cyclodextrins presented the same degrees of substitution, different results were obtained when 
the nucleophilic attack was attempted. The small amount of crude product obtained in some of 
the nucleophilic reactions seemed to be related with the amount of pyridine present in the 
tosylated product. Recrystallization revealed not to be efficient in the elimination of this 
solvent. Therefore, it is suggested that the success of this step depends on the purity of the 
tosylated derivative.  
Thus, the polisubstitution resulted from the reaction with p-toluenosulphonyl chloride and the 
lack of reproductibility of the nucleophilic reaction using the p-toluenosulfonyl cyclodextrin, 
led us to use the product resultant from the reaction between 2,4,6-
triisopropylbenzenesulfonyl and γ-cyclodextrin, as an alternative. The nucleophile reaction in 
microwaves resulted only in trace amounts of crude product, which contained γ-cyclodextrin 
and diclofenac-γ-cyclodextrin conjugate. It is possible that the steric hindrance caused by the 
substitution pattern of this derivative is not favourable for the occurrence of nucleophilic 
attack by diclofenac. Results suggested that the prevalent reaction is the hydrolysis of the 
tosylated cyclodextrin. 
Thus, further studies involving the synthesis and purification of monotosylaled γ-cyclodextrin 
need to be performed in order to improve the quality and yield of this intermediate, that is the 
key step to get reproducibility of the nucleophilic reaction (Step 2). 
2.5.2.1.3 Characterization of 6-p-toluenosulfonyl-γ-cyclodextrin 
Mass spectrometry demonstrated that the product of the tosylation reaction of γ-cyclodextrin 
with p-toluenosulphonyl chloride is mainly the monotosylated γ-cyclodextrin (1512.4 
[M+Na+K] adduct) and ditosylated γ-cyclodextrin (1666.4 [M+Na+K] adduct) and 
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tritosylated γ-cyclodextrin (1820 [M+Na+K].adduct) contaminated with some γ-cyclodextrin 
(1372 [M+K+Na+H2O] adduct).  
  
Figure 2.21 MALDI mass spectrum of the product from tosylation of γ-cyclodextrin with 
p-toluenosulphonyl chloride. (A) γ-cyclodextrin, (B) monotosylated γ-cyclodextrin, (C) 
ditosylated cyclodextrin, (D) tritosylated γ-cyclodextrin. 
2.5.2.1.4 Characterization of Mono-6-(O-2,4,6-triisopropylbenzenesulfonyl)-γ- 
cyclodextrin 
Mass spectrometry demonstrated that the product from tosylation reaction with 
triisopropylbenzenesulphonyl chloride is mainly the mono-γ-6-(O-2,4,6-
triisopropylbenzenesulfonyl)-γ-cyclodextrin (1624 [M+2Na] adduct) and di-6-(O-2,4,6-
triisopropylbenzenesulfonyl)-γ-cyclodextrin (1890 [K+2H2O] adduct). 
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Figure 2.22 MALDI mass spectrum of the product from tosylation of γ-cyclodextrin with 
triisopropylbenzenesulfonyl chloride. (A) mono-γ-6-(O-2,4,6- 
triisopropylbenzenesulfonyl)-γ-cyclodextrin; (B) di-6-(O-2,4,6-
triisopropylbenzenesulfonyl)-γ tolsylcyclodextrin.  
2.5.2.1.5 Characterization of the diclofenac-γ-cyclodextrin conjugate  
Matrix-assisted laser desorption/ionization (MALDI) spectroscopy 
Figure 2.23 MALDI mass spectrum of crude product obtained after microwave reaction 
between γ-cyclodextrin tosylated and sodium diclofenac.( A) γ-cyclodextrin; (B) 
diclofenac-γ-cyclodextrin, (C) di-diclofenac-γ-cyclodextrin. 
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Figure 2.24 MALDI mass spectrum of compound diclofenac-γ-cyclodextrin conjugate 
after purification using DIAION HP. 
Figure 2.23presents the mass spectra of the diclofenac-γ-cyclodextrin-conjugate obtained 
from microwave conditions before purification. Otherwise, in Figure 2.24 we have the mass 
spectrum after chromatographic isolation using DIAION HP resin. The value of m/z of 
1596.308 correspond to the [M+Na] adduct. 
Proton nuclear magnetic resonance (
1
H NMR) spectroscopy 
The NMR and mass spectrometric analysis indicated that the carboxyl group of diclofenac is 
covalently bound to one of the primary hydroxyl groups of γ-cyclodextrin through an ester 
bound.  
In the spectrum of the diclofenac conjugate, integration of the signals allows concluding that 
ratio between cyclodextrin and diclofenac is exactly 1:1. In this conjugate, similarly to β-
cyclodextrin conjugate the ester bond occurs at the hydroxyl of 6-position. The H-6 protons 
linked to diclofenac resonate downfield relative to the unsubstituted H-6 protons, and present 
a distinct multiplicity. In Figure 2.24, we can observe an AB system (centered at 4.308) due to 
such protons. 
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Figure 2.25 (A) 1H NMR spectrum of γ-cyclodextrin. (B) 1H NMR spectrum of sodium 
diclofenac. (C) 1H NMR spectrum of diclofenac-γ-cyclodextrin conjugate. 
2.5.2.2 Synthesis and characterization of diclofenac-α-cyclodextrin conjugate 
2.5.2.2.1 Step 1: tosylation of α-cyclodextrin 
Tosylation of α-cyclodextrin in water was not attempted, once it was reported that tosylation 
in alkaline solution results in substitution in the C-2 hydroxyl (Takahashi, Hattori et al., 
1984b; Fujita, Nagamura et al., 1985).  
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Tosylation of α-cyclodextrin was performed combining two procedures, one described by 
Keiko Takahashi et al, and the other Tang et al. after several attempts to reproduce each 
method individually (Keiko Takahashi, Kenjiro Hattori et al., 1984; Weihua Tang and Ng, 
2008).  
The reaction was performed at room temperature. It were studied different times of reaction as 
well as the proportions of reagents in order to get the monosubstituted α-cyclodextrin.  
The best results were obtained using 1/2.5 (cyclodextrin/6-p-toluenosulfonyl chloride) ratio, 
which led to obtain minimum degree of polysubstitution. However, as the mass spectra 
shows, part of the α-cyclodextrin did not react. The increase of the time of reaction did not 
give better results. 
Attempts to purify this product, by crystallization or solvent washings in order to eliminate 
the non-reacted cyclodextrin, were accompanied with loss of the major part of the product. 
Additionally, like experienced with tosylation of γ-cyclodextrin, pyridine was very difficult to 
eliminate, which was confirm by the 
1
H NMR spectra. Results suggest that pyridine can 
remain within the cyclodextrin, which is a very difficult task to remove from the mixture. 
Chromatographic purification of the product of tosylation of α-cyclodextrin with DIAION 
resin was attempted and it was successful in eliminating pyridine. However, after 
chromatography a mixture of mono and ditosilated α-cyclodextrin was obtained (6% of the 
initial amount of crude product). 
The use of an alternative solvent, like colidine, was made revealing to allow the formation of 
the same substituted cyclodextrins. However, the problem to eliminate this solvent after the 
reaction still remains. 
2.5.2.2.2 Step 2: nucleophilic reaction: microwave approach 
Due to the low quantities of tosylated cyclodextrin obtained after recrystallization, there had 
been few attempts to produce diclofenac-α-cyclodextrin conjugate. Furthermore, when the 
isolated was analysed by mass spectra it did not show any signal of diclofenac-α-cyclodextrin 
conjugate. Once again, the lack of product resulted from the absence of a clean tosylated 
derivative, free of pyridine. Further studies are needed to improve the process of tosylation of 
this cyclodextrin. 
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2.5.2.2.3 Characterization of 6-p-toluenosulfonyl-α-cyclodextrin  
Mass spectrometry demonstrated that the product from the tosylation reaction of α-
cyclodextrin with p-toluenosulphonyl chloride is mainly the monotosylated α-cyclodextrin 
(1188.382 [M+Na+K] adduct) and ditosylated α-cyclodextrin (1342.402 [M+Na+K] adduct) 
contaminated with some α-cyclodextrin (1034 [M+K+Na] adduct). 
 
Figure 2.26 MALDI mass spectrum of the product of tosylation of α-cyclodextrin with p-
toluenosulphonyl chloride. (A) α-cyclodextrin; (B) monotosylated α-cyclodextrin; (C) 
ditosylated α-cyclodextrin. 
2.6 Conclusions 
An efficient chemical method to synthesize diclofenac-β-cyclodextrin conjugate was 
developed. Additionally, the possibility to apply the same method to synthesize γ-cyclodextrin 
and α-cyclodextrin derivatives was explored. 
Initially, various approaches were investigated to synthesize β-cyclodextrin conjugates. These 
included: nucleophylic substitution with conventional heating, activation of diclofenac using 
carbodiimides, and formation of an acid chloride. All three approaches were unsuccessful in 
the synthesis of the conjugate. We came to the conclusion that these approaches did not work 
due to the particular structure of diclofenac since they were successfull in other cyclodextrin 
conjugates. 
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Microwave radiation is being explored in organic synthesis in order to accelerate reactions. 
Some authors have explored the use of this technique to promote reactions of cyclodextrin. 
However, this type of non-conventional conditions was not applied in reactions that allow the 
formation of cyclodextrin conjugates. 
In this work, using the nucleophylic approach under microwave irradiation, diclofenac-β-
cyclodextrin conjugate was synthesized in efficient conditions and conveniently short reaction 
time. The product was then purified through a polyaromatic ionic adsorbent resin. 
1
H
 
NMR 
studies confirmed the covalent link of the carboxylic group of diclofenac with the hydroxyl of 
β-cyclodextrin, and bidimensional 1H NMR ROESY allowed to conclude that diclofenac is 
not included inside the cavity of cyclodextrin.  
Preliminary chemical hydrolysis assays were performed in order to discern about the stability 
of the conjugate. The drug release behavior of these conjugates was studied in different buffer 
solutions (pH 1.2, 4.5, 6.8 and 7.4) at 37 ºC. Results showed that the conjugate was stable in 
pH 4.5 and pH 6.8 and 7.4. Moreover, hydrolysis in pH 1.2 is negligible. 
Preliminary results of β-cyclodextrin conjugate in different physiological conditions allows 
predicting that this conjugate resists to different gastrointestinal tract pHs. 
The synthesis of γ-cyclodextrin conjugate was made using the same approach and the end 
product was characterized. However, this reaction showed not to be reproducible. On the 
other hand, the production of α-cyclodextrin conjugate was not successful. Synthesis of 
diclofenac α-cyclodextrin and γ-cyclodextrin conjugates was hindered by difficulties in the 
synthesis and purification of the intermediary tosylated cyclodextrins. Further work needs to 
be done to improve the process to prepare these tosylated intermediaries, since this seems to 
be the key step to produce these conjugates. 
The first step of this thesis was very challenging and demonstrated that the chemical 
differences between cyclodextrins have to be taken in account when the aim is to synthesize 
prodrugs. Additionally, diclofenac is a very instable molecule, which prevents its conjugation 
in some chemical conditions. Overall, diclofenac-β-cyclodextrin revealed to be a molecule 
with a strong potential for colon delivery of diclofenac. Therefore, the next Chapters focus on 
the investigation of the potential of diclofenac-β-cyclodextrin to be used as a colonic prodrug. 
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3 STABILITY OF DICLOFENAC-ΒETA-CYCLODEXTRIN IN THE 
GASTROINTESTINAL TRACT. IN VITRO AND EX VIVO STUDIES USING 
SIMULATED FLUIDS AND GASTROINTESTINAL FLUIDS FROM ANIMALS 
3.1 Overview 
An ideal prodrug for colon specific drug delivery should be stable in the stomach and small 
intestine and reach the colon intact. Once the prodrug reaches the colon, the enzymes should 
catalyse the drug-carrier bond breakdown, hence releasing the drug. Moreover, this process 
should be rapid and complete. 
In Chapter II, stability studies were carried out by incubation of diclofenac-β-cyclodextrin 
conjugate in different buffer solutions in order to establish its ability to resist chemical 
hydrolysis. According to those results, the conjugate revealed to be chemically stable. The 
next aim is to evaluate the pre-systemic behaviour of the conjugate, namely its stability in the 
GI tract by performance of in vitro and ex vivo studies using appropriate media able to 
represent the physiological conditions of the GI tract. 
This Chapter firstly pursues the investigation the ability of this based cyclodextrin prodrug to 
release diclofenac in the lower intestine, using human faecal slurry to simulate colonic fluid. 
These stability studies in the lower gastrointestinal tract are performed using a well-
established marketed available model of colonic delivery, sulfasalazine, as a positive control. 
When sulfasalazine is orally administered, approximately 90 percent of it reaches the large 
intestine as an intact molecule, where bacterial azoreductase cleaves the azo bond thereby 
releasing mesalazine and sulfapyridine (Zoetendal, Akkermans et al., 1998). 
Moreover, the stability is performed in the presence of enzymes, namely ester hydrolysing 
enzymes and sugar-degrading enzymes in order to find an enzymatic media able to mimic the 
metabolism of cyclodextrin-β-cyclodextrin in the colonic environment. Concomitantly, these 
studies with enzymes are worth to understand the process involved on the metabolism of this 
conjugate. 
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Further, this Chapter investigates the ability of the conjugate to be intact in the upper 
gastrointestinal fluids, namely at gastric and intestinal level, using simulated gastric and 
intestinal fluids, described in the Pharmacopeia. 
The Chapter ends with stability studies conducted in fluids from different animals (pig, rabbit 
and rat) in order evaluate the validity of each animal model to perform in vivo experiments. 
3.2 Introduction 
Any new molecule destined to oral delivery should be tested in vitro at an early stage of 
development regarding its stability in the different environments of the GI tract, namely, 
stomach, small intestine and colon. This allows an understanding of the pre-systemic behavior 
of any molecule. Moreover, in the case of prodrugs, the stability tests will make it possible to 
determine the site and rate of prodrug-to-drug conversion. 
Different approaches are attempted in order to study and establish cyclodextrin-β-cyclodextrin 
stability in the complex environment that constitutes the luminal content of the 
gastrointestinal tract. 
According to FDA Guidelines (Fda, 2000): 
“Stability in the gastrointestinal tract may be documented using gastric and intestinal fluids 
obtained from human subjects. Drug solutions in these fluids should be incubated at 37 
o
C for 
a period that is representative of in vivo drug contact with these fluids; for example, 1 hour in 
gastric fluid and 3 hours in intestinal fluid. Drug concentrations should then be determined 
using a validated stability-indicating assay method. Significant degradation (>5%) of a drug in 
this protocol could suggest potential instability. Obtaining gastrointestinal fluids from human 
subjects requires intubation and may be difficult in some cases. Use of gastrointestinal fluids 
from suitable animal models and/or simulated fluids such as Gastric and Intestinal Fluids USP 
can be substituted when properly justified”. 
This guidance for the determination of drugs stability in the gastrointestinal tract can be 
adopted to guide the stability of prodrugs to site colonic delivery, namely of diclofenac-β-
cyclodextrin prodrug.  
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 Simulated gastrointestinal fluids 3.2.1
3.2.1.1 Simulated colonic fluid 
The primary region of the GI tract of interest to evaluate the effectiveness of a colonic 
delivery system is the colon. The lack of a Pharmacopeia simulated colonic fluid for in vitro 
studies warrants the use of other methodology to mimic the environment of the human colon. 
Studies in fresh human fluids constitute an alternative that closely reproduces the environment 
in vivo. In case of colonic release systems, the ascending colon is the primary region of 
interest not only because of the substantial residence time in this region of the lower intestine 
(Metcalf, Phillips et al., 1987; Kilian and Clive, 2005), but also due to the limited free water 
volume in the transverse colon (Schiller, Fröhlich et al., 2005). Consequently, the potential of 
colonic prodrugs should be evaluated in fluids from this region of the colon. However, human 
fluids are not easily available due to the difficulty in sampling. An alternative is the use of 
faeces to study metabolism at the level of the lower intestine. The advantage is that the 
microbiota is essentially confined to the distal intestinal tract and epithelium associated 
bacteria are apparently absent. The use of fresh human feces within an appropriate medium 
has been identified as a suitable alternative, the well-known faecal slurry (Sousa, Paterson et 
al., 2008). These faecal slurries from humans provide accurate information concerning not 
only the intestinal microbiota, but also the enzymatic and electrolytes composition (Tannock, 
1999; Basit and Lacey, 2001; Basit, Newton et al., 2002). Additionally, it is known that 
microbiota is a major component and constitutes 40-45% of faecal solids in people consuming 
Western-type diets (Cummings and Macfarlane, 1991). 
3.2.1.2 Enzymatic colonic media containing enzymes 
Given all the drawbacks associated with the use of biological fluids, namely the odour, 
complexity of its composition, the lack of homogeneity, the thickness of the faeces matrix and 
further the difficulties in the analysis of the drug release into this complex medium, 
alternative media able to simulate the colon have been investigated.  
Maria Vertzoni et al. developed two media (fasted state and fed state simulated media) able to 
mimic the ascending colonic fluids useful for the determination of solubility of drugs at this 
level (Vertzoni, Diakidou et al., 2010). These media do not contain enzymes and therefore are 
not reliable to determine the drug release from colonic delivery systems activated by 
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microbiota. Other authors have incorporated specific enzymes in a buffer medium able to 
simulate the colonic fluids. For instance, galactomannanase was included in the medium for 
the dissolution of guar gum based system (Wong, Larrabee et al., 1997), a pectinolytic 
enzyme was added to a phosphate buffer (pH 6.8) to assess the in vitro drug-release behaviour 
of pectin cross-linked with glutaraldehyde nanogel particles, a matrix for colonic drug 
delivery (Chang, Wang et al., 2007) and dextranase was included in buffer media to simulate 
the release of dextran-conjugates in the lower intestine (Mcleod, Friend et al., 1994). 
The selection of a medium to simulate the colon fluids is dependent on the rationale design of 
the delivery system. This Chapter discusses the development of a simpler enzymatic 
simulated medium able to reproduce the digestion profile of diclofenac-β-cyclodextrin in the 
large intestine. Thus, ester-hydrolysing and sugar-degrading enzymes were tested as potential 
enzymes involved on the drug release from this cyclodextrin based prodrug at colonic level.  
 
 
 
 
 
 
 
Figure 3.1 Schematic representation of enzymes involved in the hydrolysis of various 
bonds (Hydrolases EC 3.), including those acting on ester bonds (esterases EC 3.1.) and 
those that hydrolyse glycosyl compound (glycosylases EC 3.2.). Glycosidases hydrolyse 
O- and S-glycosyl compounds (EC 3.2.1). This subgroup includes cyclomaltodextrinases 
(CDases; EC 3.2.1.54), maltogenic amylases (MAases; EC 3.2.1.133) and neopullulanases 
(NPases; EC 3.2.1.135). This classification is according to Nomenclature Committee of 
the International Union of Biochemistry and Molecular Biology (NC-IUBMB). 
The stability of diclofenac-β-cyclodextrin is tested against hydrolases (EC 3) used to mimic 
enzymatically the behavior in the large intestine. Once the carrier is an oligosaccharide, its 
susceptibility to be hydrolysed by glycosylases (EC 3.2), namely by glycosidases (EC 3.2.1), 
EC 3. Hydrolases 
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i.e. enzymes hydrolysing O- and S-glycosyl compounds needs to be examined. Additionally, 
given the fact that diclofenac-β-cyclodextrin possesses an ester linkage between the drug and 
the carrier, studies are conducted in the presence of hydrolases able to act on the ester bonds, 
esterases (EC 3.1.), namely those acting on carboxylic ester (EC 3.1.1) (see Figure 3.1).  
Below is described briefly the main characteristics and occurrence of esterase and glycolytic 
enzymes in the gastrointestinal tract capable of acting against diclofenac-β-cyclodextrin 
conjugate. 
 Carboxylesterases (CES) (EC 3.1.1.) 
The mammalian CES comprise a multigene family and the isozymes are classified into five 
main CES groups (CES1-CES5) and several subgroups. The majority has been segregated 
into CES1 and CES2 families. These are involved in both drug metabolism and activation of 
ester, amide and carbamate bonds. Typically the expression of CES is maximal in the 
epithelia of most organs (Imai, 2006; Landowski, Lorenzi et al., 2006). CES1 is present 
predominantly in the liver; its expression is low along the gastrointestinal tract. CES2 is 
predominantly present in the small intestine and colon (Imai, Imoto et al., 2005). CES1 
hydrolyses a substrate with a small alcohol group and a large acyl group, but its wide active 
pocket sometimes allows it to act on structurally distinct compounds of either a large or small 
alcohol moiety (Hosokawa, 2008; Wheelock and Nakagawa, 2010). In contrast, the CES2 
isozyme recognizes a substrate with a large alcohol group and small acyl group, and its 
substrate specificity may be restricted by the capability of acyl-enzyme conjugate formation 
due to the presence of conformational interference in the active pocket (Hosokawa, 2008; 
Ohura, Nozawa et al., 2011). 
 Glycosidases (E.3.2.1.) 
CDs are relatively stable compared to the corresponding linear malto-oligosaccharides, but 
are readily degraded to glucose and maltose by specific hydrolases including 
cyclomaltodextrinases (CDases; EC 3.2.1.54), maltogenic amylases (MAases; EC 3.2.1.133) 
and neopullulanases (NPases; EC 3.2.1.135). (Park, Kim et al., 2000; Lee, Kim et al., 2002). 
Due to the fact that these enzymes have rather similar Xray structures and amino acid 
sequence identities (above 40%) it has been proposed to name them all cyclomaltodextrinases 
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(Lee, Kim et al., 2002). They hydrolyse cyclic dextrins and also linear maltodextrins, but have 
little or no activity for polysaccharides, such as starch and glycogen (Saha and Zeikus, 1992).  
Generally, cyclodextrins are not hydrolyzable by exo type amylases, such as β-amylases (EC 
3.2.1.2), which remove successive maltose units from the non-reducing ends of chains of 
polysaccharides. Cyclodextrin works as an inhibitor of β-amylases (Suetsugu, Koyama et al., 
1974). In an other hand, α-Amylase (EC. 3.2.1.1) is an endo-type carbohydrase that 
hydrolyzes α-1,4-glycosidic bonds, mainly in starch, producing α-limit dextrins and 
oligosaccharides (Alkazaz, Desseaux et al., 2001; Maarel, Veen et al., 2002). Some α-
amylases, such as human salivary α-amylase, human and porcine pancreatic α-amylase have 
been reported to hydrolyse CDs, although the rate is much slower than that for starch. 
Moreover, some bacterial and fungal α-amylases revealed to be able to hydrolise 
cyclodextrins, such as that from Aspergillus oryzae (Suetsugu, Koyama et al., 1974; Jodal, 
Kandra et al., 1984). Interestingly, cyclomaltodextrinases are intracellular enzymes, whereas 
most enzymes of the α-amylase family are extracellular enzymes (Depinto and Campbell, 
1964; Saha and Zeikus, 1990; Hashimoto, Yamamoto et al., 2001; Lee, Kim et al., 2002).  
3.2.1.3 Simulated gastric and intestinal fluids 
Beyond the investigation of the ability of a colonic prodrug to release a drug in the colon, the 
stability of it in the upper GI tract needs also needs to be evaluated. Pharmacopeia establishes 
the composition of simulated gastric and intestinal fluids, which are well-accepted by the 
worldwide scientific community. A suspension of pepsin (E.C. 3.4.23.1), a gastric 
endopeptidase, at pH 1.2 is well-known to simulate gastric fluid (SIG). To replicate the 
intestinal environment, Pharmacopeia describes a suspension of 1% (w/v) of pancreatin at pH 
6.8, the called simulated intestinal fluid (SIF). It is worthwhile pointing out that these 
simulated fluids used for in vitro testing do not faithfully reproduce the in vivo condition of 
the human gastrointestinal environment. These are simple acid and phosphate buffer solutions 
that contrast with the complex, dynamic and fluctuating gastrointestinal fluids (Lindahl, 
Ungell et al., 1997; Moreno, Oth et al., 2006). Some elements such as electrolytes, bile acids 
and a wide range of other lipids and important enzymatic co-factors are not present in the 
composition of these fluids (Lindahl, Ungell et al., 1997; Mcconnell, Fadda et al., 2008; Sarti, 
Barthelmes et al., 2011). Otherwise, other elements are available in excess as in the case of 
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pancreatic proteins, the amount of which is 5-fold higher in comparison with that in the 
intestinal lumen of humans (Lindahl, Ungell et al., 1997; Moreno, Oth et al., 2006). 
 Animal gastrointestinal fluids 3.2.2
The simulated fluids do not represent all aspects of the physiological conditions of the oral 
administration, such as pH, volume, contraction patterns, buffer capacity, bacteria, enzymes, 
components of food and others already mentioned. For this reason, and although there is 
variability between human and animals, namely in terms of bacterial activity, the fluids 
collected from animals can be used for human predictions of drug metabolism as reviewed by 
Sousa et al. (Sousa, Paterson et al., 2008). These GI fluids from animals can represent better 
the in vivo metabolic fate than simulated fluids (Sarti, Barthelmes et al., 2011). The challenge 
is to establish the best animal model to be further used in the in vivo experiments. The main 
anatomic and physiological differences between some animal models are described on 
Chapter I. In the case of colonic prodrugs, when the prodrug is converted to the active drug by 
the enzymatic reaction, the conversion can be highly species-dependent (Stella, Borchardt et 
al., 2007). For instance, Beagle dogs (Carnivora order) are not suitable to perform 
pharmacokinetics studies of ester prodrugs, due to the absence of carboxylesterase isozyme in 
the small intestine of these animals (Imai, 2006). Dogs are not suitable models to test non-
steroid anti-inflammatory drugs once they are very sensitive to ulcer-inducing properties of 
these drugs (Swindle, Makin et al., 2011). As a non-rodent species, pig (Artiodactyla order) is 
considered an alternative to the dog or monkey (Swindle, Makin et al., 2011). Although pig is 
physiologically similar to humans, some anatomic differences are significant namely: the 
existence of a well-defined caecum contrarily to that in human, and also a bigger colon 
(Kararli, 1995). Pig is considered a superior model for colonic delivery when compared with 
smaller laboratory animals, namely for studies of oral intake of intact dosage forms intended 
for man, due to the large size (Sarfraz, Sarfraz et al., 2011). It has been used to study colonic 
ester prodrugs, namely of colonic prodrugs dextran-based (Harboe, Larsen et al., 1989). As 
for an non-rodent, rabbit (Lagomorpha order) is other alternative and it has been use to test 
colonic formulations (Freire, Podczeck et al., 2010; Mustafin, Kabanova et al., 2011). 
However, rats (Rodentia order), due namely to the small size and low cost, are used 
extensively in pre-clinical tests of drugs, including prodrugs to colon delivery (Mcleod, 
Friend et al., 1994; Kamada, Hirayama et al., 2002). Additionally rats have been used to 
perform the in vitro stability test of colonic prodrugs, as described previously. In this Chapter, 
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it is explored the behaviour of diclofenac-β-cyclodextrin in gastrointestinal fluids from 3 
different animal models: pig, rat and rabbit.  
3.3 Aims and Objectives 
The aim of this Chapter is firstly to investigate the ability of the diclofenac-β-cyclodextrin 
conjugate to release diclofenac in the colon and its capacity to resist to the environment in the 
upper GIT tract.  
To pursue this, the following objectives were defined (Table 3.1): 
 
- Determination of the stability of the conjugate in simulated colon fluids (faecal 
slurries) and in an enzymatic media able to reproduce the environment of the colon; 
- Determination of the stability in the upper GI tract, namely in simulated gastric fluid 
(SGF) and in simulated intestinal fluid (SIF). 
Secondly, this Chapter aims to investigate the best animal model to be further used on the in 
vivo studies. For this, the following objective was defined: 
 
- Conduct stability experiments in gastrointestinal fluids from animals (pig, rabbit and 
rats). 
 
 
 
 
 
 
 
 
Table 3.1 Schematic representation of the main objectives of this Chapter. 
Determination of stability of diclofenac-β-cyclodextrin in upper and lower GI tract using 
simulated fluids and animal fluids. 
Stability on the lower 
GIT 
Stability on the upper 
GIT 
Simulated fluids Animal fluids 
(rat, pig, rabbit) 
Simulated gastric and 
intestinal fluids Gastric Fluids  
Simulated colonic fluids 
(Human Faecal slurries) 
Enzymatic medium 
Intestinal fluids 
Caecum fluids 
Colon fluids 
In vitro stability studies 
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3.4 Materials 
 Reagents and chemicals 3.4.1
Sodium diclofenac (MW = 318.14 g/mol) and sulfasalazine (MW = 398.394 g/mol) were 
purchased from Sigma Aldrich, diclofenac-β-cyclodextrin (MW = 1411 g/mol) was 
synthetized according to the method reported in Chapter II. 
Sodium chloride (NaCl), potassium hydroxide (KOH), sodium hydroxide (NaOH), 
dipotassium hydrogen orthophosphate (K2HPO4) potassium dihydrogen orthophosphate 
(KH2PO2), hydrochloric acid (HCl), HPLC grade acetonitrile, HPLC grade methanol and 
HPLC grade water were purchased from Fisher Scientifics UK Limited. 
Trifluoroacetic acid (TFA) and dimethylformamide (DMF), 4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid, N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), L-
cysteine HCl, bile salts, vitamin K, sodium bicarbonate (NaHCO3), haemin, resazurin, and 
calcium chloride dehydrate CaCl2.2H2O were acquired from Sigma Aldrich (Dorset, UK). 
Calcium chloride hexahydrate (CaCl2.6H2O), magnesium sulphate heptahydrate 
(MgSO4.7H2O) and sodium acetate trihydrate (NaCH3COONa.3H2O) were obtained from 
VWR (Leicestershire, UK).  
Peptone water and yeast extract were purchased from Oxoid Limited (Hampshire, UK). 
 Enzymes 3.4.2
All the enzymes were purchased from Sigma-Aldrich. 
Pepsin derived from porcine gastric mucosa (Reference: P700) (EC. 3.4.23.1); 
Pancreatin from porcine pancreas ( ≥3 x USP specification) (Reference: P1625) (EINECS 
232-468-9); 
α-Amylase from Aspergillus oryzae (Reference: 10065) (EC. 3.2.1.1); 
α-Amylase from Bacillus lechiniformes (Reference: A3403) (EC. 3.2.1.1);  
α-Amylase from porcine pancreas (Reference: A 3176) (EC. 3.1.1.1); 
Esterase form porcine liver (PLE) (Reference: 46058) (EC. 3.1.1.1). 
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 Animals  3.4.3
All procedures with animals were conducted in accordance with the Home Office standards 
under the Animals (Scientific Procedures) Act 1986.  
The GI tract of pigs was obtained from freshly killed animals (cross-breed of large white and 
landrace, 95–110 kg, 6 months) at Cheale Meats Ltd. (Essex, UK).  
The GI tract of rabbits was obtained from Adult New Zealand white rabbits (2.1-2.3 kg, 9-10 
weeks) at UCL Institute of Ophthalmology.  
The GI tract of Wistar rats (8 weeks) were obtained from Harlan Olac Ltd at UCL. 
All animals were healthy and fed ad libitum prior to the experiments. 
The animals were killed humanely and the gastrointestinal tracts from pig, rabbit and rats 
were immediately sectioned into the stomach, small intestine, caecum, and colon, with the 
small intestine and colon being further subdivided. The small intestine was divided in 3 parts: 
duodenum, jejunum and ileum. The lower intestine was divided into caecum and colon. 
Further, the pig colon was divided in two parts, anterior (colon A) and posterior (colon B).  
After division, the gastrointestinal fluids were collected from each section of the GI tract and 
kept in flasks in the freezer at - 80 
0
C. 
Figure 3.2 Gastrointestinal tract of pig (A), rabbit (B) and rat (C) before collection of 
the respective fluids. 
 Instrumentation and chromatographic conditions 3.4.4
An HPLC system (model HP1100 series, Hewlett Packard, Germany) equipped with 
an autosampler (Agilent 1100 series, 119 Germany) was used. A reversed-phase X-Terra C-
18 column, 5 µm, 4.6 mm × 250 mm (Waters, USA), with a pre-column, was employed. 
Mobile phase consisted of 0.1% TFA in water (A) and acetonitrile (B). The injection volume 
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was 20 µL, the flow rate 1.0 mL/min and the detection wavelength was 254 nm. All the 
assays were performed at 30 
0
C. The gradient system was: 0-15 minutes 25-60% B; 15-22 
minutes 60-25% B, with a flow rate of 1.0 mL/min. 
3.5 Methods 
 Stability of the diclofenac-β-cyclodextrin conjugate in simulated fluids 3.5.1
3.5.1.1 Stability studies in the lower GI tract 
The stability was carried out in simulated colonic fluid prepared as human faecal slurry and 
the use of an enzymatic media able to mimic the release in the colonic medium was 
investigated.  
3.5.1.2 Stability studies in human faecal slurries  
Faecal slurries were utilized to simulate the conditions of the colon (Basit and Lacey, 2001; 
Basit, Newton et al., 2002). Fresh faeces from healthy adults were collected in pre-weighed 
sterile plastic containers. The volunteers were on no medication and had not taken antibiotics 
for at least the previous six months. The plastic receptacle containing freshly voided human 
faeces was transferred into an anaerobic workstation (Electroteck 500TG workstation, 
Electrotek, UK) (37 
o
C and relative air humidity of 70%) as soon as possible after defecation 
in order to preserve viability of the microbial population.  
Faeces were diluted with PBS pH 6.8 (Appendix A) in order to obtain 40% (w/w) slurry. The 
mixture was then homogenized and sieved through an open mesh fabric (Sefar Nitex
TM
 
Heiden, Switzerland, pore size 350 µm) to remove any unhomogenised fibrous material. 
Afterwards, the sieved homogenized faecal slurry was diluted 50% (w/w) with basal medium, 
which was prepared as described below.  
 Preparation of basal medium: 
The quantity of each ingredient is described in Table 3.2. Peptone water and yeast extract 
were weighed into a glass flask containing 1.3 L of distilled water and autoclaved at  
125 
o
C for 20 minutes. In a 200 mL volumetric flask containing about 150 mL of distilled 
water, NaCl, K2HPO4, MgSO4.7H2O and CaCl2.6H2O were weighed and dissolved under 
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stirring. After that, tween 80 was added and stirred until completely dissolved. Bile salts 
followed by L-cysteine were added and stirred until completely dissolved. Vitamin K, haemin 
(dissolved in 2 drops of NaOH 1M) and the resazurin solution were added. Sodium 
bicarbonate and distilled water were added to make final volume of 200 mL. The addition of 
NaHCO3 to the basal medium was just added before filtering and the flask was stopped during 
stirring to avoid dissolution of oxygen. The attained solution was filtered through 0.45 μm 
filters (Millex GP syringe-driven filter units, Millipore, Ireland) into the autoclaved 1.3 L 
solution containing the peptone water and yeast extract. This step was performed aseptically 
in a Laminar Flow Cabinet. The bottle was kept tightly closed and at room temperature until 
be used. 
Basal media was used to support the activity of microbiota in the faecal slurry for accurate 
prediction of the degradation of the compounds. 
Table 3.2 Composition of basal medium. 
 
 
 
 
 
 
 
 
Solution of diclofenac-β-cyclodextrin (2.4 mg/mL) was prepared in PBS 6.8 with DMF to 
guarantee complete dissolution of the conjugate in the medium, as described by Koichi Udo et 
al.(Udo, Hokonohara et al., 2010), and 300 µL of this solution was mixed with 900 µL of 
faecal slurries in the anaerobic workstation (at 37 
o
C and relative air humidity of 70 %). A 
control experiment was also run in parallel in faecal slurry that was subjected to autoclaving 
Ingredient 
Quantity 
per Litre 
Peptone water 2 g 
yeast extract 2 g 
NaCl 0.1 g 
K2HPO4 0.04 g 
MgSO4.7H2O 0.01 g 
CaCl2.6H2O 0.01 g 
NaHCO3 2 g 
Haemin 0.005 g 
L-cysteine HCl 0.5 g 
Bile salts 0.5 g 
Tween 80 2 mL 
Vitamin K 10 μL 
Resazurin olution 0.25% 4 mL 
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at 130 ◦C for 20 minutes. This was conducted to inactivate the bacterial enzymes in the 
slurry. 
Thereafter, these solutions were incubated and shaken at 100 rpm (VXRbasic Vibrax®, 
Leicestershire, UK). The final concentrations of the conjugate and DMF were 600 µg/mL and 
1.0%, respectively. At fixed intervals, 100 µL of fluid from each solution was withdrawn, 
mixed with 300 µL of methanol and centrifuged at 10 000 rpm for 10 minutes at room 
temperature. The supernatant was then removed and analyzed by HPLC (see Table 3.3). Each 
experiment was performed in triplicate. 
In order to compare the inter-individual degradation profile of conjugate stability tests were 
performed in faecal slurries from 3 different male subjects processed in separate. 
Sulfasalazine was used as a positive control. Solutions of diclofenac-β-cyclodextrin  
(2.4 mg/mL) and sulfasalazine (0.4 mg/mL) were prepared in PBS 6.8 with DMF and the 
experiment was performed following the steps described anteriorly and according to the 
described in Table 3.4. 
Table 3.3 Details for stability experiments of diclofenac-β-cyclodextrin in faecal slurries, 
using autoclaved faecal slurries as a control. 
Table 3.4 Details for stability experiments of diclofenac-β-cyclodextrin versus 
sulfasalazine in faecal slurries from 3 different subjects processed separately. 
Media 
Conjugate 
concentration  
Incubation 
Conjugate 
concentration 
(incubation) 
Sampling
volume 
Final 
volume 
(addition 
methanol) 
Final 
conjugate 
concentration  
Faecal 
slurry 
2.4 mg/mL 
300 µL of 
conjugate + 
900 µL of 
media 
0.6 mg/mL  100 µL 400 µL 0.15 mg/mL  
Autoclaved 
faecal slurry 
Prodrugs 
concentration 
Incubation 
(faecal slurry) 
Prodrugs 
concentration 
(incubation) 
Sampling 
volume 
Final 
volume 
(addition 
methanol) 
Final prodrugs 
concentration 
2.4 mg/mL of 
conjugate and 
 0.4 mg/mL of 
sulfasalazine 
300 µL of 
prodrug + 900 
µL of media 
 
0.6 mg/mL of 
conjugate and 
0.1 mg/mL of 
sulfasalazine 
100 µL 400 µL 
0.15 mg/mL of  
conjugate and  
0.025 mg/mL of 
sulfasalazine 
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3.5.1.3 Stability studies in simulated colonic media containing enzymes 
In presence of esterase from porcine liver solution (39 units/mL). 
Solutions of conjugate (0.8 mg/mL) were prepared in HEPES/NaOH buffer (pH 7.4) (see 
Appendix C) with 1% of DMF. After that, esterase from porcine liver (39 units/mL) was 
added to the previous solutions. This procedure was adapted by that described by F. Hirayama 
et al. (Hirayma, Ogata et al., 2000). 
In presence of α-amylases solutions: Bacillus lechiniformes (250 units/mL) porcine 
pancreas (250 units/mL) and Aspergillus oryzae (20-250 units/mL). 
Solutions of conjugate (0.8 mg/mL) were prepared in 0.01M CaCl2/0.2 M acetate buffer (pH 
5.5) (see Appendix C) with 1% of DMF. After that, the respective α-amylase was added to the 
previous solutions. Stability tests with α-amylase from Aspergillus oryzae were conducted 
with different concentrations of enzyme 20, 40 or 250 units/mL while with α-amylase from 
Bacillus lechiniformes and with α-amylase from porcine pancreas were conducted at 250 
units/mL. 
In presence of α-Amylase from Aspergillus oryzae (250 units/mL) and esterase from 
porcine liver (39 units/mL) simultaneously. 
Solutions of conjugate (0.8 mg/mL) were prepared in 0.01 M CaCl2/0.2 M acetate buffer pH 
5.5 or in HEPES/NaOH buffer (pH 7.4) with 1% of DMF. After that, α-amylase and esterase 
were added to the previous solution.  
In presence of α-Amylase from Aspergillus oryzae (250 units/mL) followed by the presence 
of esterase (39 units/mL). 
Solutions of conjugate (0.8mg/mL) were prepared in 0.01 M CaCl2/0.2 M acetate buffer (pH 
5.5) with 1% of DMF. After that, α-amylase (250 units/mL) was added and the solution 
incubates at 37 ºC under 100 rpm. After 12 hours of incubation, the pH of the solution was 
changed to 7.4 by the addition of NaOH 0.1 N and the esterase was added to the solution.  
All the previous prepared samples were incubated at 37 ºC and shaken at 100 rpm. 100 µL of 
sample was withdrawn immediately after enzyme addition and at different time points 
hereafter, mixed with 400 µL of methanol and centrifuged at 10 000 rpm for 10 minutes at 
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room temperature (Centrifuge eppendorf 5415). The supernatant was then removed and 
analysed by HPLC to determine the concentration of conjugate. Each experiment was 
performed in triplicate. This procedure was adapted by that described by F. Hirayama 
(Hirayma, Ogata et al., 2000). 
 
Table 3.5 Details for stability experiments of diclofenac-β-cyclodextrin conducted in the 
presence of different enzymes. 
3.5.1.4 Stability in gastric and intestinal simulated fluids  
3.5.1.4.1 Stability in simulated gastric fluids (SGF) and in simulated intestinal  
fluids (SIF) 
Solutions of diclofenac-β-cyclodextrin conjugate 0.8 mg/mL were prepared in SGF and in SIF 
with 1% of DMF. The simulated gastric and intestinal fluids were prepared according to USP 
Conjugate Enzyme 
Enzyme 
concentration 
(units/mL) 
Media 
Final 
volume 
(addition 
methanol) 
(µL) 
Final 
conjugate 
concentration 
(mg/mL) 
 
 
0.8 mg/mL 
(1% DMF) 
 
Esterase from 
porcine liver 
39  
HEPES/NaOH 
(pH 7.4) 
400  0.15  
α-amylase from 
Aspergillus 
oryzae 
20 
 40 
250  
0.01M CaCl2/0.2M 
acetate buffer 
 (pH 5.5) 
400  0.15  
α-amylase from 
porcine liver 
250  
0.01M CaCl2/0.2M 
acetate buffer  
(pH 5.5) 
400  0.15  
α-amylase from 
Bacillus 
lechiniformes 
250  
0.01M CaCl2/0.2M 
acetate buffer 
 (pH 5.5) 
400  0.15  
α-Amylase and 
esterase from 
porcine liver 
simultaneously 
250  
39  
0.01M CaCl2/0.2M 
acetate buffer 
 (pH 5.5) 
400 0.15  
α-Amylase and 
after 12 h 
addition of 
esterase from 
porcine liver  
250  
39  
0.01M CaCl2/0.2M 
acetate buffer  
(pH 5.5) for 12h.  
Ajust of pH to 7.4 
before addition of 
esterase  
400 
0.15  
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specifications (Test solutions, United States Pharmacopeia 30, NF 25, 2007), (Appendix C). 
These solutions were incubated at 37 
o
C and shaken at 100 rpm. At fixed intervals, 100 µL of 
fluid was withdrawn, mixed with 400 µL of methanol and centrifuged at 10 000 rpm for 10 
minutes at room temperature (Centrifuge eppendorf 5415). The supernatant was then removed 
and analyzed by HPLC to determine the concentration of conjugate. Each experiment was 
performed in triplicate. 
Table 3.6 Details for stability experiments of diclofenac-β-cyclodextrin in SGF and SIF. 
Media 
Conjugate 
concentration  
 Sampling 
volume  
Final volume 
(addition 
methanol) 
Final conjugate 
Concentration 
Simulated gastric fluid 
(SGF) (0.1 N HCl,  
pH 1.2 with pepsin) 
0.8 mg/mL 100 µL 500 µL 0.16 mg/mL 
Simulated intestinal fluid 
(SIF) (phosphate buffer 
pH 6.8 with pancreatin) 
0.8 mg/mL 100 µL 500 µL 0.16 mg/mL 
 
 Stability of the diclofenac-β-cyclodextrin conjugate in animal fluids 3.5.2
3.5.2.1 Stability in gastric and intestinal fluids 
To performe the stability studies, gastric and intestinal fluids that had been collected and kept 
in the freezer were left at room temperature until completely thawed. After that, fluids were 
centrifuged at 10 000 rpm during 10 minutes. The supernatants obtained were separated and 
used to conduct the stability experiments. Solutions of diclofenac-β-cyclodextrin (2.4 mg/mL) 
were prepared in SGF without pepsin and in PBS pH 6.8 with DMF (Table 3.7). To conduct 
the stability in gastric fluids from animals, 100 µL of the conjugate solution prepared in SGF 
without pepsin was mixed with 900 µL of stomach fluids from pig, rabbit or rats. In the case 
of intestinal fluids, 100 µL of the conjugate solution prepared in PBS 6.8 was mixed with 900 
µL of duodenum, jejunum or ileum fluids from pig, rabbit or rats. The final concentrations of 
the conjugate and DMF were 0.240 mg/mL and less than 1% respectively. Thereafter, these 
solutions were incubated at 37 
o
C and shaken at 100 rpm. At fixed intervals, 100 µL of fluid 
was withdrawn, mixed with 200 µL of methanol and centrifuged at 10 000 rpm for 10 minutes 
at room temperature. The supernatant was then removed and analysed by HPLC. Each 
experiment was performed in triplicate. 
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Table 3.7 Details for stability tests of conjugate in gastric and intestinal fluids from pig, 
rabbit and rats. 
Conjugate 
concentration 
Animal 
fluid 
Incubation 
Conjugate 
concentration 
Incubation 
Sampling 
volume 
Final 
volume 
(addition 
methanol) 
Final  
Conjugate  
concentrati
on 
2.4 mg/mL in 
SGF without 
pepsin 
Stomach 
100 µL of 
conjugate + 
900 µL of 
animal fluid 
0.24 mg/mL 100 µL 300 µL 
0.08 
mg/mL 
2.4 mg/mL in 
PBS 6.8 
Duodenum 
Jejunum 
Ileum 
3.5.2.2 Stability studies in caecum and colonic fluids 
The stability of conjugate was carry out in fluids collected form the lower intestine of 
animals, namely caecum and colonic fluids. Sulfasalazine was used as a control and was 
incubated concomitant with the conjugate. Caecum and colonic frozen fluids were left at 
room temperature until completely thaw. Thereafter, the caecum fluids (rat, rabbit and pig) 
and also the fluids from the anterior colon of pig (colon A) were centrifuged at 10 000 rpm 
during 10 minutes and the supernatant was used to perform the stability studies. The colon 
fluids (rats, rabbit and fluids from the posterior colon of pig (colon B)) were prepared 
according to the method described before for preparation of human faecal slurries (see 
3.5.1.2) due to the absence of liquid fluid. The stability studies were performed as described 
above and according to the scheme presented in Table 3.8. 
Table 3.8 Details for stability tests of conjugate versus sulfasalazine in caecum and 
colonic fluids from pig, rabbit and rat. 
Animal 
fluid 
Prodrugs 
concentration in 
PBS 6.8 
Incubation 
Prodrugs 
concentrations 
(Incubation) 
Sampling 
volume 
Final 
volume 
(addition 
methanol) 
Final  
prodrug 
concentration 
Caecum 2.4 mg/mL of 
conjugate 
and 
0.4 mg/mL of 
sulfasalazine 
100 µL of 
prodrugs 
solution + 
900 µL of 
animal 
fluid 
0.24 mg/mL 
of conjugate 
and 
0.04 mg/mL 
of 
sulfasalazine 
100 µL 300 µL 
0.08 mg/mL of 
conjugate and 0.0133 
mg/mL of 
sulfasalazine 
Colon 
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3.6 Results and discussion 
 HPLC method development 3.6.1
The HPLC method for quantification of conjugate, diclofenac and sulfasalazine is described 
in section 3.4.4 was developed taking in account the previous experiments. The choice of the 
solvent of precipitation was tested in one of the most complex mediums, faecal slurries. The 
aim was to confirm which solvent could provide better recovery of drugs from the incubated 
samples. The experiments showed that methanol allows the extraction of the drugs with better 
recovery than acetonitrile, which can be explained by the best solubility of the tested 
molecules in methanol. Additionally, samples precipitated with methanol providing cleaner 
chromatograms than those with acetonitrile.  
A typical chromatogram produced after injection of one sample prepared by precipitation of a 
human faecal slurry sample containing diclofenac-β-cyclodextrin and sulfasalazine is 
represented in Figure 3.3. The retention times for the conjugate, sulfasalazine and diclofenac 
were 6.9, 13.0 and 18.6 minutes, respectively.  
The same method was adopted to perform all the stability studies. All the experiments, blank 
samples were run previously to be certain of no existence of interferences between the 
componentes of each matrix and the analytes. 
 
Figure 3.3 HPLC chromatogram of diclofenac-β-cyclodextrin (r.t. = 6.9 minutes), 
sulfasalazine (r.t = 13.0 minutes) and diclofenac (r.t. = 18.6 minutes) in human faecal 
slurry. 
  
Diclofenac-β-cyclodextrin 
Sulfasalazine 
Diclofenac 
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 Stability of diclofenac-β-cyclodextrin conjugate in simulated fluids 3.6.2
3.6.2.1 Stability in the lower gastrointestinal tract 
While in the upper gastrointestinal tract, the digestive enzymes play the most important role in 
the mechanism of hydrolysis, in the lower intestine, fermentation is the main process of 
digestion of subtracts.  
3.6.2.1.1 Stability studies of diclofenac-β-cyclodextrin in human faecal slurries  
Conjugate was added to the human faecal slurry and results demonstrated that the conjugate 
was readily hydrolysed in the human faecal slurry, and within 2 hours the conjugate was 
completely degraded, observed by the rapid liberation of free diclofenac, as shown in Figure 
3.4. By contrast, the conjugate was stable in the autoclaved faecal slurry (control). These 
results confirmed that cleavage of the conjugate is due to bacterial enzymatic activity in the 
slurry. Bacteroides species account for ca. 20% of the human faecal and ferment a wide 
variety of polysaccharides (Reddy, Palmer et al., 1984). 
 
Figure 3.4 Mean levels of diclofenac-β-cyclodextrin (□) and diclofenac (▪) in human 
faecal slurry (test). Mean levels of diclofenac-β-cyclodextrin (○) and diclofenac (●) in 
autoclaved faecal slurry (control). Each point represents mean ± S.D. (n=3). 
Zoetendaal et al reported the existence of considerable variation in human faecal microbiota 
composition between individuals. These authors concluded that, in humans, there is a strong 
genetic link between an individual and its microbiota, so that each individual has a unique 
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microbial community (Zoetendal, Akkermans et al., 1998). For this reason, it was recommend 
by McBurney and Thompson to use at least three donors when human faeces were used as 
inocula (Mcburney and Thompson, 1989). Taking in account this, the metabolism of the 
conjugate was studied in faecal slurry from 3 male humans in order to assess the variability 
inter-subjects. Sulfasalazine was used as positive control. The stability profile of conjugate 
and sulfasalazine is shown in Figure 3.5 A and B, respectively.  
These results indicate that metabolism of both prodrugs depends on the source of faecal 
slurry, which can be associated with different diets. 
 
Figure 3.5 Mean levels of diclofenac-β-cyclodextrin conjugate (A) and mean levels of 
sulfasalazine (B) in three different samples of faecal slurry from male individuals from 3 
different male individuals (▲, ■, ♦). Each point represents mean ± S.D. (n = 3).  
It has been reported that diet may have a profound influence on microbiota. Hence, a diet rich 
in protein and animal fat is associated to a domine of Bacteroides genus (Bacteroidetes 
Phylum) while a diet rich in carbohydrates is associated to Prevotella genus (Bacteroidetes 
Phylum). Moreover, the same authors revealed that the European microbiome is dominated by 
Bacteroides enterotype, whereas the African microbiome was dominated by the Prevotella 
enterotype (Wu, Chen et al., 2011). It would be necessary to increase the number of donors to 
have evidence how the metabolism of prodrugs varies according to the source of matrix.  
Further, these results show that in all the faecal slurries the degradation of sulfasalazine is 
faster than the degradation of the conjugate. This suggests that the mechanism involved in the 
degradation of sulfasalazine is faster than that responsible for the degradation of conjugate. 
As described in Chapter I, azoreductase (EC 1.7.1.6) is the enzyme responsible for the 
activation of sulfasalazine. This is a flavin mononucleotide (FMN)-dependent enzyme, that is 
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produced by numerous intestinal bacteria, namely Escherichia coli, Bacillus subtilis, 
Enterococcus faecalis, Rhodobacter sphaeroides, and Pseudomonas aeruginosa (Ryan, 
Laurieri et al., 2010). There is some evidence that azoreductase activity occurs inside the cell, 
on certain bacterial species (Peppercorn and Goldman, 1972; Song, Zhou et al., 2003). 
However, azoreduction can be accomplished outside the bacterial cells with the assistance of 
electron transport agents such as nicotinamide adenine dinucleotide phosphate (NADPH), 
which is a more general reaction (Scheline, 1973). Otherwise, in the case of diclofenac-β-
cyclodextrin, as described before, esterases and/or glycosylases will be involved in its 
metabolism. Also, it was reported that Bacteroides are the main species responsible for 
degradation of cyclodextrins (Antenucci and Palmer, 1984). Therefore, the metabolism rate of 
both prodrugs is different not only due to the different mechanism of degradation but also due 
to different microbiota species involved on the enzymes production. 
3.6.2.1.2 Stability studies in simulated colonic media containing enzymes 
It is difficult to specify which enzymes are responsible for the release of diclofenac from the 
conjugate in the faecal slurry. There are a huge variety of microorganisms that are able to 
produce a variety of enzymes. The hydrolysis studies of the conjugate, using ester 
hydrolysing enzymes and sugar-degrading enzymes were conducted in order to attempt the 
development of an in vitro enzymatic media able to mimic the biological fluids. 
Stability in presence of esterases 
Results from stability studies in the presence of esterases showed that diclofenac is not 
released during the 24 hours of incubation. This allows concluding that this ester bond is not 
susceptible to esterase hydrolysis, as observed in Figure 3.6.  
Pig liver esterase (PLE) is a carboxylic esterase (E.C 3.1.1.1.) and it was chosen since it has 
been used as a widely accepted model enzyme for ester-hydrolysing molecules. Stability, low 
costs, and the ability of hydrolysing a wide range of substrates with high stereoselectivity 
represent additional advantages of this enzyme, which operates without the need of co-
enzymes (Tamm, 1992; Huang, Shiotsuki et al., 1996). 
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Figure 3.6 Stability of diclofenac-β-cyclodextrin in the presence of esterase from porcine 
liver (39 Units/mL) in HEPES NaOH buffer (pH 7.4). Each point represents mean ± S.D. 
(n = 3). 
This study was performed according to previous studies that investigated the stability of 
cyclodextrins conjugates, namely of dimethyl-β-cyclodextrin-4-biphenylylacetic acid 
conjugate (Ventura, Paolino et al., 2003a), β-cyclodextrin 5-fluorouracil acetic acid conjugate 
(Udo, Hokonohara et al., 2010) and of β-cyclodextrin-butyric acid(Hirayma, Ogata et al., 
2000). Basically, the conjugate was incubated with 39 units/mL of esterase in HEPES/NaOH 
buffer pH 7.4 (Hirayma, Ogata et al., 2000). As observed with diclofenac-β-cyclodextrin, 
esterase had no effect on the ester linkage of β-cyclodextrin-butyric acid conjugate (Hirayma, 
Ogata et al., 2000). However, in the case of dimethyl-β-cyclodextrin biphenylacetic acid 
conjugate, the drug was released in presence of this esterase with a t1/2 value of 4 hours 
(Ventura, Paolino et al., 2003a). This result obtained with diclofenac-β-cyclodextrin conjugate 
reinforces the idea that the conjugation with β-cyclodextrin is less susceptible to hydrolysis by 
esterase than the conjugation with a derivative of β-cyclodextrin. This is probably due to the 
higher hydrophilicity of the methylated carrier when compared with the natural β-
cyclodextrin and consequently less intramolecular association between drug and carrier. 
Moreover, it was found that esterase activity is higher towards more water soluble substrates 
(Fojan, Jonson et al., 2000). 
A previous study showed that complexation of diloxanide furoate with β-cyclodextrin, caused 
a stabilization of this drug against esterase. This effect was not only due to protection of the 
drug through formation of cyclodextrin complexes. The authors suggested that the inhibitory 
effect against esterase can occur due to the complexation of cyclodextrin with amino acids of 
the lateral chains that participate in the active site of the enzyme (Monteiro, Chiaradia et al., 
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2003). Therefore, interactions between cyclodextrins and enzymes should be taking into 
account when stability studies are performed in the presence of enzymes.  
Stability in presence of amylases  
The assessment of efficacy of 3 different types of amylases (amylase from Bacillus 
lechiniformes, amylase from porcine pancreas and amylase from Aspergillus Oryzae) to digest 
the conjugate was carried out. Figure 3.7 shows the quantity of conjugate (%) after incubation 
in presence of three different amylases plotted versus time.  
 
Figure 3.7 Mean levels of diclofenac-β-cyclodextrin in presence of different α-amylases 
(250 units/mL): α-amylase from Bacillus lechiniformes (♦), α-amylase from Aspergillus 
oryzae (■) and α-amylase from porcine pancreas (●) in 0.2 M acetate buffer (pH 5.5) 
containing 0.01 M CaCl2 at 37 °C. Each point represents mean ± S.D. (n = 3). 
Amylase from porcine pancreas is part of pancreatin, which is commonly used to represent 
the digestion within the small intestine, as described before. The intention here is to study its 
activity against cyclodextrins isolated, since in the studies with pancreatin amylases are mixed 
with a variety of other enzymes, including lipases and proteases. Results observed in the 
presence of this amylase are in agreement with previous results with films of cyclodextrins, 
which had shown that this enzyme does not degrade β-cyclodextrin (Fetznera, Bo¨Hmb et al., 
2004). This emphasizes the idea that α-amylase from porcine pancreas is not active against 
this conjugate.  
α-Amylase from Bacillus lechiniformes, a highly thermostable enzyme, was selected as it 
resembles the properties of colonic amylases. It has been used as a model enzyme to resemble 
the colonic digestion of amylase (Siew, Man et al., 2004). When the conjugate was incubated 
with this enzyme, it was not observed its degradation. 
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The amylase from fungus Aspergillus oryzae was selected since it was able to degrade 
cyclodextrin (Jodal, Kandra et al., 1984). As observed in Figure 3.7, only this enzyme was 
able to digest the conjugate.  
Analysis of HPLC chromatograms of the hydrolysates obtained after incubation of the 
conjugate with α-amylase from Aspergillus Oryzae after 0, 6 and 24 hours revealed that 
during incubation new peaks have apperead, however non of them correspond to the 
conjugate or the diclofenac. However, after 24 hours of incubation, although the conjugate 
had completely disappeared, the digestion of conjugate with this enzyme only allowed to 
release around 9% of diclofenac.  
In order to understand the progress of the enzymatic reaction, and how the concentration of α-
amylase from Aspergillus Oryzae can affect the rate of degradation and the formation of the 
intermediate compounds, the conjugate was incubated with three different concentrations of 
enzyme. The results obtained are present in Figure 3.8, and reveal that the conjugate was 
hydrolysed by the enzyme according to first-order kinetics, with t1/2 values of 13.3, 7.4 and 
2.7 hours at enzyme concentration of 20, 40 and 250 units/mL, respectively. 
In Figure 3.9 is possible to observe the evolution of the reaction between the conjugate and 
different concentrations of amylase from Aspergillus oryzae. Chromatograms showed that 
after 24 hours of incubation, in samples incubated with 20 and 40 units/mL of enzyme, part of 
the conjugate was still intact, while in samples incubated with 250 units/mL, all the conjugate 
was digested. Otherwise, after 24 hours of incubation, in the case of low concentrations of 
enzyme, 20 and 40 units/mL, it was not observed any release of diclofenac from the 
conjugate. In the course of the hydrolysis, it was registered the formation of 2 new peaks that 
were not identified. These should be linear maltooligomers (Jodal, Kandra et al., 1984) 
coupled to diclofenac, since only the drug was responsible for the ultraviolet detector 
response at the wavelength used (λ = 254nm). 
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Figure 3.8 First-order plots for hydrolysis of the conjugate in the presence of Aspergillus 
oryzae α-amylase in acetate buffer (pH 5.5) at 37 °C at different concentrations of α-
amylase (20 (■), 40 (▲) and 250 (●) units/mL). 
 
Figure 3.9 HPLC chromatograms of the enzymatic reaction of conjugate im presence of 
different concentrations of α- amylase from Aspergillus Oryzae (20, 40 and 250 units/mL) 
at 0, 6, and 24 hours. 
α-amylase from Aspergillus Oryzae can digest the conjugate, however new intermediate 
compounds are formed prior to release of diclofenac. These unknown compounds, that are 
fragments from the digestion of cyclodextrin, can be identified using LC-MS. 
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It is important to note that in case of incubation with faecal slurry, no formation of 
intermediate peaks in HPLC chromatograms was observed. In the case of stability studies in 
human faecal slurry the rate of disappearance of diclofenac-β-cyclodextrin is inversely 
proportional to the rate of appearance (release) of diclofenac. These results suggest that this 
enzyme per se is not able to simulate the mechanism involved in the release of diclofenac, at 
the level of the lower intestine. 
It is reported that the new compounds formed in the first period of the reaction between 
cyclodextrin and this enzyme, called higher-membered maltooligomers (maltohexaose, 
maltopentaose, maltotetraose), are also substrates of the enzyme and consequently these can 
be competitive inhibitors of the enzymatic reaction (Suetsugu, Koyama et al., 1974; Jodal, 
Kandra et al., 1984). Moreover, it is reported that lower-membered maltooligomers (glucose, 
maltose and maltotriose) formed during the reaction are not substrates of the enzyme, but by 
linking to the enzyme-protein they may become “non-competitive” inhibitors (Jodal, Kandra 
et al., 1984).  
This inhibition effects caused by the degradation products can explain the slow digestion and 
consequently the poor release of drug. Otherwise, results suggest that amylase alone is not 
able to lead to complete release of drug, at least in 24 hours of experiment.  
The combination of amylase and esterase was made in order to access the ability of both in 
the release of diclofenac from the conjugate. It was expected that, even if interaction occured 
between esterase and cyclodextrin, once the last one is degraded, esterase would be free to act 
against the ester linkage. 
Stability of diclofenac-β-cyclodextrin in the presence of amylase and esterase 
The concomitant incubation of amylase and esterase with the conjugate has the same effect 
than the incubation with amylase alone (Figure 3.10). This suggests that amylase was 
degrading the cyclodextrin carrier, while esterase did not act against cyclodextrin, 
independently on the structure of the carrier obtained after digestion by amylase.  
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Figure 3.10 Mean levels of diclofenac-β-cyclodextrin (▲) and diclofenac (∆) in the 
presence of α-amylases from Aspergillus oryzae (250 units/mL) and carboxylic esterase 
(39 units/mL) in acetate buffer (pH 5.5) at 37oC. Mean levels of diclofenac-β-
cyclodextrin (■) and diclofenac (∆) in the presence of α-amylases from Aspergillus oryzae 
(250 units/mL) in acetate buffer (pH 5.5) at 37oC. 
This could be due to the fact that esterase enzyme was not incubated in its optimum medium 
(HEPES/NaOH pH 7.4). In order to clarify this presupposition, the same experiment was 
conducted in HEPES/NaOH pH 7.4 and results showed a decrease of the rate of degradation 
of the conjugate when compared to results observed in Figure 3.10. Moreover, it was not 
observed release of diclofenac during the first 6 hours of experiment (results not presented). 
The change on pH leads to alteration on the activity of α-amylase proved by the slower 
disappearance of the conjugate at pH 7.4. However, no alterations were observed on the 
quantity of diclofenac released. 
Therefore, other experiment was performed in the presence of amylase at pH 5.5, and after 12 
hours of incubation the pH was changed to 7.4 before incubation of esterase according to 
studies reported by Koichi Udo et al. (Udo, Hokonohara et al., 2010). Thus, the study was 
conducted using the optimum pH to guarantee the bioactivity of the enzymes. 
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Figure 3.11 Mean levels of diclofenac-β-cyclodextrin (■) and diclofenac (□) in the 
presence of α-amylases from Aspergillus oryzae (40 units/mL) and carboxylic esterase 
(39 units/mL) in acetate buffer (pH 5.5) at 37 oC. The esterase (39 units/mL) was added 
12 hours after the α-amylase. A- addition of the α-amylase; B- addition of the esterase. 
These results show that, if esterase is added 12 hours after digestion of the conjugate in 
presence of amylase, a higher quantity of diclofenac is released. Time of the experiment 
should be prolonged in order to conclude about the ability to completely release of diclofenac. 
These results suggest that the mechanism of drug release from this kind of prodrug, with a 
cyclodextrin as a carrier, involves sequential drug liberation. This mechanism comprises an 
initial enzyme-mediated cleavage of the carrier backbone (cyclodextrin) towards the action of 
amylases, which allows reduction of the steric protection of the ester diclofenac-cyclodextrin 
bond. With the progressive fragmentation of cyclodextrin, small fragments will become 
substrates for esterases and other hydrolases residing within the colon. This sequential 
hydrolysis mechanism was demonstrated previously in the hydrolyses of the  
β-cyclodextrin-n-butyric acid conjugate and the β-cyclodextrin-5-fluorouracil conjugate 
catalysed by α-amylase (Aspergillus oryzae) and carboxylic esterase (porcine liver) 
(Hirayama, Ogata et al., 2000; Udo, Hokonohara et al., 2010). 
However, it is important to note that this sequential mechanism cannot be assumed for all the 
cyclodextrin conjugates. Bacterial enzymatic degradation depends not only on the 
susceptibility of the chemical bond, but also on the struture of the molecule surrounding the 
susceptible bond. This was found previously through the study of naproxen-cyclodextrin 
conjugates, which was not degraded on rat colonic fluids due to the steric hindrance 
surrounding the ester bond caused by the naphthalene structure presented in naproxen (El-
Kamel, A.M.Abdel-Aziz et al., 2008). 
0
20
40
60
80
100
120
0 5 10 15 20 25 30
In
it
ia
l 
(%
) 
Time (Hours) 
A 
B 
Chapter III 
115 
Overall, the combination of α-amylase, able to degrade cyclodextrin carrier, and an esterase 
can lead to release of diclofenac form this cyclodextrin-based prodrug. However, with the 
concentrations of enzymes used, the rate of release is not comparable with that observed in 
human faecal slurry. A faster degradation of cyclodextrin backbone needs to take place on the 
degradation process observed in the presence of amylase. This can be conducted with higher 
concentrations of enzymes as indicated by results presented in Figure 3.9. 
3.6.2.2 Stability of diclofenac-β-cyclodextrin conjugate in the upper gastrointestinal 
tract 
3.6.2.2.1 Simulated stomach and intestinal fluids  
Incubation of conjugate in simulated gastric and intestinal fluids were taken as a starting point 
to study the stability in upper gastrointestinal tract. Results from these in vitro studies 
revealed that the conjugate is not susceptible to be hydrolyzed in these simulated fluids. 
 
Figure 3.12 Mean levels of diclofenac-β-cyclodextrin conjugate in simulated gastric fluid 
(♦) and  in simulated intestinal fluid (▲). Each point represents mean ± S.D. (n = 3). 
As expected, once this conjugate does not present a peptide structure, pepsin (EC.3.4.23.1) is 
not able to affect the stability of the conjugate. Additionally, pancreatic enzymes do not affect 
the integrity of the conjugate.  
These results are the first indication that conjugate may resist to the attack of digestive 
enzymes in gastric and intestinal media and reach the lower intestine intact. 
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 Stability of diclofenac-β-cyclodextrin conjugate in animal fluids 3.6.3
3.6.3.1 Stability in gastric and intestinal fluids 
Conjugate was incubated with stomach and intestinal fluids of each animal model. Figure 
3.13 shows the stability of the conjugate after incubations with fluids of animals (rat, pig and 
rabbit) from stomach and small intestine (duodenum, jejunum and ileum). Results show that 
conjugate is stable in the contents of stomach and small intestine. The profile obtained with 
these biological fluids is the same obtained using simulated gastric and intestinal fluids, 
although these fluids from animals are enriched by many elements that are not present in the 
artificial fluids. These results with animal fluids reinforce the idea provided by simulated 
fluids relative to the stability of conjugate in the upper gastrointestinal tract. 
 
Figure 3.13 Stability of diclofenac-β-cyclodextrin in stomach, duodenum, jejunum and 
ileum contents from pig (■), rat (▲) and rabbit (♦). Each point represents mean ± S.D. 
(n = 3). 
A previous study involving drugs with amide and/or ester bonds concluded that intestinal 
juice from pig had a major capacity to mimicry the human conditions than the simulated 
intestinal fluid, when oseltamivir was tested. The higher metabolism in intestinal juice pig 
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than in simulated intestinal fluid was also observed for atazanavir carbamate and diloxanide 
furoate. The higher metabolism in collected juice was attributable to its enzymatic activity 
(Sarti, Barthelmes et al., 2011).  
Moreover, no differences were observed between the fluids of the upper GI tract of different 
animals, which mean that the conjugate has the same behaviour independently on the specie. 
Therefore, animal fluids can be replaced with simulated fluids to carry out the stability studies 
on the upper gastrointestinal tract of this conjugate.  
It is important to note that, despite the high levels of bacteria in rat stomach, these do not 
affect conjugate stability. This might be due to the inexistence e/or inability of enzymatic 
bacteria capable to operate on the conjugate. Otherwise, it is known that rabbits practice 
caecoprophagy, which is associated with fermentation at the level of the stomach. However, 
fermentation only exists when caecoprophes are present and it does not occur in the gastric 
media. Additionally, only the supernatant obtained after centrifugation of fluids was used, 
which avoided destruction and mixture of the caecoprophes with the gastric fluid. Moreover, 
these studies were carried out using the supernatant of the fluids obtained after centrifugation 
and some enzymes can be bound to particulate matter left in the pellet (Ikesue, Kopečkovà et 
al., 1993). For this reason some authors instead of the centrifugation, proceed to dilution of 
fluids before stability experiments. However, a study conducted for determination of α-
amylase activity in the supernatants of fluids used in these stability tests showed that a huge 
activity of amylase is observed in stomach of rats when compared with pigs and rabbits 
(Appendix D).  
Enzymes in the luminal fluids can also come from dead gut wall cells, which will be abraded 
into the intestine. Therefore, sometimes it is worth to include studies with microssomes to be 
sure about the stability in intestinal mucous (Borde, Karlsson et al., 2012). However, previous 
studies with intestine homogenates of rats without contents had shown negligible degradation 
of the cyclodextrin prodrugs (Hirayama, Ogata et al., 2000; Kamada, Hirayama et al., 2002).  
Results of diclofenac-β-cyclodextrin are according to those reported before which 
investigated the stability of cyclodextrin conjugates in fluids from rats. For instance, butyric 
acid β-cyclodextrin was stable with any release of drug in stomach and intestinal contents for 
8 hours (Hirayma, Ogata et al., 2000). Okamato et al. demonstrated that in contents from 
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stomach and small intestine of rats, the cyclodextrin-5-ASA released 5-ASA only in small 
amounts (< 12%) during 48 hours (Zou, Okamoto et al., 2005). Comparing the stability of 
ethyl 4-biphenylylacetate with the stability of the equivalent cyclodextrin prodrug, the first 
was rapidly hydrolysed in contents from stomach and small intestine of rat, while only 10% of 
the cyclodextrin ester prodrugs were hydrolysed in the same contents (Uekama, Minami et al., 
1997a). Another study that compares the stability between prednisolone-succinate-α-
cyclodextrin and prednisolone succinate showed that in case of cyclodextrin prodrug the 
quantity remained after 6 hours of incubation was 80-90%, while prednisolone succinate 
alone was rapidly hydrolysed (Hideki Yano, Fumitoshi Hirayama et al., 2002). These studies 
demonstrated that the type of carrier influences the stability of the ester prodrugs and 
apparently the size of the carrier is determinant for the stability of the ester prodrugs in fluids 
from the upper GI tract. Thus, these authors justified the resistance of the conjugate against 
the ester hydrolysis in the contents from the stomach and small intestine due to a large steric 
effect of the bulky cyclodextrin moiety (Uekama, Minami et al., 1997a; Hideki Yano, 
Fumitoshi Hirayama et al., 2002).  
3.6.3.1.1 Stability studies in caecum and colonic fluids 
Results of stability of the conjugate and sulfasalazine in caecum fluids from rat, pig and rabbit 
and from anterior colon of pig (colon A) are represented in Figure 3.14 and Figure 3.15. 
These show that caecum and colon A pig fluids do not degrade the conjugate. Sulfasalazine is 
also not metabolised. This suggests an absence of enzymatic activity or inactivity of the 
microbiota at least for 6 hours of experiment in these pig fluids. Contrarily, in the case of rat 
and rabbit fluids, it is observed degradation of both prodrugs.  
The degradation of sulfasalazine is faster than the degradation of conjugate. In caecum rat 
fluids, sulfasalazine is completely degraded in 30 minutes of incubation, while in the case of 
conjugate 60% is degraded after 6 hours of incubation. With rabbits, after 5 hours of 
incubation in caecum fluid, 60% of the conjugate was metabolised. For sulfasalazine, the 
degradation occurs with a high rate in the first 2 hours of incubation but after the % of 
prodrug remained constant, around 18%. These profiles of diclofenac-β-cyclodextrin 
conjugate and sulfasalazine degradation in caecum fluids show that the metabolism of both 
prodrugs is variable between these three species.  
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Figure 3.14 Stability of diclofenac-β-cyclodextrin in caecum contents from pig (■), 
rabbit (▲), rat (♦) and in pig colon A fluids (●). Each point represents mean ± S.D. (n = 
3).  
Figure 3.15 Stability of sulfasalazine in caecum contents from pig (■), rabbit (▲) and rat 
(♦) and in pig colon A fluids (●). Each point represents mean ± S.D. (n = 3).  
It was observed that both prodrugs suffer degradation in colonic fluids. Profiles of 
degradation of conjugate and sulfasalazine are represented in Figure 3.16 and Figure 3.17, 
respectively.  
One more time, the degradation of sulfasalazine is faster than the degradation of conjugate. In 
pig fluids, after 6 hours of incubation, 60% suffered degradation while in case of sulfasalazine 
70% was degraded considering the same time of incubation In case of rabbits, the percentage 
of conjugate remained after 6 hours of incubation in colonic fluids is 24%, while sulfasalazine 
is completely metabolised. The fastest rate of degradation in colonic fluids was observed in 
rats, herein sulfasalazine and conjugate were degraded completely after 45 minutes and 3 
hours, respectively.  
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Figure 3.16 Stability of diclofenac-β-cyclodextrin conjugate in colon contents prepared 
as a faecal slurry from pig (■), rabbit (▲) and rat (♦). Each point represents mean ±
S.D. (n = 3).  
 
Figure 3.17 Stability of sulfasalazine in colon contents prepared as a faecal slurry from 
pig (■), rabbit (▲) and rat (♦). Each point represents mean ±S.D. (n = 3).  
Comparing the metabolism in caecum and colonic fluids, the degradation of both prodrugs is 
faster in colonic than in caecum fluids in all the animals. In case of pigs, Butine and Leedle 
reported a higher microbial counts in the colon than in caecum (Butine and Leedle, 1989). 
But, Bach Knudsen et al. found that the densities of microorganisms in the caecum and colon 
appear to be quite similar (Bach Knudsen and Hansen, 1991). In terms of microbial activity, a 
study that compared the in vitro fermentation between 3 different portions of gastrointestinal 
tract (caecum, colon and rectum) of pig found that fermentation is slower in caecum (Bauer, 
Williams Barbara et al., 2004) which is according to results present here.  
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However, other studies found a reverse microbial activity, i.e. higher in caecum than in colon 
of pigs. For instance, Jensen and Jørgensen, found out that the highest microbial activity 
(highest bacterium counts, highest ATP concentration, low pH) was found on the caecum and 
proximal colon, where substrate availability is greatest (Jensen and Jørgensen, 1994). Other 
study that determined the metabolic activity by ATP concentrations found that it is less in 
colon than in caecum, which occurs probably due to energy becoming limiting during 
movement of digesta through the large intestine (Bach Knudsen and Hansen, 1991). Also 
Awati et al. found higher volatile fatty acids concentrations in the caecum than in the distal 
colon of pigs (Awati, Williams et al., 2006), which is associated with the higher quantity of 
substrate.  
The controversy between studies led to speculate that the metabolic activity measured 
depends not only on the fermented subtract and the respective end products measured, but 
also depends on the fed state of the animals. These pigs had ad libitum access to food on the 
moment of collection of the fluids, and therefore the microbiota had enough substrate 
available. Thus, when an external substrate is added to the media, even if the metabolic 
activity is high, it could not be the preferable substrate for the microbiota, which consequently 
implies a slow rate of digestion. Thus, the activity of the intestinal ecosystem is a reflection of 
the relative availability for fermentation in each compartment and depends on the type of 
substrate. This can explain the highest rate of metabolism of both prodrugs in the colon than 
in caecum, whereby the prodrugs work as a substrate in the absence or lack of other substrate 
for the microbial enzyme. The effect of food on the metabolism of both prodrugs is discussed 
further in Chapter IV. 
Moreover, degradation in colonic fluids is probably faster, given that colonic fluids were 
prepared using all the amount of fluids, and therefore all the bacteria (even diluted) were 
presented. Otherwise, in case of caecum fluids, the slow release can be associated with the 
lack of some enzymes in the supernatant used. The centrifugation can lead to loss of enzymes 
that can be attached to the complex mixture digested contents that were precipitated after 
centrifugation, as referred above. Indeed, colonic fluids suffer dilution before the experiment, 
while the caecum was not subjected to any dilution. Thus both centrifugation and dilution of 
fluids may lead to an underestimation of the rate of metabolism in vivo. However, the 
thickness of the crude fluids makes it difficult to work without previous centrifugation or 
dilution. 
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Overall, hydrolysis rates of these prodrugs by luminal fluids on the lower gastrointestinal tract 
were different between species. However, bacterial strains seem to commonly inhabit the gut 
of laboratory animals and humans, since similar metabolic activity was noted in human faecal 
slurries, and colonic fluids form pigs, rabbits and rats. Bacteroides (Bacteroidetes Phylum) are 
believed to be the main species responsible for degradation of the cyclodextrin carrier. 
Bacteroides genus is able to induce enzymes adapting to the available substrates. They are 
able to grow on cyclodextrin as the sole carbon source. Also cyclodextrinase were isolated 
from two selected Bacteroides genus (Antenucci and Palmer, 1984). Moreover, species from 
Proteobacteria Phylum isolated from colon of pig (P. mirabilis and E. fergusonii) 
demonstrated to increase the release of bisoprolol from a film-incorporated β-cyclodextrin 
after pre-incubation in β-cyclodextrin containing nutrient medium (Fetznera, Bo¨Hmb et al., 
2004). 
The stability of the conjugate was not assessed using animal faeces. However, previous 
studies in rabbits had concluded that faeces could be used as an alternative source of inoculum 
to caecum contents to study in vitro caecum fermentation (Bovera, D’urso et al., 2006). Other 
study with rabbits confirmed that in vitro fermentation characteristics of faeces were highly 
related to those of caecum content by measurement of the degraded organic matter, potential 
gas production; volatile fatty acids and NH3 production (Bovera, D’urso et al., 2009). Other 
authors also pointed out that using faeces from pig to perform in vitro fermentation studies 
can overestimate the microbial activity of the caecum (Bauer, Williams Barbara et al., 2004). 
Otherwise, in the case of rats it was reported that the faecal material does not provide accurate 
information concerning the intestinal microbiota, because significant epithelial microbial 
associations occur in the proximal digestive tract (Tannock, 1999). Interestingly, rat caecal 
contents have been widely utilized as alternative dissolution medium of human colon (Yang, 
2008). This is because of the similarity colonic microbiota between human and rodent, when 
the number of Bacteroides and Bifidobacteria were counted (Hawksworth, Drasar et al., 
1971). In fact, rat was the only animal used before in order to study the in vitro stability 
assays of cyclodextrin conjugates. In this work comparing the metabolism between animals, 
rat is the animal that allows a faster degradation rate of both prodrugs. Actually, amylase 
activity at the level of the lower GI tract is also higher in rats than in rabbits and pigs 
(Appendix D). It is worth to note that the substrate used on the determination of α-amylase 
was starch. Therefore, the substract was not cyclodextrin, which prevents the direct 
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correlation between rate of metabolism of cyclodextrin conjugate and amylase activity. 
However, after breakdown of the cyclic structure of cyclodextrin, the dextrin formed is 
susceptible to be degraded by the same α-amylase that degrades starch. Therefore, the higher 
activity of α-amylase in rats can be responsible for the faster metabolism of the conjugate in 
this animal model.  
3.7 Conclusion 
This Chapter finds out that this conjugate can deliver diclofenac specifically at the level of the 
colon. Cyclodextrin can function as a colon targeting carrier of diclofenac when an ester 
linkage is formed between them. 
The conjugate is degraded at the level of the lower intestine with simultaneous release of 
diclofenac as demonstrated by results in human faecal slurries. This stability behaviour is due 
to specific hydrolysis of β-cyclodextrin by microbiota existent on the lower intestine. These 
results prove that gut microbiota is the key factor that determines the hydrolysis of the 
conjugate. The rate of degradation relied on the he synergistic interaction between the prodrug 
and the gut microbiota. Enzymes able to degrade cyclodextrins to linear dextrins are essential 
to initiate the metabolism of the conjugate at the level of the colon. 
The conjugate is completely stable in simulated gastric and intestinal fluids, and also in 
collected fluids from the upper GI tract of animals. Digestive enzymes are not involved in the 
degradation of diclofenac-β-cyclodextrin. 
Stability in fluids from the lower intestine of animals demonstrated that the faster metabolism 
of diclofenac-β-cyclodextrin was observed in rat fluids and therefore rat is presented as an 
adequate animal model to perform further studies. Comparing with sulfasalazine, the 
metabolism of sulfasalazine was always higher than that observed for conjugate.  
These preliminary results are promising, and suggest that diclofenac-β-cyclodextrin is able to 
release diclofenac, in the colon. In vivo studies are now necessary to have the in vivo proof of 
concept. 
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4 INFLUENCE OF FOOD ON GUT FLUIDS AND METABOLISM OF 
DICLOFENAC-ΒETA-CYCLODEXTRIN VERSUS SULFASALAZINE IN RATS 
4.1 Overview 
A screening of the in vitro performance of diclofenac-β-cyclodextrin conjugate in the 
different simulated gastrointestinal fluids, including different animal fluids, has been reported 
in Chapter III. Results showed that this prodrug is specifically degraded by microbiota in the 
large intestine, allowing diclofenac to be released into the colon.  
In respect to oral administration, it is known that food can affect the bioavailability of drugs. 
Generally patients are advised to take their medicines with food or on an empty stomach. 
However, these are imprecise instructions that are open to individual interpretations, and 
consequently are expected to contribute to a greater variability and lower therapeutic efficacy. 
Research on feeding regimens, such as timing of meals in relation to drug administration is 
necessary to increase the understanding of their influence on drug disposition. 
The aim of this study is to understand how different feeding regimens can affect the 
physiological conditions in the gastrointestinal tract and to understand how food intake 
influences the degradation of the conjugate in the large intestine. Concomitantly with 
diclofenac-β-cyclodextrin conjugate, the effect of feeding regimens on the metabolism of 
sulfasalazine - a well-known commercially available colonic prodrug of reference - was also 
studied.  
In vitro studies (Chapter III) demonstrated that rats provided the faster metabolism of both 
prodrugs, diclofenac-β-cyclodextrin and sulfasalazine. Therefore, this was the animal model 
used in this Chapter to access the influence of different feeding states on the metabolism of 
prodrugs.  
4.2 Introduction 
The presence of food in the gastrointestinal tract reduces gastrointestinal motility, thereby 
delaying the arrival of a colonic drug carrier to its site of action (Mittelstadt, Hemenway et al., 
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2005; Varum, Merchant et al., 2010; Varum, Hatton et al., 2013). Food intake also influences 
the amount of water in the gut that is available for drug dissolution prior to absorption. Food 
also influences pH of gut content, which as well as controlling drug release from pH-
responsive drug carriers, also influences the ionisation of weakly acidic/basic drugs and thus 
their aqueous solubility, stability and absorption (Stella, Borchardt et al., 2007; Varum, 
Merchant et al., 2010). Food also influences the performance of colonic prodrugs, whose 
conversion to drugs relies on gut bacterial enzymes. Bacterial activity in the colon depends on 
the quantity and quality of available substrates for fermentation, and determines the intensity 
and direction of gut bacterial metabolism of prodrugs and thereby drug absorption (Agorama, 
Woltosza et al., 2001; Mountzourisa, Kotzampassib et al., 2009). 
Diclofenac has been studied as one of the drugs whose pharmacokinetic parameters are 
influenced by the presence of food. The administration of an enteric coated diclofenac sodium 
formulation (50 mg) immediately after a standard breakfast showed that food does not have 
significant effect on the extent of diclofenac absorption when compared with the fasted state. 
However, delay in the onset of absorption (varying from 2.5 to 12 hours in fed and from 1.5 
to 2.75 hours in fasted state) and a reduction in peak plasma levels of approximately 30% was 
observed in the presence of food (Willis, Kendall et al., 1981). Other study conducted in 
humans with diclofenac hydrogel beads (150 mg) originated comparable effects on the 
presence of food. The administration immediately after breakfast did not affect the 
bioavailability, however the Cmax decreases 38% and the Tmax increases three fold in the fed 
state comparing with the fasted state (Thakker, Mangat et al., 1992). Billa et al. showed that 
after administration of gum xanthan tablets of sodium diclofenac (100 mg) in healthy men in 
fed state, AUC was not significantly affected and the Tmax  increased (Tmax values 2.6±0.3 
hours in fasted state and 5.5 ± 0.8 hours in fed state) (Billa, Yuen et al., 2000). This is 
consistent with the findings of Willis et al. (1981), Thakker et al. (1992) and Chan et al. 
(1990) (Willis, Kendall et al., 1981; Chan, Mojaverian et al., 1990; Thakker, Mangat et al., 
1992). Moreover, no differences were observed between the AUC of gum xanthan tablets and 
the buffer solution (pH = 7) of diclofenac in both dietary stats, in agreement with the findings 
of Riad et al. (1989) (Riad, Sawchuk et al., 1995; Billa, Yuen et al., 2000).  
On the other hand, Billa et al., found out that the Cmax of diclofenac is higher in fed state  
(Cmax = 347±112 ng/ml) than in fasted state (Cmax = 661.5±158.5 ng/ml), although the gastric 
emptying time was longer in presence of food. The faster release and absorption of diclofenac 
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was attributable to an interaction between food and the formulation. In fed state, the longer 
residence of the tablets in stomach leaded to a loss of the integrity of the xanthan gum matrice 
due to the low pH, allowing rapid influx of water into the matrix system with a faster rate of 
drug release (Billa, Yuen et al., 2000).  
Additionally, the pharmacokinetic parameters are dependent on the type of formulation, as 
demonstrated by Chan et al. who found that gastric emptying of sodium diclofenac, either in 
solution or as a precipitate, occurred more quickly than the emptying of Heidelberg capsule 
(Chan, Mojaverian et al., 1990). Another author, Zmeili et al. (1996) reported no significant 
change in Cmax in the fasted and the fed states with their enteric-coated controlled release 
tablet (Zmeili, Hasan et al., 1996).  
These studies proved that the presence of food affects the rate of absorption and the 
concentrations of diclofenac in plasma, which depends on the the physical properties of the 
dosage form, and also depends on the amount and composition of the meal which affects the 
gastric emptying time (Billa, Yuen et al., 2000). However, the presence of food has no 
influence on the extent of diclofenac absorption, independent of the formulation.  
Given the critical influence of the fasted/fed state on the performance of colonic prodrugs as 
described above, we determined the influence of different feeding regimens on gastro-
intestinal contents, pH and metabolism of the colonic prodrug, in order to establish the most 
appropriate fasted/fed state that should be employed for its in vivo assessment in rats. 
The study was conducted in different feeding regimens: fed ad libitum, 12-hour fast, 12-hour 
fast followed by one hour feeding, which was itself followed by either 30 minutes or 4 hours 
of fast, prior to the animals being killed, and measurements being taken. These four regimens 
were selected for a number of reasons: firstly, as stated above, most oral drug delivery 
experiments are conducted on overnight-fasted rats; secondly, a control of the 12-hour fast i.e. 
animals being fed ad libitum; thirdly, a 4-hour fast after feeding, to ensure complete gastric 
emptying of food ingested (Booth, Gibson et al., 1986), fourthly, a control experiment for the 
latter, i.e. 30 minutes fast after feeding assures that the ingested food has not arrived in the 
lower intestine (caecum and colon) (Brown, Greenburgh et al., 1994).  
The rat is an appropriate model to use in early drug development; its mean intestinal transit 
time is comparable to that in humans despite the different gastro-intestinal lengths, transit 
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time is significantly shorter in the fasted state compared to the fed state, as in man, and its 
gastrointestinal motility is under the control of the migrating myoelectric complex (MMC), 
like in man (Tuleu, Andrieux et al., 1999; Mittelstadt, Hemenway et al., 2005). Rats are thus 
widely used as an in vivo model and have been used to assess different colonic prodrugs, 
including cyclodextrin-based ones (Minami, Hirayama et al., 1998; Kamada, Hirayama et al., 
2002). 
As far as we know, the effect of fasting on the metabolism of cyclodextrins and the respective 
conjugates has not been subject of investigation. Otherwise, few studies have looked at the 
effect of food on the metabolism of other colonic prodrugs. One of the studies reported that 
metronidazole and olsalazine were found to be practically stable in the material from the 
contents of the ascending colon from human collected in the fed state. Otherwise, olsalazine 
was degraded up to 20% to 5-ASA within 10 minutes in the fasted ascending colon (Vertzoni, 
Carlsson et al., 2011). However, previous study in humans had shown that the systematic 
availability of olsalazine was not affected by food (Ryde and Ahnfelt, 1988). These results 
leaded Vertzoni et al. to conclude that the metabolism of olsalazine was limited in the 
ascending colon and became higher in descending colon both in fasted and fed state 
(Vertzoni, Carlsson et al., 2011). Another study reported that fasted rats had lower activities 
of  α-galactosidades, α-glucosidades, and β-glucosidades and higher activities of β-
galactosidase and azoreductase (Mountzourisa, Kotzampassib et al., 2009). 
4.3 Aims and Objectives 
This Chapter aims to investigate the influence of feeding regimen in Wistar rats on: 
i) Distribution and pH contents along the gut; 
ii) Metabolism of diclofenac-β-cyclodextrin within the caecal and colonic contents, 
using sulfasalazine as a control. 
This enables an understanding of how the regimen state affect the pharmacokinetics of 
prodrugs and enable to choose the most favorable feeding state to perform the in vivo studies.  
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4.4 Materials and methods 
 Reagents and chemicals 4.4.1
Sodium diclofenac (MW=318.14 g/mol), sulfasalazine (MW=398.394 g/mol) were purchased 
from Sigma. Diclofenac-β-cyclodextrin (MW=1411 g/mol) was synthesized according to the 
method reported in Chapter II. 
Sodium chloride, potassium hydroxide, sodium hydroxide, potassium dihydrogen phosphate, 
HPLC grades acetonitrile, methanol and water were purchased from Fisher Scientifics. 
Peptone water and yeast extract were obtained from Oxoid Limited (Hampshire, UK). 
Magnesium sulphate heptahydrate and calcium chloride hexahydrate were obtained from 
VWR (Leicestershire, UK). Trifluoroacetic acid (TFA) and dimethylformamide (DMF), 
sodium bicarbonate, haemin, l-cysteine HCl, vitamin K and resazurin were obtained from 
Sigma Aldrich (Dorset, UK). All other chemicals and solvents were of HPLC reagent grade 
and were used without further purification. Phosphate buffer saline (PBS) pH 6.0 and pH 6.8 
were prepared according to the USPXXIV.  
 Animals  4.4.2
All the procedures had been approved by the School’s Ethical Review Committee and were 
conducted in accordance with the Home Office standards under the Animals (Scientific 
Procedures) Act, 1986. Studies were performed using healthy adult male Wistar rats (8 weeks, 
240-250 g) purchased from Harlan Olac Ltd. (Oxfordshire, UK). All animals were housed in 
rooms with controlled conditions: 20 
o
C, 40-60% humidity, 15-20 air changes per hour. 
Animals underwent a period of acclimatization, with free access to standard rat chow and 
water for 7 days prior the experiment. Twelve hours before the beginning of each experiment, 
the animals were housed in individual metabolic cages, whose floors were perforated to 
restrict the ability of animals to eat their own faeces and allowed the collection of their urine 
and faeces. Water was available ad libitum through the experiment. 
 Feeding regimens 4.4.3
Four Groups (A, B, C and D) of 5 rats were given different food intake regimens. Rats from 
Groups A, B and C were fasted for 12 hours overnight. Subsequently, Group A rats were 
killed. Groups B and C rats were allowed to feed for one hour, after which they were fasted 
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for either 30 minutes (Group B) or 4 hours (Group C), before being killed. Group D rats were 
not fasted at all, and were given access to food ad libitum. The different feeding regimens are 
shown in Figure 4.1. 
 
 
Figure 4.1 Schematic representation of the different feeding regimens of rat groups A, B, 
C and D. A: 12-hour fast; B: 12-hour fast followed by 1-hour feeding, followed by 30-
minutes fast; C: 12-hour fast, followed by1-hour feeding, followed by 4-hour fast; D: fed 
ad libitum. 
Before starting the experiment, all animals were weighted. After 12 hours of fasting or 
feeding, different parameters were measured including: the volume of the water consumed, 
the volume of urine produced, the mass of feces produced, and the body weight loss.  
Animals were killed following a Schedule One Method (CO2 asphyxiation), after which the 
intestinal tract was removed. The pH and mass of gut contents were determined as follows. 
 Determination of pH and mass of the gastrointestinal luminal contents 4.4.4
The pH of the contents was measured in situ by placing the pH probe (H160 Portable pH 
Meter, Hach, Düsseldorf, Germany) within the luminal contents of each gastrointestinal 
section. It was measured at the anterior (labelled I in Figures) and posterior (except for colon), 
(labeled II in Figures) of each section of the stomach, small intestine (divided into three 
sections approximating to the duodenum, jejunum and ileum), caecum and colon before the 
gut contents were collected into previously weighed vials. The wet masses were recorded, and 
12 h fasted
12 h fasted
12 h fasted
12 h fasted
1 h fed
1 h fed
4 h fasted
30 min 
fasted
D
C
B
A
Fasted
Fed
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the vials were stored at – 80 C. The pH of the distal part of colon contents could not be 
reliably measured due to its solid nature. 
 Determination of stability of prodrugs (diclofenac-β-cyclodextrin and sulfasalazine), 4.4.5
in caecal and colonic contents 
Stability tests were performed inside an anaerobic workstation (Electrotek 500TG 
workstation, Electrotek, UK) at 37 C and 70% RH. The caecum and colonic contents from 
each group of rats were mixed with PBS – of differing pHs as explained below - in order to 
obtain a 40% w/w slurry as prepared in Chapter III. The pH of the PBS differed for the 
different samples, but matched the in situ measured pH in the different gastrointestinal 
sections (section above), in order to maintain the pH of the gut contents. Thus, gut contents 
from Groups A and B rats were mixed with PBS pH 6.8, while those from Groups C and D 
rats were mixed with PBS pH 6.0. The slurries were then homogenized using a glass rod and 
sieved through an open mesh fabric (Sefar NitexTM, pore size 350 µm) to remove any 
unhomogenised fibrous material. The sieved faecal slurry was then diluted 50% (w/w) with 
basal medium containing peptone water, yeast extract, NaCl, K2HPO4, MgSO4·7H2O, 
CaCl2·6H2O, NaHCO3, haemin, l-cysteine HCl, bile salts, tween 80, vitamin K and resazurin, 
was described previously in Chapter III (Basit and Lacey, 2001; Basit, Newton et al., 2002).  
Two solutions of each prodrug sulfasalazine (5 mg/mL) and diclofenac-β-cyclodextrin (2.4 
mg/mL) were prepared in PBS at pH 6.8 and pH 6.0, both containing 4% (v/v) of 
dimethylformamide. Subsequently, 100 µL of these solutions were mixed with 900 µL of 
caecal or colonic fluids prepared above; the fluids from Groups A and B rats being mixed 
with prodrug solutions at pH 6.8, while those from Groups C and D rats were mixed with 
prodrug solutions at pH 6.0 in order to maintain the pH constant (Table 4.1). The final 
concentrations of the conjugate, sulfasalazine and DMF were 0.5 mg/mL, 0.24 mg/mL and 
0.4% (v/v), respectively. 
Thereafter, these mixtures were incubated and shaken at 100 rpm (VXRbasic Vibrax®, 
Leicestershire, UK), with 50 µL aliquots being withdrawn at times 0, 15, 30, 60, 90, 120, 180, 
240, 360, 400, 600, 720 and 1440 minutes. The aliquots were immediately mixed with 100 µL 
of methanol and centrifuged at 10 000 rpm for 10 minutes at room temperature, after which 
the supernatant was removed and analyzed via HPLC for prodrugs concentrations.  
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Table 4.1 Schematic representations of procedure to perform stability tests of conjugate 
and sulfasalazine in caecum and colon fluids from rats. 
[Drug] 
Phosphate 
buffer  
Group Contents Incubation 
[drug] 
incubation 
Sampling 
Volume 
Final [drugs] 
5 mg/mL of 
sulfasalazine 
and 
2.4 mg /mL of 
diclofenac-β-
cyclodextrin 
 pH 6.8 
A 
pH~6.8 
caecum 
100 µL 
drug 
solution + 
900 µL of 
fluid 
0.5mg/mL 
of conjugate 
and 
0.24mg/mL 
of 
of 
diclofenac-
β-
cyclodextrin 
50 µL 
(0.4% 
DMF) 
16.7 µg/mL of 
sulfasalazine 
and 
80 µg/mL of 
diclofenac-β-
cyclodextrin 
colon 
B 
pH~6.8 
caecum 
colon 
pH 5.9 
C 
pH~5.9 
caecum 
D 
pH~5.9 
colon 
 HPLC analysis 4.4.6
All HPLC runs were performed using an Agilent 1100 series system equipped with a UV 
detector and a XTerra reverse phase C-18 column with 5 µm particle size, 4.6 mm internal 
diameter and 250 mm length. The mobile phase (consisting of acetonitrile and 0.1% 
trifluoroacetic acid (TFA) in water) was pumped at a flow rate of 1 mL/min. A gradient 
system of 0.1% TFA in water (A) and acetonitrile (B) was followed: 0-15 minutes 25-60% B; 
15-22 minutes 60-25% B. The sample injection volume was 20 µL and detection wavelength 
was 254 nm at 30 ºC. Each measurement was performed in triplicate. Results were acquired 
and processed with the Agilent Chemstation Data System Software 7. 
 Data analysis 4.4.7
Statistically significant differences in the total mass of contents between Groups and in the 
mass and pH of contents per section among Groups were evaluated using One-way analysis of 
variance (ANOVA), followed by Tukey test. General linear model (repeated measurements) 
was used to assess the differences of pH contents between Groups with different regimens of 
food intake (A, B, C and D). The relationship between mass and pH was investigated using 
Pearson Correlation Coefficient. Degradation kinetics of diclofenac-β-cycodextrin were 
determined by fitting the percent prodrug remaining versus incubation time curves to a first-
order kinetic model, and subsequently calculating reaction rate constant (K) and half-life (t1/2). 
Statistically significant differences in the rate constant and half-life of diclofenac-β-
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cyclodextrin conjugate between Groups were analysed using Kruskal–Wallis test, with 
Nemenyi’s post-hoc analysis. All tests, apart from Nemenyi’s test were carried out using 
SPSS 21.0 for Windows®. The Nemenyi test was conducted as described (Jones, 2002). 
Results were considered statistically significant when p < 0.05. 
4.5 Results and discussion 
 Influence of feeding regimens on body weight of the rats, mass of faeces and 4.5.1
volume of urine 
The changes in body weight of the rats, mass of faeces and volume of urine produced, 
quantity of food and volume of water consumed per group were summarized in the Table 4.2. 
In all the animals kept fasted overnight (A, B, C and D) it was verified a loss of body weight 
(~5%) after 12 hours. This loss of weight was expected in these fasted overnight animals, 
however animals from Group D also demonstrated weight loss. Moreover, in Group D, loss of 
weight is higher (~12%), herein it was not expected since these rats were fed ad libitum. This 
body weight loss can be explained due to the higher production of feces observed in this 
group of rats. This was already observed before in a study with rats on an ad libitum diet 
(Jeffrey, Burrows et al., 1987). The same study had observed that rats on a controlled diet 
maintained their body weight. 
After feeding, the animals from Group B and C did not show any production of faeces. This 
can mean that the food ingested before 12 hours of fasting did not have enough time to be 
digested and consequently to be excreted by the gastrointestinal tract of rats. It is important to 
note that rats eat only small part of their food during the day and and consume 80% of their 
total daily food intake at night, taking 5-8 meals during the night, hence during the feeding of 
the animals the room was kept dark (Nebendahl, 2000). 
Measurements of the solid and water contents in fed and fasted female Wistar rats had shown 
that the water amount was also higher in the fed state (7.8 ± 1.5 mL) against 3.2±1.8 mL in 
the fasted state, attributable to the increase of secretions and water bound with the ingested 
food (Mcconnell, Basit et al., 2008). The higher quantity in fed state can be favourable to the 
dissolution of drugs or formulations. However, possible interactions of food with drugs have 
to be considered.  
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As the photographs of each section of the gastrointestinal tract (Figure 4.2) show, the animals 
from Group B (Figure 4.2-II), C (Figure 4.2-III) and D (Figure 4.2-IV) present the stomach 
and the colon full comparing with the fasted animals (A) (Figure 4.2-I).  
Moreover, when the stomach is full it is possible to distinguish between the glandular and the 
non-glandular part. Herein, the non-glandular part is thin and translucent and the glandular is 
opaque, muscular and reddish involving the fundic and pyloric regions (Ghoshal and Bal, 
1989).  
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Table 4.2 Summary of the parameters measured in rats from different Groups of rats (A, B, C and D). The values represent the mean of 
5 rats per group ± SD. 
 
 
  
 Time = 0 After 12 hours After 1 hour of feeding followed by fasting 
Group body weight 
(grams) 
mass of 
feces 
(grams) 
volume of 
urine 
(mL) 
water 
consumed 
(mL) 
weight of 
food 
consumed 
(grams) 
Body weight 
(grams) 
 
water 
consumed 
(mL) 
volume of 
urine 
(mL) 
mass of 
faeces 
(grams) 
weight of 
food 
consumed 
(grams) 
Body 
weight 
(grams) 
 
A 271.3 ± 12.85 5.44 ± 0.90 17.6 ± 2.42 20.7 ± 5.20 _ 256.4 ± 10.07 _ _ _ _ _ 
B 265.52 ± 8.72 2.98 ± 0.47 20.6 ± 3.98 19.22 ± 3.54 _ 251.6 ±6.67 8.1 ± 3.11 1.2 ± 0.75 0 3.74 ± 1.72 258.5 ± 9.71 
C 246.52 ± 8.72 2.42 ± 0.61 17.8 ± 3.12 14.02 ± 3.05 _ 232.96 ± 4.13 25.72 ± 17.89 17.6 ± 16.75 0 3.9 ± 2.66 236.68 ± 
2.99 
D 259.39 ± 18.57 6.24 ± 2.36 16.4 ± 6.86 25.04 ±10.62 74.78 ± 4.60  229.98 ±7.60 _ _ _ _  
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Figure 4.2 Photographs of different sections of the gastrointestinal tract of rats:(I) Stomach; (II) Duodenum; (III) Jejunum; (IV) Ileum; 
(V) Cecum; (VI) Colon, from Groups A, B, C and D. 
I II III 
IV V VI 
I 
IV V VI 
II III 
I II III 
IV 
I II III 
IV V VI 
 
 
 
 
V VI 
A B 
C 
D 
Non-
glandular 
Glandular 
Chapter IV 
139 
 Influence of feeding regimens on the mass of gastrointestinal contents 4.5.2
It was observed that the aspect of the contents was variable along the gastrointestinal tract of 
the same rat and between rats of different groups. Basically, at the level of the stomach, the 
contents had a yellow color and food present seemed almost intact. At the level of the small 
intestine, contents were liquid and viscous and had a dark brown color. In caecum, contents 
were semi-solid with a dark brown color. This color was less intense in animals from Group 
C, giving the impression that food did not have enough time to be completely fermented. In 
the proximal colon, contents were generally semi-solid, while in the distal colon, when 
presented, they were solid in form of pellets. As it was reported, the initial part of colon is the 
site of initial dehydration of the contents and the distal portion the responsible for the 
formation of faecal pellets (Ferre and Ruckebusch, 1985).  
As expected, feeding regimens influenced the total mass of gastrointestinal contents (Figure 
4.3), and these were statistically different among the four Groups  
(ANOVA, p<0.05).  
 
Figure 4.3 Total mass of gastrointestinal contents in healthy male rats in different 
Groups. A: 12 hours fast, B: 12 hours fast then 1 hour fed then 30 minutes fast, C: 12 
hours fast then 1 hour fed then 4 hours fast; D; fed. Each bar represents mean ± S.D, n = 
5.  
The total gut content weights of the fed Group D was almost twice from that of the 12-hour 
fasted Group A rats (post hoc Tukey, p<0.05). This result in male Wistar rats reflects the 
previous report in female Wistar rats, where similar values for gut contents are reported 
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(Mcconnell, Basit et al., 2008). When Group B rats were allowed to feed for 1 hour, they ate 
sufficiently during the hour, such that their total gut contents mass were similar to those in 
Group D that were allowed food ad libitum throughout the experimental duration (p>0.05). 
On the other hand, Group C rats, which were fed for 1 hour and fasted for 4 hours prior to 
being killed, had similar mass of gut contents as Group A rats (p>0.05).  
Analysis of the distribution of gastrointestinal contents (Figure 4.4 and Figure 4.5) shows the 
influence of feeding/fasting states and timings. Groups A and C (which were fasted for 
substantial durations prior to being killed) have similar profiles to each other (Figure 4.4).  
 
Figure 4.4 Mass of luminal contents in different gastrointestinal sections in rat Groups. 
Each bar represents mean ± S.D. n = 5. 
In all Groups, the major quantity of fluids was found in the caecum, except for Group B 
where the highest quantity of fluids was found in stomach. Groups B and D (which had 
short/no fasting times prior to being killed) also had similar profiles to each other. The major 
difference in the four profiles is the large stomach contents in Groups B and D, compared to 
minimal stomach contents in Groups A and C. In contrast, the small intestinal contents 
measured in the duodenum, jejunum and ileum are low and similar across all groups. 
Fasted animals (Group A) have minimal stomach contents, slowly increasing contents in the 
duodenum, jejunum and ileum, with most of the gut contents being located in the caecum, and 
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the mass of contents dropping in the colon. A 12-hour fast in Group A rats (Figure 4.1) means 
that any food eaten prior to the fast has moved down the gastro-intestinal tract to the caecum. 
However, it is important to note that, as reported before in a study with Sprague Dawley rats, 
the quantity of food remaining in the stomach after an overnight fasting is variable and 
depends on the diet type and on the diet regime (Jeffrey, Burrows et al., 1987).  
In contrast, the profile for the fed Group D rats is very different compared to that of Group A, 
with larger masses in the stomach and in the colon of the fed animals. 
Greater variability in the gut (especially stomach) contents is also seen in Group D rats fed ad 
libitum. This variability in the quantity of food remaining in the stomach can be attributable to 
the house condition, caged singly, which may cause stress to the rat (Nebendahl, 2000).  
 
Figure 4.5 Mass of luminal contents in the different gastrointestinal sections in the rat 
Groups. The data shown in Figure 4.4 has been replotted to assist comparison of the 
different gastrointestinal regions. Each bar represents mean ± S.D, n = 5. 
Rats with full/partially full stomachs are expected to show variable gastric emptying times, 
leading to variable drug release from the drug carrier, and hence greater variability in the 
latter’s performance. This explains why most in vivo experiments in laboratory animals are 
conducted in the fasted state when oral drug absorption is assessed.  
The similar profiles of Groups B and D rats show that a 30 minutes fast after feeding is 
obviously not sufficient for gastric emptying. In contrast, the similarity of profiles of Group C 
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rats to those of Group A shows that gastric emptying has taken place after 4 hours. The Group 
A and C profiles indicate that during the 5 extra experimental hours undergone by Group C 
rats, the gastrointestinal contents moved down the gut, such that it was observed more of it in 
the colon. 
 In situ pH of the gastrointestinal contents  4.5.3
The pH of the contents measured along the gastrointestinal tract for the different Groups of 
rats is shown in Figure 4.6 
 
Figure 4.6 In situ pH of gastrointestinal contents in the different sections of the 
gastrointestinal tract in the rat groups. I and II refer to the anterior and posterior parts 
respectively. Each point represents mean ± S.D, n = 5. 
Profiles are as expected and reflect those previously reported in rats (Mcconnell, Basit et al., 
2008) and man (Dressman, Berardi et al., 1990). The pH value is variable in the stomach 
depending on food intake and its buffering/dilution effect on gastric HCl, rising in the small 
intestine due to pancreatic juice secretion, and slightly falling in the large intestine due to the 
production of short chain fatty acids (SCFA) by bacterial fermentation of dietary fiber. The 
largest differences among the Groups occur in the early sections of the gastrointestinal tract 
(the stomach) with smaller differences in the caecum and colon (Figure 4.7). In contrast, the 
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small intestinal pH is immune to the effects of fasting/feeding regimens. Similarities between 
pH profiles for Groups A and C rats (repeated measures ANOVA, p>0.05), and those of 
Groups B and D rats (repeated measures ANOVA, p>0.05) shown in Figure 4.7, reflect the 
influence of feeding/fasting states and times.  
 
  
Figure 4.7 In situ pH of gastrointestinal contents along the gastrointestinal tract of rat 
Groups A(○), B(∆), C(□) and D(◊). I and II refer to the anterior and posterior parts, 
respectively. Same data as in Figure 6 has been re-plotted to ease comparisons.  Each 
point represents mean ± S.D, n = 5. 
Groups A and C rats which have no or limited food in the stomach show a low pH in the first 
part of the stomach (forestomach) compared to Groups B and D rats, which have more food 
(see Figure 4.5 for food contents). Indeed, a correlation of 0.7 (Pearson, p<0.05) was found 
between the mass of the stomach contents and pH in stomach I in rats, reflecting the buffering 
and dilution effects of food in the stomach (Evans, Pye et al., 1988 ; Fallingborg, Christensen 
et al., 1989). In contrast to stomach I, the pH in the lower part of the stomach (Stomach II) 
was low in all Groups and was independent of food presence (Pearson, p>0.05). This 
correlates with previous reports that in rats, the non-glandular stomach I (forestomach) is used 
for storage and mechanical digestion of food (Ghoshal and Bal, 1989), whose 
0
1
2
3
4
5
6
7
8
9
S
to
m
a
c
h
 I
S
to
m
a
c
h
 I
I
D
u
o
d
e
n
u
m
 I
D
u
o
d
e
n
u
m
 I
I
J
e
ju
n
u
m
 I
J
e
ju
n
u
m
 I
I
Il
e
u
m
 I
Il
e
u
m
 I
I
C
e
c
u
m
 I
C
e
c
u
m
 I
I
C
o
lo
n
 I
In
 s
it
u
  
p
H
 
Group A
Group B
Group C
Group D
Chapter IV 
144 
presence/absence is the principal factor responsible for the local pH (Ward and Coates, 1987), 
while the pH in the glandular HCl-secreting Stomach II is influenced mainly by microbial 
products, despite HCl-secretion being stimulated by the presence of food (Ward and Coates, 
1987). It must be noted that in man, the whole stomach is glandular and harbours few 
bacteria, in contrast to the large bacterial numbers in rats (Kararli, 1995). 
As mentioned above, the pH profiles of the four groups of rats diverge at the large intestinal 
caecal and colonic fractions. Although differences are small, the lowest pHs are seen in 
Groups C and D, with the highest in Groups A and B. Comparison of Figures 4.4 and 4.6 
suggest a correlation between mass contents and pH measured. Indeed a strong correlation (r 
= -0.9, Person p<0.05) was found between the mass contents and the pH in the first part of the 
colon (Colon I) when all the data was analysed, i.e. n=20. This reflected in the production of 
bacterial fermentation byproducts, the short chain fatty acids (acetate, propionate and 
butyrate) (Scott, Gratz et al., 2013). With a greater mass of dietary fiber, a greater bacterial 
metabolism and production of short fatty acids is observed (Ferguson, Tasman-Jones et al., 
2000; Paturi, Butts et al., 2012).  
A higher pH in the large intestine of Group A fasted rats (compared to Group D fed rats) was 
observed in previous reports both in rats (Mcconnell, Basit et al., 2008) and in men (Evans, 
Pye et al., 1988 ; Fallingborg, Christensen et al., 1989) and may be explained by their lower 
concentrations of SCFA compared to rats fed ad libitum (Mountzourisa, Kotzampassib et al., 
2009). Similar pH in large intestine in Groups A and B suggest that food ingested by Group B 
rats during the 1 hour feeding has not travelled down the gastro-intestinal tract during the 30 
minutes fast prior to measurement. Meanwhile, pH in the lower large intestine in Group C rats 
suggests that food ingested prior to a 4-hour fast has travelled down the gastro-intestinal tract 
to some extent. This shows the importance of the fasting/fed states and feeding regimens 
when evaluating colonic drug carriers in the rat in vivo model. The fasted rat (most commonly 
used model) may demonstrate a poor performance of a pH-controlled colonic drug carrier, 
due to an insufficiently low pH in the colon, rather than due to a poor formulation. On the 
other hand, while the fed rat may possess the correct (low) colonic pH required for drug 
release from such a pH-controlled carrier, variable feeding by a group of animals could lead 
to variability in gut contents, transit times, drug release and absorption profiles, which could 
in turn mask the true potential of the colonic drug carrier.  
Chapter IV 
145 
Table 4.3 The pH values, measured in situ, of the contents of the different 
gastrointestinal sections in rat Groups A, B, C and D. I and II refer to anterior and 
posterior parts respectively. Mean ± SD are shown, n=5. 
Gastrointestinal 
Section 
pH ± SD 
Group 
 A B C D 
Stomach I 2.44 ±  0.84 5.41 ± 0.49 2.27 ± 0.81 4.19 ± 1.08 
Stomach II 3.47 ± 1.55 2.33 ± 0.20 2.32 ± 1.10 3.03 ± 0.70 
Duodenum I 6.38 ± 0.32 3.70 ± 1.15 4.94 ± 1.26 5.10 ± 1.29 
Duodenum II 6.71 ± 0.59 6.11 ± 0.13 6.25 ± 0.14 6.72 ± 0.69 
Jejunum I 6.80 ± 0.34 6.18 ± 0.18 6.32 ± 0.16 6.40 ± 0.09 
Jejunum II 6.60 ± 0.22 6.59 ± 0.25 6.57 ± 0.25 6.31 ± 0.58 
Ileum I 6.63 ± 0.18 6.81 ± 0.55 6.70 ± 0.40 6.57 ± 0.45 
Ileum II 7.15 ± 0.54 7.07 ± 0.32 7.21 ± 0.54 6.45 ± 0.71 
Caecum I 7.08 ± 0.37 7.01 ± 0.26 5.85 ± 0.14 6.56 ± 0.24 
Caecum II 6.90 ± 0.27 6.77 ± 0.29 6.17 ± 0.26 5.87 ± 0.27 
Colon I 6.84 ± 0.42 6.91 ± 0.40 5.91 ± 0.38 5.53 ± 0.51 
pH directly affects the population of different groups of bacteria, and hence affects the  end 
products of fermentation (Scott, Duncan et al., 2008). Studies with a continuous flow 
fermenter have shown that a pH value of 5.5 gave fourfold higher butyrate concentrations 
than a pH of 6.5. This increase of butyrate production was accompanied by acetate 
consumption. At pH 6.5, there is a decrease in butyrate and a two-fold increase of the 
propionate production. Other studies with human faecal microbial have shown that lactate is 
rapidly converted to acetate, butyrate and propionate at pH as low as 5.9, but at pH 5.2 
reduced the utilization of lactate while its production was maintained (Belenguer, Duncan et 
al., 2007).  
Bacteroides are the main bacteria involved in the degradation of cyclodextrins (Antenucci and 
Palmer, 1984), and therefore the abundance of these species in the lower intestine will affect 
the rate of fermentation of the conjugate at this level. The growth of Bacteroides occurs 
ideally at pH 6.5, coinciding with propionate formation. When the pH is not favorable to 
Bacteroides, pH 5.5 the butyrate producers dominate and leads to formation of butyrate 
(Walker, Duncan et al., 2005). 
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Moreover, it is important to note that the rate of production of short chain fatty acids (which 
influence the pH) are also associated with the rate of transit time. Basically the reduction of 
SCFA production leads to a slower transit time, related with the increase of absorption as the 
digesta takes longer to pass through the colon and partially by decrease of bacterial number. 
(Stephen, Wiggins et al., 1987). Contrarily, the increase of SCFA increases the rate of transit 
time (Richardson, Delbridge et al., 1991). 
 Evaluation of the stability of diclofenac-β-cyclodextrin and sulfasalazine in caecum 4.5.4
and colon contents 
The stability of prodrugs in caecal and colonic fluids is shown in Figure 4.8. Moreover Figure 
6 indicates that the disappearance of diclofenac-β-cyclodextrin coincides with the appearance 
of free diclofenac in each release medium; therefore confirming the prodrug is able to liberate 
the drug in a colonic environment. It can be seen that, in all the animal Groups: 
1.  Degradation of sulfasalazine is much faster than that of diclofenac-β-cyclodextrin in 
both milieus. Sulfasalazine is degraded by azoreductases, which are produced by many 
different bacterial species in the large intestine. The supply of the enzyme azoreductase being 
almost unlimited, degradation of sulfasalazine can take place without delay, and does not 
seem to be influenced by the feeding regimen. In fact, the degradation of sulfasalazine was so 
fast that the degradation profiles have few time points, and curves were not fitted for further 
analysis of reaction rates and half-lives. 
In contrast, the metabolism of cyclodextrin conjugate is much more complex, and involves 
two types of enzymes - amylase and esterase. The esterase can only act after the amylase has 
started degrading the cyclodextrin carrier, as reported previously (Hirayma, Ogata et al., 
2000). Moreover, the compounds formed in the initial stages of amylase-degradation of 
cyclodextrin - high-membered maltooligomers (maltohexaose, maltopentaose, maltotetraose) 
- are themselves substrates for the amylases, and can therefore act as competitive inhibitors of 
the enzymatic reaction (Suetsugu, Koyama et al. 1974; Jodal, Kandra et al. 1984). In addition, 
while the lower-membered maltooligomers (glucose, maltose and maltotriose) formed during 
the reaction are not substrates for the amylase, they can become “non-competitive” enzyme 
inhibitors by linking to the enzyme protein (Jodal, Kandra et al. 1984). Thus, the diclofenac-
cyclodextrin conjugate shows potential as a sustained-release formulation. 
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Figure 4.8 Mean levels of diclofenac-β-cyclodextrin and sulfasalazine remaining when 
prodrugs were incubated in caecal and colonic contents from rats from Groups A (○), B 
(∆), C (□), and D (◊). Each point represents mean ± S.D, n = 3. 
2. The degradation of both prodrugs is faster in colonic contents as compared to caecal 
contents (Figure 4.4). This could be due to a number of reasons; such as the caecal slurry 
having a lower bacterial concentration (due to its greater liquid content), or the caecal slurry 
being more nutrient-rich (the caecum being the main site of bacterial fermentation), such that 
less prodrug is metabolized by the bacteria as a source of substrate. 
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Table 4.4 Degradation rate (k, min−1) and half-life (t1/2 , min) for diclofenac-β-
cyclodextrin in caecal and colonic contents of rat Groups A, B, C and D. 
 CAECUM COLON 
Groups  k (min-1) t1/2 (min) k (min
-1
) t1/2 (min) 
A 0.004 ± 0.001 185 ± 22 0.016 ± 0.001 44 ± 2 
B 0.002 ± 0.000 397 ± 56 0.013 ± 0.005 60 ± 22 
C 0.001 ± 0.000 490 ± 76 0.003 ± 0.001 250 ± 43 
D 0.003 ± 0.000 249 ± 27 0.008 ± 0.002 90 ± 16 
3.  The rate of degradation of CD-drug conjugate by bacterial enzymes was influenced by 
the feeding regimen in the colon (Figure 4.8). Degradation was fastest from Groups A and B 
fasted rats, followed by Group D, followed by Group C (Table 1). This order of degradation 
rates K was statistically significant (p<0.05, Kruskal Wallis, followed by Nemenyi’s test). 
The fast prodrug degradation in Group A rats (which had been fasted for 12 hours) could be 
due to a lack of nutrient in the colon for the bacterial enzymes to act on, which therefore act 
exclusively on the prodrug, degrading the latter. Similarly, in Group B rats, the colon is 
nutrient-poor, and exclusive enzyme action on the prodrug leads to the fast degradation of the 
latter. Although Group B rats were fed for one hour (Figure 4.1), food did not have time to 
move down to the colon by the time rats were killed, 30 minutes after the one-hour feeding 
time. In contrast, food and nutrient were present in the colon of Group D fed rats, and 
competition between nutrient and prodrug for enzyme action led to slower prodrug 
degradation. The slower rate of prodrug degradation in Group C rats (compared to Group D 
rats) shows an even greater amount of nutrient in the colon of Group C rats, and hence greater 
competition of enzyme action. It is possible that the bolus intake of food by Group C rats 
during the one hour feeding arrives in the colon at some point during the four hours of fasting, 
such that there is overwhelming competition for the enzyme.  
The dilution of the contents from Group A and B were processed at pH 6.8, while the dilution 
of contents from group C and D at pH 6.0, according to the mean value of the pH measured 
anteriorly (Table 4.3). Thus these pH differences on the incubation media also affect the 
activity of enzymes, which can explain the faster metabolism in fasted state. 
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In the fed state is expected a decrease on the activity of Bacteroids and consequently on the 
metabolism of cyclodextrin carrier due to the diminuish of pH associated with the production 
of SCFA, which can also reinforce the explanation associate with the decrease of metabolism 
in fed state.  
Overall, it is interesting to note that the rates of degradation of diclofenac-β-cyclodextrin in 
colonic contents in Group A and B is close to the rate of degradation observed in the human 
faecal slurries collected from individuals without any food intake control, as reported 
previously in Chapter II. 
In contrast to the obvious influence of feeding regimen on prodrug degradation in the colon, 
the influence was less obvious in the caecum. The degradation curves for all rat groups have 
similar profiles, especially at the beginning of the in vitro degradation reaction (Figure 4.8). 
Caecum has such a high content of material in all rat groups (Figure 4.5) that feeding/fasting 
did not seem to alter the nutrient content and subsequently, any competition between nutrient 
and prodrug for enzyme action. One point to note though is the completion of prodrug 
degradation in Group A fasted rats caecal contents at 600 minutes (Figure 4.8) in contrast to 
the other groups. This correlates with the fact that Group A fasted rats had a lowest amount of 
nutrient (and hence competition for enzyme action) in their caecum. 
4.6 Conclusion 
This study demonstrates the importance of feeding regimens, specifically the timing of meal 
ingestion, on the gastrointestinal conditions in rats and how this influences the metabolism of 
colonic prodrugs, namely diclofenac-β-cyclodextrin. In addition to changes in the distribution 
of gut contents along the GI tract, which directly affects the gastrointestinal transit time, 
different feeding regimens are accompanied by changes in the pH of gut contents, specifically 
in the stomach and large intestine. Moreover, differential gut contents in the large intestine 
have an impact on the microbiota activity, which affects the rate of diclofenac-β-cyclodextrin 
metabolism, and hence drug release and absorption. We also showed that the different feeding 
regimens did not seem to im-pact on the metabolism of sulfasalazine, which was rapidly 
metabolized. Thus, we conclude that while the feeding regimen influences the performance of 
the colonic prodrug, diclofenac-β-cyclodextrin, that influence has to be measured for each 
prodrug individually, given the different metabolism pathways of different colonic carriers. 
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5 DICLOFENAC-ΒETA-CYCLODEXTRIN VERSUS SULFASALAZINE FOR 
COLONIC DRUG TARGETING: IN VIVO PERFORMANCE IN RATS 
5.1 Overview 
The influence of feeding regimen on the performance of diclofenac-β-cyclodextrin was 
studied previously in rats (Chapter IV). Results showed that its metabolism depends on the 
feeding regimen, herein fasted state, leading to a faster metabolism of this conjugate.  
An in vivo proof of concept is required not only to confirm the ability of the conjugate to 
provide targeting of diclofenac on the large intestine, but also to study the bioavailability of 
diclofenac when absorption takes place at the colonic level. Based on results from the stability 
experiments of both prodrugs, and considering the greater variability on the gastrointestinal 
transit time caused by food intake, oral administration was conducted in the fasted state. The 
main advantage of conducting these studies under fed conditions would be the elimination of 
the additional step of food removal, which could reduce potential stress on the animals caused 
by fasting (Mittelstadt, Hemenway et al., 2005). 
Sulfasalazine is a prodrug activated at a colonic level, as previously described, releasing 5-
aminosalicylic acid (mesalazine) and sulfapyridine. A delay between the oral intake of 
sulfasalazine and the appearance of the respective metabolites in the blood circulation is 
expected. When administered concomitantly with other potential colonic prodrugs, this 
prodrug works as a control, providing us with an idea of the time necessary for it to reach the 
colon by the appearance of its metabolites in plasma.  
Hence, this Chapter presents a comparative in vivo study in fasted rats that considers oral 
administration of a suspension of prodrugs, diclofenac-β-cyclodextrin and sulfasalazine to a 
group of rats (Group I), and also the simultaneous quantification analysis of the respective 
active drugs diclofenac and sulfapyridine in plasma. Moreover, a control group of animals 
(Group II) was dosed orally with sulfapyridine and diclofenac. The comparison of 
pharmacokinetic parameters between both groups, namely plasmatic concentrations and time 
of absorption, allowed determining the ability of the conjugate to release diclofenac in the 
large intestine. The dose of drugs administrated to Group II was equivalent to the dose of free 
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drugs administered to Group I; this was usefull to assess differences in the bioavailability 
between each drug and the respective colonic prodrug.  
5.2 Introduction 
When administered orally, diclofenac absorption is rapid and complete in humans and in 
animal models, namely rats (Peris-Ribera, Torres-Molina et al., 1991; Giagoudakis and 
Markantonis, 1998). Diclofenac is poorly soluble in acidic media (pKa = 4), and therefore its 
release, dissolution and absorption is favorable when pH is high. On the other hand, when the 
pH is low, this drug will precipitate or will not be released (Chan, Mojaverian et al., 1990; 
Riad, Sawchuk et al., 1995). However, diclofenac suffers first-pass metabolism, such that 
~50% of the drug reaches the systemic circulation in the unchanged form. The plasma half-
life time is between 1 to 2 hours (Davies and Anderson, 1997).  
When it reaches the colon, this drug is not degraded and is additionally well absorbed 
(Tannergren, Bergendal et al., 2008). Nevertheless, when diclofenac reaches the colon, 
namely in the form of diclofenac-β-cyclodextrin, its absorption will depend on the rate of 
drug release, which is directly depends on the activity of microbiota. Moreover, in the form of 
the conjugate, a longer time is expected between the time of oral intake of diclofenac-β-
cyclodextrin and the appearance of diclofenac in blood when compared with the 
administration of free diclofenac.  
Sulfasalazine is a well-known colonic prodrug available on the market. When administered 
orally, approximately 10-30% of the sulfasalazine is absorbed unchanged, with the remaining 
is cleaved in 5-aminosalicylic acid (mesalazine) and sulfapyridine when reaching the colon. 
After cleavage, about 60-80% of the available sulfapyridine is absorbed and mainly excreted 
in the urine, whereas the mesalazine moiety is not so well absorbed being mainly excreted in 
faeces (Azad Khan and Truelove, 1980; Buggé, Gautam et al., 1990). Therefore, sulfasalasine 
metabolites can be used as a marker of colonic targeting. Due to the low levels of mesalazine 
in plasma and consequently the requirement of a more sensitive method for its quantification 
when compared with sulfapyridine, being this last one used as an indicator of colonic delivery 
(Lee, Zhang et al., 2012). As reported previously, the first appearance of sulfapyridine in 
plasma can be used as a marker to determine the transit time through the small intestine 
(Sjödin, Visser et al., 2011). 
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As in Chapter IV, the rat was chosen as an animal model to perform the in vivo studies. Rat 
has been used widely as an animal model mainly due to its size and cost effectiveness. 
Additionally, the mean intestinal transit time in rats seemed comparable with humans in the 
order of 20 to 30 hours, even  though the lengths of their small gut are different (Gruber, 
Longer et al., 1987; Kararli, 1995; Tuleu, Andrieux et al., 1999) Additionally, rats have been 
used to performed in vivo studies with diclofenac (Reyes-Gordillo, Muriel et al., 2007; León-
Reyes, Castañeda-Hernández et al., 2009) and sulfasalazine (Chungi, Dittert et al., 1989 ; Lee, 
Zhang et al., 2012). They were particularly suited for the determination of pharmacokinetic 
parameters after oral administration of powder or liquid formulations (Kararli, 1995). 
Furthermore, rats have also been used to assess the performance of different colonic delivery 
prodrugs, including those that use cyclodextrins as a carrier. 
5.3 Aims and Objectives 
This Chapter aims to perform in vivo studies in order to: 
i) Assess the ability of diclofenac-β-cyclodextrin to release diclofenac into the large 
intestine using sulfapyridine (sulfasalazine metabolite) as a marker of colonic 
absorption; 
ii) Compare the pharmacokinetic parameters between drugs and prodrugs.  
5.4 Materials and methods 
 Reagents and chemicals 5.4.1
Diclofenac Sodium (MW=318.14 g/mol), sulfasalazine (MW=398.394 g/mol), sulfapyridine 
(MW=249.29 g/mol), and trifluoroacetic acid (TFA) were purchased from Sigma. Diclofenac-
β-cyclodextrin (MW=1411 g/mol) was synthesised according to the method described in 
Chapter II. Sodium chloride, Microtainer tubes containing K2EDTA, HPLC grades 
acetonitrile, methanol and water were purchased from Fisher Scientifics UK Limited. 
Phosphate buffer pH 7.4 was prepared according to the USPXXIV.  
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  In vivo study 5.4.2
5.4.2.1  Animals  
Adult male healthy Wistar rats (8 weeks, 240-250 g) were purchased from Harlan Olac Ltd. 
(Oxfordshire, UK). All the procedures had been approved by the School of Ethical Review 
Committee and were conducted in accordance with the Home Office standards under the 
Animals (Scientific Procedures) Act, 1986. All animals were housed in rooms with controlled 
conditions: 20 
o
C, 40-60% humidity, 15-20 air changes per hour. Animals underwent a period 
of acclimatization with free access to standard rat chow and water for 7-days prior the 
experiment. Twelve hours before the beginning of each experiment, animals were housed in 
separate metabolic cages. The latter were perforated at the bottom, which restricted the ability 
of animals to eat their own faeces and allowed to collect their urine and faeces, separately. 
Water was available ad libitum through the experiment. 
5.4.2.2  Drugs and Prodrugs suspensions 
Two different suspensions were prepared freshly just before dosing in sodium chloride 0.9%. 
One of the suspensions contains diclofenac-β-cyclodextrin (17.7 mg/mL) and sulfasalazine 
(20 mg/mL) and the other contains sodium diclofenac (4 mg/mL) and sulfapyridine (12.5 
mg/mL).  
Doses and drug administration schedule of sodium diclofenac (20 mg/kg) and sulfasalazine 
(100 mg/kg) were selected based on previous reports (León-Reyes, Castañeda-Hernández et 
al., 2009; Zhang, Zheng et al., 2011; Lee, Zhang et al., 2012). Otherwise, the quantity of 
diclofenac-β-cyclodextrin (88.5 mg/kg) is equivalent to 20 mg/kg of diclofenac and the 
quantity of sulfapyridine is the correspondent to 100 mg/kg of sulfasalazine. 
5.4.2.3 Experimental design 
For this study, rats were assigned to two groups of 7: I (test) and II (control). Rats were fasted 
overnight (12 hours) and again throughout the first 12 hours of study, with free access to 
water. The first suspension containing prodrugs was administered to test rats (group I) and the 
second containing the respective drugs to control ones (group II). Oral administration (1.2 
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mL) was performed using a polypropylene syringe (3 mL) equipped with a 18-G ×3 curved 
gavage needle with 2.25-mm for p.o. in rats.  
5.4.2.4  Blood sampling  
Blood samples (250 - 300 µL) were collected via the tail after cutting 2 - 3 cm of the tail with 
a scalpel, accompanied with massage under anesthesia. As drops of blood appeared, they were 
collected into 500 µL microtainer tubes. The original wound in the tail was reopened by 
removing the clot to continue blood sampling at pre-determined time points, which were 30, 
90, 120, 180, 240, 360, 480, 720 and 1440 minutes, for rats in group I (test) and 10 ,30, 45, 
90, 120, 240, 360, 480, 720 and 1440 minutes in group II (control). 
Plasma was obtained after centrifugation of blood samples at 13 000 rpm for 10 minutes at 4 
ºC (Thermo Scientific Heraeus Fresco 17 refrigerated microcentrifuge). Plasma were 
transferred to labeled eppendorfs and kept at -20 ºC until analysis.  
5.4.2.5  Sample preparation 
Frozen plasma samples (100 μL) were allowed to thaw at room temperature. 100 µL of 
acetonitrile with 2.5 % (v/v) of KOH 0.2 M was added to the plasma sample and the mixture 
was mixed vigorously on a vortex mixer for 10 seconds. Samples were then centrifuged for 10 
minutes at 10 000 rpm at 4 ºC. Subsequently, 100 µL of the supernatant were diluted with 20 
µL of water and analyzed by HPLC.  
 Simultaneous quantification of diclofenac and sulfapyridine in plasma by high-5.4.3
performance liquid chromatography with UV detection 
Diclofenac and sulfapyridine analysis was done by high-performance liquid chromatography 
(HPLC) using an Agilent 1100 series system equipped with a UV detector. Results were 
acquired and processed with the Agilent Chemstation Data System Software 7. HPLC 
analysis was conducted by using a XTerra reverse phase C-18 column with 5 µm particle size, 
4.6 mm internal diameter and 250 mm length. Sample injection of 50 µL, detection 
wavelength 273 nm, flow rate of 1 mL/min at 40 ºC and a total run time of 24 minutes. A 
gradient system of 0.1% TFA in water (A) and acetonitrile (B) was followed: 0-15 minutes, 
11-80% (B), 15-22 minutes 80-22% (B), 22-24 minutes 22-11% (B). 
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A stock solution of sodium diclofenac (50 mg/100mL) and sulfapyridne (50 mg/100 mL) was 
prepared adapting the recipe described by Doxsee et al. (Doxsee, Gout et al., 2007) following 
the next steps. First, 50mg of sulfapyridine was dissolved in 5 mL of NaOH 0.1 M under 
stirring. When completely dissolved, 70 mL of phosphate buffer pH 7.4 was added 
continuously under stirring. After the decrease in pH, 100 µL of HCl 2 M was then added to 
the solution followed by addition of 53.7 mg of sodium diclofenac equivalent to 50 mg of 
diclofenac free acid. Finally, phosphate buffer pH 7.4 was added to make up the solution to 
100 mL. Appropriate dilutions of the stock solution in phosphate buffer 7.4 were performed in 
order to obtain standard working solutions with the next concentrations: 2.5, 5, 8, 10, 30, 50, 
150 and 200 µg/mL. All these solutions were refrigerated at - 4 ºC and protected from light.  
Appropriate solutions of diclofenac and sulfapyridine in plasma were prepared in the range of 
0.25 μg/mL to 20 μg/mL. 90 µL of blank plasma was spiked with 10 µL of standard working 
solutions, followed by the extraction of both drugs as described above (2.2.2). Plasma was 
obtained by centrifugation of blood collected by cardiac puncture from rats at 13 000 rpm for 
10 minutes at 4 ºC and keep in the freezer at -20ºC. 
5.4.3.1 Validation of the analytical method 
The optimized analytical method was validated with the assessment of selectivity, linearity, 
accuracy, precision, recovery, limits of detection (LOD) and lower limit of quantification 
(LLOQ). 
 Selectivity 
To evaluate the selectivity, the capacity of the method to differentiate and quantify diclofenac 
and sulfayridine in presence of the other components of the plasma, blanks samples of plasma 
were run using plasma from different rats (n=6). 
 Limits of detection (LLOD) and quantification (LLOQ)  
Separate plasma samples of low concentrations were prepared to investigate the LLOD, which 
is as the lowest concentration of diclofenac and sulfapyridine that could be detected but not 
necessarily quantified in the plasma. It was determined by visual evaluation of the minimum 
level at which the analytes can be reliably detected. LLOQ is defined as the lowest 
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concentration of diclofenac and sulfapyridine quantifiable with suitable precision and 
accuracy. LLOQ allows evaluating the sensitivity of the method. 
 Linearity 
The linearity of the method was verified using diclofenac and sulfapyridine concentration 
range of 0.25 μg/mL to 20 μg/mL, prepared in plasma as described before.  
 Accuracy and precision 
Precision indicates the closeness of agreement (i.e., the degree of scatter between a series of 
measurements obtained from multiple sampling of the same homogeneous sample) and was 
determined by repeatability (intra-day) and intermediate precision (inter-day) for three 
consecutive days. Precision was calculated by the relative standard deviation [R.S.D.(%) = 
(standard deviation/average concentration)*100], which should be lower than 15%. 
The accuracy of the method expresses the closeness of agreement between the nominal value 
and the value observed, calculated by the coefficient of variation  
[C.V.(%) = (observed concentration-nominal concentration)/nominal concentration], which  
must be within 15%. 
The inter-day precision and accuracy of the method was assessed by analysing four different 
plasma concentration levels of 0.25, 1, 5 and 20 µg/mL on 3 different days, while the intra-
day precision was measured using 6 determinations per concentration within the same day. 
Recovery  
Extraction efficiencies for diclofenac and sulfapyridine in plasma were determined by 
comparing replicate (n=6) peak area of extracted plasma samples to those obtained with non-
plasmatic standards with the same concentration for the LLOQ 0.25 µg, intermediate 
concentration 1 µg/mL and high concentration 20 µg/mL. The extraction efficiency was 
determine by calculating the percentage recoveries  
[recovery (%) = (peak area of plasma standard) / (peak area of water standard)*100]. 
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5.4.3.2  Pharmacokinetics analysis 
Diclofenac and sulfapyridine concentrations in plasma (μg/mL) as a function of the time of 
administration (in hours) was plotted for both groups I and II. The maximum diclofenac and 
sulfapyridine concentration in the plasma (Cmax) is the arithmetic mean of 7 rats, whereas the 
corresponding time (tmax) was read directly from the graph. The area under the diclofenac and 
sulfapyridine plasma concentration-time curve (AUC0-24 hours) was calculated using OriginPro 
9.0. 
5.4.3.3  Statistical analysis 
Statistical analysis was performed using SPSS 21.0 for Windows®. Data was analysed using 
parametric tests. Maximum plasma concentration (Cmax), time to maximum plasma 
concentration (Tmax) and area under curve (AUC0–24 hours) for diclofenac and sulfapyridine 
between groups I and II were compared using the Student t-test. 
5.5 Results and discussion 
 Development of a HPLC method 5.5.1
In order to investigate the behavior of sulfasalazine and conjugate after oral administration, 
the development of a suitable and validated method able to quantify the main compounds 
absorbed in the blood was necessary. Moreover, both drugs are metabolized in the liver, 
resulting in the formation of the corresponding metabolites which can also be considered for 
the development of the analytical method (Roškar and Lušin, 2012). Therefore, the choice of 
a proper analytical method to quantify drugs and/or their metabolites plays a significant role 
in the interpretation of pharmacokinetic data.  
The most frequent method for quantitative determination of medicines in plasma is HPLC 
analysis coupled to different detectors such as mass spectrometry or a UV detector. Although 
some drawbacks are associated with the lack of sensitivity of the UV detector, namely when 
low concentrations need to be measured (Chmielewska, Konieczna et al., 2006), HPLC with 
UV detection has been widely used in quantification of diclofenac in plasma or serum 
samples from humans (Giagoudakis and Markantonis, 1998; Idkaidek, Amidon et al., 1998; 
Billa, Yuen et al., 2000; Su, Chou et al., 2003; J., N. et al., 2007; Lissy, Scallion et al., 2010; 
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Sarfraz, Sarfraz et al., 2011) and from rats (Yong, Oh et al., 2005; Huntjens, Strougo et al., 
2008) (Tammara, Narurkar et al., 1994; Tabata, Yamaoka et al., 1995; Reyes-Gordillo, Muriel 
et al., 2007; Pathan, Karwa et al., 2010). Otherwise, HPLC techniques for the quantification 
of sulfasalazine, sulfapyridine and aminosalicylic acid had been reported for analysis of 
plasma samples from rats (Lanbeck and Lindström, 1978; Chungi, Rekhi et al., 1989; Yuen, 
Peh et al., 1997) and also from human serum (Buggé, Gautam et al., 1990; Lee, Waller et al., 
2010). 
However, until now, no technique for simultaneous analysis of these analytes have been 
reported. Herein, a new method for quantification of both prodrugs and respective metabolites 
in plasma was developed. 
Regarding diclofenac-β-cyclodextrin, this prodrug is not absorbed into the blood, given the 
fact that cyclodextrins are poorly absorbed through biological membranes including those of 
the gastrointestinal tract, due to their high MW (ranging from almost 1000 to > 2000 Da) 
(Loftsson, Jarho et al., 2005). Moreover, as in vitro studies showed, when conjugate reaches 
the colon, the degradation of cyclodextrin releases the drug directly without formation of any 
other intermediate compound resulting from cyclodextrin metabolism. Hence, diclofenac is 
the main compound that will be absorbed into the plasma and therefore quantified.  
Otherwise, when sulfazalasine is administered orally, 15% is absorbed intact from the small 
intestine into the bloodstream without any activation. Neverthless, some of this will return to 
the intestine through the bile enterohepatic circulation. The great majority of this prodrug 
reaches the colon where the azo bond is cleaved, producing sulfapyridine and mesalazine 
(Lee, Waller et al., 2010). Mesalazine is poorly absorbed at the level of the colon, and as 
reported previously, it is not possible to quantify this in plasma after oral administration of 
100mg/kg (Lee, Zhang et al., 2012). In other hand, sulfapyridine is well absorbed when 
administered to rats (Lee, Zhang et al., 2012), and was considered in the development of the 
method as the marker of sulfasalazine activation in the colon.  
Initially, the HPLC method was developed to include the quantification of diclofenac, 
sulfasalazine and sulfapyridine in plasma. Due to the fact the metabolites resulting from drug 
hepatic metabolism are not available commercially, they were not quantified. 
Chromatographic conditions were optimized using extracted spiked blank plasma with the 
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analytes, and herein the resultant chromatograms showed a good resolution of the peaks. 
Afterwards, when the method was applied to extract plasma samples after oral administration 
of sulfasalazine and diclofenac-β-cyclodextrin in rats, chromatograms did not show any 
background interference at the retention time of sulfapyridine and diclofenac. However, 
chromatograms revealed some peak interference for the retention time of sulfasalazine, which 
corresponds to metabolites produced. Thus, due to the lack of time to continue the 
development of other methods able to quantify sulfasalazine without any interference, the 
HPLC method established was only towards the analysis of diclofenac and sulfapyridine.  
 
Extraction conditions: 
Given the small quantity of blood and consequently of plasma, the combination of the method 
of extraction, volume of injection and wavelength were determinedto allow good 
reproducibility and precision at low levels of concentration of analytes in plasma. Sample 
preparation is commonly carried out by (a) liquid-liquid extraction, (b) solid-phase extraction 
or (c) precipitation of plasma proteins (Ashri and Abdel-Rehim, 2011). Between these 
techniques, protein precipitation is a very simple, fast and straightforward method widely 
used to extract drugs from plasma. Acetonitrile is considered to be the most effective solvent 
for disrupting protein binding (Telepchak, August et al., 2004). 
Initially, the ability of two water-miscible solvents, acetonitrile and methanol, was tested for 
protein precipitation. Results demonstrated that acetonitrile is the best organic plasma protein 
precipitant, particularly at a 1:1 (precipitant/plasma) volume ratio to extract diclofenac. 
However, in the case of sulfapyridine, acetonitrile did not provide reproducible results, 
namely for low concentrations of the drug in plasma. Consequently, acetonitrile alone was not 
enough to concomitantly extract both analytes, and further studies were performed. 
Sulfapyridine is a basic drug (pKa = 8.4), hence the addition of base helps its extraction into 
an organic solvent due to disruption of protein binding by eliminating the charge of the 
molecule (Prabu and Suriyaprakash, 2012). Thus, various concentrations of bases in 
acetonitrile were tested, namely NH4OH and KOH, and it was found that the addition of 2.5% 
of KOH 0.2 M was a suitable choice to extract sulfapyridine from plasma. At the same time, 
the extraction of diclofenac is not affected by the presence of base in the solvent of extraction. 
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To avoid peak distortion in chromatograms, samples of the extracted solutions were diluted 
with water just before injection, allowing for reproducibility of the shape of the peak.  
A representative chromatogram of blank plasma is shown in Figure 5.1 A. 
 A typical chromatogram produced by the developed HPLC method for the standard solutions 
of sulfapyridine and diclofenac at their limit of quantification is shown in Figure 5.2-B and 
Figure 5.3-C. Retention times for sulfapyridine and diclofenac were 5.8 and 16.2 minutes, 
respectively.  
 
 
Figure 5.1 HPLC chromatograms of the (A) blank plasma, (B) spiked plasma at levels of 
low limit of quantification, (C) spiked plasma at levels of the upper limit of the 
calibration ranges. 
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  Validation of the analytical method 5.5.2
For validation of the method, the main regulatory document from the United States Food and 
Drug Administration for Bioanalytical Method Validation (FDA 2001) was followed (Fda, 
2001). 
Eight-point calibration curves were constructed for sulfapyridine and diclofenac in plasma. 
Results of regression indicated good linearity (R
2
 = 0.999) for both molecules (Table 5.1) in 
the wide concentration ranges of 0.25-20 µg/mL, previously selected considering the drugs 
concentrations observed in previous in vivo studies (Reyes-Gordillo, Muriel et al., 2007; 
León-Reyes, Castañeda-Hernández et al., 2009; Zhang, Zheng et al., 2011; Lee, Zhang et al., 
2012).  
Table 5.1 Regression statistics for diclofenac and sulfapyridine. 
Analyte Range 
(µg/mL) 
N slope intercept Correlation 
coefficient 
Diclofenac 0.25-20 4 46.338±2.843 0.540±0.360  0.999±0.001 
sulfapyridine 0.25-20 4 49.7935±0 -0.315±0.961 0.999±0.000 
The accuracy values obtained for the four different fortification levels ranged from 2.65 and 
11.81% for diclofenac, and between 0.85 and 2.20% for sulfapyridine. 
Intra-day precision values ranged from 2.50% to 8.23 %, whereas the inter-day precision 
values were below 5%. The intra-day precision values ranged from 3.32 and 9.14% for 
diclofenac, and from 2.83 and 8.46% for sulfapyridine, whereas the inter-day precision ranged 
from 2.53 and 6.00% for diclofenac and from 2.71 and 7.87% for sulfapyridine. These results 
confirmed the precision and accuracy of the analytical method optimized in this study, which 
are in accordance with acceptance criteria described by FDA. 
A colon-specific drug delivery system should be able to minimize drug release in the stomach 
and small intestine.  In order to be certain of this, the analytical method used for the 
quantification of the drug must have low limits of detection and quantification. The LOD and 
LOQ of the method used in the present study were 0.05 and 0.25 μg/mL, respectively for both 
analytes, which is in line with previous studies for diclofenac and sulfapyridine (Zhang, 
Zheng et al., 2011; Lee, Zhang et al., 2012). 
Chapter V 
165 
Table 5.2 Intra- and inter-day precision, accuracy, limit of detection and limit of 
quantification of diclofenac and sulfapyridine in rat plasma. 
Concentrations 
µg/mL 
Precision 
(R.S.D., %) 
Accuracy 
(AR, %) LLOD 
µg/mL 
LLOQ 
µg/mL 
Diclofenac Intra-day Inter-day Intraday 
20 3.32 2.53 2.65   
5 3.94 3.08 3.17 0.1 0.25 
1 9.14 6.00 11.81   
0.25 5.52 5.72 5.55   
Sulfapyridine Intra-day Inter-day Intraday   
20 3.29 5.06 -2.9   
5 2.83 2.71 -0.85 0.1 0.25 
1 6.02 6.09 1.46   
0.25 8.46 7.87 2.20   
The percentage recoveries (see Table 5.3) were 98.76%, 81.23% and 74.85% for the 
diclofenac 88.01%, 87.15% and 73.02% for the sulfapyridine at concentrations of 20 µg/mL, 
1 µg/mL and 0.25 µg/mL, respectively. 
Table 5.3 Recovery percentage of diclofenac and sulfapyridine from rat plasma. 
Nominal 
concentration 
(µg/mL) 
Diclofenac Sulfapyridine 
 Recovery (%) RSD Recovery(%) RSD 
0.25 98.76 7.23 88.01 3.01 
1 81.23 15.92 87.15 8.72 
20 74.85 14.85 73.02 15.32 
 Diclofenac and sulfapyridine plasma levels 5.5.3
The mean plasma concentration–time profiles of diclofenac and sulfapyridine for the rats 
dosed orally with diclofenac-β-cyclodextrin (88.5 mg/kg) and sulfasalazine (100 mg/kg) in 
group I (test) are shown in Figure 5.2. 
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Figure 5.2 Concentration-time profiles (n=7) of diclofenac and sulfapyridine in Wistar 
rats after simultaneous oral administration of diclofenac-β-cyclodextrin (88.5 mg/kg) 
and sulfasalazine (100 mg/kg). Each point represents mean ± S.D., n = 7. 
Figure 5.3 shows the diclofenac and sulfapyridine plasma concentrations-time profile 
obtained after oral administration of sodium diclofenac and sulfapyridine in a dose of 20 
mg/kg and 62.5 mg/kg in group II. 
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Figure 5.3 Concentration-time profiles (n=7) of diclofenac and sulfapyridine in Wistar 
rats after simultaneous oral administration of sodium diclofenac (20 mg/kg) and 
sulfapyridine (62.5 mg/kg). Each point represents mean ± S.D., n = 7. 
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The mean and the individual pharmacokinetics parameters: AUC0–24 h, Cmax, and Tmax are 
reported in Table 5.4 and  for diclofenac and sulfapyridine, respectively. 
 
Table 5.4 Pharmacokinetic parameters of diclofenac following oral administration of 
diclofenac-β-cyclodextrin (group I) and sodium diclofenac (group II) to rats (n=7). 
Diclofenac  
Group Parameter 
Rats  
I  II  III  IV V  VI  VII Mean SD Range 
I 
Cmax 
(µg/mL) 
0.59 1.65 1.68 1.19 0.51 1.68 0.41 1.10 0.59 0.41-1.68 
tmax (hours) 8.00 12.00 12.00 6.00 12.00 12.00 8.00 10.00 2.58 6.0-12.0 
AUC(0-24h) 
(µg h/mL) 
6.09 14.88 18.09 5.52 5.55 16.01 1.72 9.69 6.44 1.72-18.09 
II 
Cmax 
(µg/mL) 
9.14 16.08 10.60 9.44 9.06 1.97 1.93 8.32 4.98 1.93-16.08 
tmax (hours) 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.00 0.17 
AUC(0-24h) 
(µg h/mL) 
20.43 14.86 16.98 13.31 31.14 26.00 9.15 18.84 7.63 9.15-31.14 
 
 
 
Table 5.5 Pharmacokinetic parameters of sulfapyridine following oral administration of 
sulfasalazine (group I) and sulfapyridine (group II) to rats (n=7). 
Sulfapyridine 
Group Parameter 
Rats  
I II  III  IV  V  VI VII Mean SD Range 
I 
Cmax  
(µg/mL)  
5.33 4.78 14.20 4.32 4.04 7.98 7.21 6.84 3.57 4.04-14.20 
tmax  
(hours) 
24.00 3.00 6.00 12.00 8.00 8.00 8.00 9.86 6.79 3.0-24 
AUC(0-24h) 
(µg h/mL) 
56.20 40.52 85.72 54.45 58.33 94.77 25.45 59.35 24.11 25.45-85.72 
II 
Cmax 
(µg/mL) 
18.77 19.29 14.45 9.51 11.95 7.60 7.85 12.77 4.89 7.60-19.29 
tmax (hours) 4.00 0.75 4.00 4.00 0.17 0.17 1.50 2.08 1.85 0.17-4 
AUC(0-24h) 
(µg h/mL) 
68.60 51.83 64.47 48.83 79.76 55.35 63.53 61.77 10.71 48.83-79.76 
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In group I (test), as it was expected considering that sulfasalazine and the diclofenac-β-
cyclodextrin are both specific colonic prodrugs, a delay in the appearance of the respective 
drugs, diclofenac and sulfapyridine, in plasma was observed. The lag time between dosing of 
diclofenac-β-cyclodextrin and the appearance of diclofenac in plasma was 4 hours, and the 
maximum peak in plasma was reached after 10.00 ± 2.58 hours (tmax) of administration (Cmax 
1.10 ± 0.59 μg/mL). In case of sulfasalazine (group I), the maximum peak of sulfapyridine is 
reached at 9.86 ± 6.79 hours (tmax) with a Cmax of 6.84 ± 3.57 μg/mL. 
In contrast, in group II, no lag time was observed between oral intake of drugs and their 
appearance in blood. The maximum peak plasma concentrations of diclofenac occurred fairly 
rapidly after oral administration (Cmax of 8.32 ± 4.98 μg/mL at 10 minutes post-
administration), but also declined rapidly thereafter, maintaining low plasmatic levels until 12 
hours post-dose. Also in the case of sulfapyridine, its appearance in plasma occurred 
immediately after administration. The maximum peak of sulfapyridine was obtained earlier at 
2.08 ± 1.85 hours (Tmax) following administration with a Cmax of 12.77 ± 4.89 µg/mL. In this 
case, the appearance of sulfapyridine in plasma occurred immediately after administration.  
The mean AUC(0-24h) values obtained with administration of each prodrug (group I) and the 
respective drug (group II) are 9.69 ± 6.44 µg h/mL and 18.84 ± 6.73 µg h/mL, respectively in 
the case of diclofenac, and 59.35 ± 24.11 µg h/mL and 61.77 ± 10.71 µg h/mL in the case of 
sulfapyridine.  
In this study, in vivo proof of concept was obtained in rats for colonic target release of 
diclofenac-β-cyclodextrin. The pharmacokinetics profiles obtained are very different between 
prodrugs and the respective drugs.  
Following administration of diclofenac, and based on previous reported studies, its plasmatic 
profile (Figure 5.3) is related to the low half-life time of diclofenac, and with the irregular 
absorption of this poorly soluble molecule (Zhang, Zheng et al., 2011). Otherwise, following 
the oral administration of sulfapyridine suspension, it was expected that it dissolved mostly in 
stomach according to its pKa value of 8.4. However, its plasmatic profile indicates a slow 
absorption, which may be due to the low solubility of this molecule in water < 0.1g/100mL. 
When administered in the form of prodrugs, both drugs suffered a decrease in the Cmax, as 
compared to the free drug. However, this decrease was shown to be sharper in case of 
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diclofenac. These results showed a decrease of 87% in the maximum plasma diclofenac 
concentration (t-test, p < 0.01), and a significant increase in the mean time required to reach 
the maximum level (t-test, p < 0.01) following diclofenac-β-cyclodextrin administration 
compared with diclofenac sodium administration. There was 53% decrease in the maximum 
plasma sulfapyridine concentration (t-test, p < 0.05) and a significant increase in the mean 
time required to reach the maximum level (t-test, p < 0.05) following sulfasalazine 
administration relative to sulfapyridine administration. 
Although the plasmatic tmax of drugs after administration of prodrugs is not significantly 
different for sulfapyridine and diclofenac (t-test, p > 0.05), the lag time for the appearance of 
diclofenac in blood was longer than that for sulfapyridine. This fast appearance of 
sulfapyridine was in agreement with results reported previously that had shown that 
appearance of sulfapyridine in plasma was rapid (~5 min) following direct instillation of 
sulfasalazine in the caecum in the fasted state in humans (Kellow, Borody et al., 1986). It 
could be argued that these results are also in accordance with in vitro ones that had shown the 
slow rate degradation of diclofenac-β-cyclodextrin when compared with sulfasalazine 
(Chapter III and IV).  
Relative to the AUC0-24h, there was no significant change in bioavailability for sulfapyridine 
(t-test, p > 0.05) between groups I and II, though the same was not observed for diclofenac. In 
the case of diclofenac, after administration of the diclofenac-β-cyclodextrin the bioavailability 
was about half of the bioavailability when the free drug was administrated (t-test p < 0.05).  
Different explanations can be given for the disparity of AUC0-24h between both prodrugs 
(Figure 5.4), including the slow rate of degradation of diclofenac-β-cyclodextrin as compared 
with sulfasalazine at the level of the large intestine in rats, as shown in previous in vitro 
studies (Chapter III and IV). This slow degradation can be associated with the small volume 
of watery environment necessary to guarantee the dissolution of the diclofenac-β-cyclodextrin 
and release of diclofenac to the lumen of the colon for subsequent absorption (Gleiter, 
Antonin et al., 1985; Schiller, Fröhlich et al., 2005). The quantity of free water available in 
gut contents is otherwise too small compared with the quantity present in the in vitro media 
used to perform stability experiments.  
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Figure 5.4 Schematic representation of the hipothesis that can explain the diminuished 
of plasmatic bioavailability of diclofenac when this is administered in the form of 
cyclodextrin prodrug. 
Otherwise, it appears that the residence time of the diclofenac-β-cyclodextrin and/ or 
diclofenac in colonic contents of rats is insufficient for the diclofenac-β-cyclodextrin to be 
completely metabolized and/or for the drug released to move to the lumen and to be absorbed.  
Rats have a large caecum, though the colon is neither sacculated nor long, unlike in humans. 
(Kararli, 1995). Indeed, humans have a poorly define caecal region, which is continuous with 
the colon. Additionally, the human colon is sacculated and consists of ascending, transverse 
and sigmoidal segments. Based on these anatomic differences between rats and humans, a 
different bioavailability of diclofenac released from the conjugate is expected between both 
species. As reported, the absorption in humans is much faster, and also to a greater extent than 
in rats due to these anatomic differences (Desesso and Jacobson, 2001). 
In order to clarify the pharmacokinetic parameters, a longer duration of sampling would be 
necessary to correctly estimate the extrapolated area under the curve (Yáñez, Remsberg et al., 
2011). According to the literature, as long as the conjugate is completely degraded, diclofenac 
will be well absorbed (Gleiter, Antonin et al., 1985; Billa, Yuen et al., 2000; Schiller, Fröhlich 
et al., 2005; Tannergren, Bergendal et al., 2008). Thus, as long as the diclofenac-β-
cyclodextrin is completely degraded, the amount of diclofenac released could be absorbed in 
its totality. 
Colon 
Blood 
metabolism 
absorption 
elimination 
Faeces 
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5.6 Conclusion 
These results confirm the in vivo ability of this diclofenac-β-cyclodextrin to target and release 
diclofenac in the colon. The lag time of appearance in blood of diclofenac with a delay in the 
tmax as observed for sulfapyridine demonstrated the colonic release of diclofenac from the 
diclofenac-β-cyclodextrin. However, results demonstrated that the bioavailability of 
diclofenac decreases by half when administered in its prodrug form. Contrarily, the 
bioavailability of sulfapyridine is not altered when administered in the form of sulfasalazine, 
as compared with the administration of free drug. These differences can be associated with 
slow metabolism of diclofenac-β-cyclodextrin when comparing with sulfasalazine, or can be 
related with limitations on the time necessary for complete absorption of diclofenac.  
Overall, this study confirms the in vivo ability of this newly cyclodextrin prodrug to target and 
release diclofenac specifically in the colon. 
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6 GENERAL DISCUSSION AND FUTURE WORK 
6.1 General Discussion 
This dissertation describes the development of a new oral prodrug for colonic specific 
delivery of diclofenac. A diclofenac-β-cyclodextrin conjugate was successfully synthetised 
and characterised. Additionally, in vitro and in vivo experiments allowed a further 
understanding of its behaviour along the GI tract and to assess its potential to target and 
release diclofenac specifically into the colon. 
The goal of developing a new system to target the colon exploited the idea of utilising 
cyclodextrins as a carrier for colonic target delivery. These oligosaccharides, mainly α- and β-
cyclodextrins, remain intact in the upper GI tract and are enzymatically degraded exclusively 
at a colonic level. Thus, using cyclodextrin as a carrier, the idea of creating a prodrug for 
colon-specific delivery of diclofenac emerged.  
This project started with the investigation of a method suitable for the synthesis of diclofenac-
cyclodextrin conjugates. This became a big challenge due to the high amount of unsuccessful 
results faced whilst exploring conventional synthetic routes that in theory would be able to 
create an ester linkage between diclofenac and cyclodextrin. Beyond all the reactive hydroxyl 
groups of cyclodextrin that are available to react, diclofenac was shown to be very sensitive 
and easily suffered an intramolecular reaction, which limits its intermolecular reactivity. 
After, the study of different conventional approaches using different conditions, the 
nucleophilic route performed under microwave irradiation allowed for the successful and 
efficient production of the diclofenac-β-cyclodextrin conjugate. This process assured 
reproducible synthesis of the conjugate with the advantage of drastically decreasing the 
reaction time when compared to the conventional eating method. The novelty and innovation 
associated with this process of preparation of a diclofenac-cyclodextrin conjugate prompted 
the need for protecting the intellectual property of this work by a patent. 
After overcoming the first challenge related to the synthesis process, the next step concerned 
carrying out studies which demonstrated the ability of a cyclodextrin to remain intact in the 
upper GI tract and carry a drug to the colon when both were covalently linked. Different 
Chapter VI 
176 
stability studies were designed and performed, namely using simulated gastrointestinal fluids 
and gastrointestinal fluids collected from different animals (rat, rabbit and pig). The prodrug 
demonstrated resistance to both chemical and enzymatic degradation in the upper GI tract. 
Otherwise, at the level of the lower intestine, the conjugate suffered degradation with 
simultaneous release of diclofenac. Parallel studies with sulfasalazine were carried out in 
order to compare its performance with diclofenac-β-cyclodextrin. Results demonstrated that 
sulfasalazine metabolism was always faster than the metabolism of the conjugate. This leads 
to the conclusion that the mechanism subjacent to sulfasalazine degradation is faster than the 
mechanism that allows for release of a drug from a cyclodextrin.  
The slowest release of the drug from the cyclodextrin prodrug can be attributed to the fact that 
this conjugate requires the intervention of two different enzymes: amylases and esterases. 
Although we have an ester prodrug, this is not degraded by esterases in the upper GI tract. It 
seems that cyclodextrin creates a steric hinderance around the ester linkage, which prevents 
esterase to attack. Firstly, cyclodextrin has to be degraded, which just occurs at colonic level, 
and after that, enough space is generated allowing esterase to attack with consequent 
breakdown of the ester linkage, which coincides with the release of diclofenac. 
Thereafter, studies were conducted in an attempt to understand the influence of feeding 
regimen on the physiological conditions and metabolism of colonic prodrugs. Studies have 
previously shown that different feeding regimens affect dramatically the physiological 
conditions in the gastro-intestinal tract. These observations have therefore an influence on the 
metabolism of pro-drugs and subsequently expected to interfere with the drug disposition. In 
fact, the metabolism of diclofenac-β-cyclodextrin was faster in fluids collected from fasted 
rats. The ideal colonic prodrug would present a rate of metabolism not affected by the 
changes on the microbiota activity; in other words, its metabolism would not be affected by 
the presence or absence of food. 
This thesis ended with in vivo studies conducted to show how the conjugate behaves after oral 
administration in rats, using sulfapyridine as a marker of colonic absorption. These studies 
represented a proof of concept for the colonic target delivery of diclofenac-β-cyclodextrin, 
and release of diclofenac. This was evidenced by the lag time observed for diclofenac 
appearance in plasma after oral delivery of conjugate, similar to that observed for 
sulfapyridine after administration of sulfasalazine. Comparison of the plasmatic 
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bioavailability of diclofenac after oral administration of the prodrug and the bioavailability 
after oral intake of the own drug showed that the plasmatic bioavailability is reduced to half 
when diclofenac was administered in the conjugate form. 
Therefore, these results led to the conclusion that diclofenac-β-cyclodextrin allows for release 
of diclofenac at a colonic level. Although diclofenac is well absorbed, some factors are 
present which prevent its complete absorption. The decrease of plasmatic concentration can 
be associated with excretion of the intact conjugate, and therefore its incomplete metabolism. 
Additionally, at colonic level, the viscous contents/mucous with small volumes of fluid create 
difficulty for diclofenac dissolution, and consequent difficulty in reaching the colonic mucous 
to be further absorbed. These hypotheses need to be explored in order to assess the reason for 
the different blood concentration between drug and prodrug. 
Overall, this work provided a proof of concept of the ability of diclofenac-β-cyclodextrin to 
release diclofenac at a colonic level. Given the short half life time of diclofenac in plasma, 
this prodrug can be considered as an useful chronopharmacological therapeutic agent for the 
management of arthritis pain. Moreover, the concomitant formulation of this prodrug with 
free diclofenac and its oral administration assures sustained therapeutic blood levels of 
diclofenac, avoiding the repeated daily dosing of diclofenac.  
It is expected that this anti-inflammatory molecule in the form of a colonic prodrug causes 
less mucosal irritation when compared with the free drug, due to its lower direct contact with 
the mucous. This can be expected due to its low affinity for the lipidic membranes, not only 
due to the large size of the molecule, but also due to the hydrophilic nature of the cyclodextrin 
surface.  
Moreover, the cyclodextrin carrier brings health benefits related to its fermentation that 
produce short-chain fatty acids (SCFA) - important for the maintenance of the health and 
integrity of the colonic epithelium.  
6.2 Future work 
Whilst carrying out this Project, a number of ideas were identified and can be further 
investigated. Some ideas are the direct result of the conducted research described in this thesis 
that are related to development of the synthetic process for producing diclofenac-cyclodextrin 
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conjugates and investigation of its performance after oral intake as a colonic-specific prodrug. 
The last ideas are associated with the potential pharmacological advantages. 
Potential topics to further develop are outlined below: 
Although diclofenac-β-cyclodextrin was produced using a reliable method with a high degree 
of purification, more needs to be done in order to optimize its yield. The first idea that arises 
is the exploration of the possibility of purification of the intermediate tosylated cyclodextrin 
product. Additionally, would be interesting to explore one way to scale up the reaction and the 
product purification. Preliminary experiments using the Biotage system showed to be an 
efficient automatic method for purification.  
Since dimethylformamide (DMF) is a protic solvent used to perform the nucleophilic 
reaction, its use should ideally be avoided on account of its toxicity. Thus, the use of other 
solvents less toxic than DMF on the performance of the nucleophilic reaction should be 
investigated further. Preliminary experiments with an aprotic solvent, PEG-200, proved to be 
a suitable solvent to produce the conjugate.  
Since this new process of synthesis takes advantage of microwaves and allows the synthesis 
of the conjugate in a short period of time compared with the conventional approach, this 
process could be adapted for the synthesis of other cyclodextrin conjugates.  
Improvement of the synthesis process of the α- and γ- cyclodextrin tosylated derivatives and 
access of the right conditions to synthetize the respective diclofenac conjugates.  
Diclofenac was shown to be a highly reactive molecule by an intramolecular reaction 
mechanism, and which suffers modifications according to the pH change. HPLC analysis of 
the diclofenac released from the conjugate and also of the diclofenac after incubation in 
different buffer media revealed the appearance of extra peaks on the HPLC chromatogram. 
These extra peaks need to be accurately analysed by LC-MS in order to clarify its origin. 
Further investigation into the stability of the conjugate in gastrointestinal fluids from other 
animal models such as monkeys, guinea pigs, or dogs using a greater number of subjects per 
species, may also be used. This will also allowed assessing which animal model gives a better 
prediction of the human behaviour. Also, the possible gender differences on the metabolism 
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of the conjugate should be investigated, as the studies presented here only included male 
species.  
To better predict the behaviour of the conjugate in humans, it is also essential to assess its 
stability in human gastrointestinal fluids, which should involve a reasonable number of 
individuals (including male and female). Moreover, the metabolism can be accessed in fluids 
collected from individuals with colonic diseases in order to assess its performance. 
Investigate the causes associated with the decrease in bioavailability of diclofenac when 
administered as the conjugate form in rats. Ideally, all faeces produced after oral intake of 
diclofenac-β-cyclodextrin should be collected, and the existence/absence of conjugate and/or 
diclofenac determined. Also, at the end of the study (after 24 hours of oral intake), 
gastrointestinal fluids should be collected and evaluated for the presence of diclofenac and/or 
conjugate. Also, the conjugate can be radiolabelled to easily follow its transit through the 
gastrointestinal tract after oral intake. 
Evaluation of the acute and chronic ulcerogenicity of diclofenac-β-cyclodextrin versus 
diclofenac at the level of upper GI tract (stomach and small intestine), and also at the level of 
the lower GI tract (colon) using the rat as an animal model. Study design for the in vivo 
determination of anti-inflammatory activity of diclofenac-β-cyclodextrin versus diclofenac 
using the carrageenan induced rat paw edema model may additionally be carried out.  
A deeper understanding of the pharmacological effect of this conjugate is necessary, including 
its potential to be used as a chronotherapeutic agent for rheumatic arthritis.  
Assess other potential targets (colonic cancer).  
Development of an appropriate formulation (capsule or tablets) of diclofenac-β-cyclodextrin. 
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APPENDIX 
Appendix A - Chapter I 
 Preparation of the buffer pH 1.2 
Sodium chloride (200 mg) was added to a 100 mL flask and dissolved in water followed by 
addition of 700 µL HCl (10 M) to adjust the pH to 1.2. 
Table 1 Composition of the buffer 1.2. 
Formula Amount 
Sodium chloride 200 mg 
HCl 1M 8 mL 
 Preparation of acetate buffer pH 4.5  
Acetate buffer pH 4.5 was prepared according to to the USPXXIV as described in Table 2.  
Table 2 Composition of the buffer phosphate pH 4.5 described in USP Indicated 
volumes are required to prepare 100 ml of buffer solution. 
Formula Amount 
Sodium acetate trihydrate 299 mg 
Acetic acid 2N  1.4 mL 
 
 Preparation of phosphate buffers  
Phosphate buffers pH 6.8 and pH 7.4 were prepared according to the USPXXIV by mixing 
the corresponding quantities of salt solutions as specified in Table 3.  
Table 3 Composition of compendial phosphate buffers. Indicated volumes are required 
to prepare 200 ml of buffer solution. 
 Phosphate buffer pH 6.8 Phosphate buffer pH 7.4 
0.2 M KH2PO4 (mL) 50 50 
0.2M NaOH (mL) 22.4 39.1 
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Appendix B -  Chapter II 
Reaction of sodium diclofenac with benzyl chloride. 
2.5g of sodium diclofenac (7.86 mmol) is dissolved in 10 mL of DMF and 50 mL of 
acetonitrile at 50 
0
C. 1g K2CO3 was added followed by 1 mL of benzyl bromide and the 
mixture reacted during 2 hours. Addition of hexane and eter in on attempted to precipitate the 
resulting product did not work. The resulting solution was evaporated and the product of 
reaction was left in the minimum quantity of solvent at air. After 3 days it was observed 
formation of crystals with high dimensions. Analysis of 
1
H NMR shows that crystals 
correspond to the ester of diclofenac.  
1
H NMR (500 MHz, CDCl3) δ (ppm): 6.94 (m, 2H, H-5’’,H-6’’), 7.13 (dd, 1H, H-4’), 7.23 (d, 1H, H-
4’’), 7.33(d, 7H, H-3’, H-5’, H-1’’’, H-5’’’, H-2’’’, H-4’’’, H-3’’’), 6.88 (s, NH-amine) 6.55 (d, H-
7’’), 3.86 (s, H-2’’) 5.18 (s,H-7) 
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Appendice C - Chapter III 
 Preparation of simulated gastric fluid (SGF) 
Sodium chloride (200 mg) was added to a 100 mL flask and dissolved in water 
followed by addition of 700 µL HCl (10 M) to adjust the pH to 1.2. Pepsin (320 mg) was then 
added to the medium (see Table 1). 
Table 1 Composition of the simulated gastric fluid according to USP formula. 
FORMULA AMOUNT 
Sodium chloride 200 mg 
HCl (10M) 700 µL 
Pepsin 320 mg 
Water Up to 100 mL 
 Preparation of simulated intestinal fluid (SIF) 
The simulated small intestinal fluid was prepared through dissolution of 680 mg 
potassium phosphate monobasic in water. To this solution 770 µL of 0.2 M sodium hydroxide 
solution was added and the remaining water added to make the volume up to 100 mL. After 
adjusting the pH to 6.8 ± 0.1 with either 0.2 M of NaOH or 0.2 M hydrochloride acid, 1 g of 
pancreatin (from porcine pancreas, 3 USP units activity/g) was added and shaken gently. 
Table 2 Composition of the simulated intestinal fluid according to USP formula. 
FORMULA AMOUNT 
Potassium dihydrogen orthophosphate 680 mg 
Sodium hydroxide 0.2 M 770 µL 
Pancreatin (3USP units/g) 1 g 
Water Up to 100 mL 
The composition of pancreatin enzyme as described by the USP and the composition 
of pancreatin enzyme obtained from Sigma-Aldrich used for the present studies are 
represented in the Table 3. 
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Table 3 Composition of the pancreatin.  
ENZYM
E 
AMOUNT 
USP 
(units/mg) 
Sigma-Aldrich (x3 USP) 
(units/mg) 
 
Amylase 25 75 
Lipase 2 6 
Tripsin 25 75 
 Preparation of HEPES/NaOH buffer 
 
The HEPES/NaOH buffer were prepared according to the described in Table 4. 
 
Table 4 Composition of the buffer HEPES/NaOH buffer. 
Formula : HEPES/NaOH  Quantity 
HEPES 0.2M 25 mL 
NaOH 2.04 mL 
Water Up to 100 mL volume 
 
 Preparation of 0.01M CaCl2/0.2M acetate buffer pH 5.5.  
The buffer acetate pH 5.5 was prepared according to theTable 5..  
The solution of 0.01M of CaCl2 in acetate buffer was prepared by dissolving 1.47g of 
CaCl2.2H2O in the acetate buffer pH 5.5. 
Table 5 Compostion of the acetate buffer pH 5.5. 
 
 
 
 
  
Formula: Acetate buffer 5.5, 0.2M amount 
Acetic acid 1M 2.02 mL 
Sodium acetate 0.3M 59.92 mL 
Water  Up to 100mL volume 
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Appendix D - Chapter IV 
Determination of amylase activity using the EnzCheck Ultra amylase Assay Kit 
α-Amylase activity in gastrointestinal fluids was determined by the EnzChek Ultra Amylase 
Assay Kit (E33651).  
Materials 
The EnzChekt Ultra Amylase Assay Kit (E33651) was purchased from Molecular Probes. The 
Kit contains:  
Substract: DQ starch from corn BODIPY FL conjugate; 
Reaction buffer: 0.05 M MOPS (3-(N-morpholino) propanesulfonic acid)), pH 6.9; 
Sodium acetate 50mM, pH 4.0; 
α-amylase from Bacillus sp. (Sigma A-6380) was purchased from Sigma Aldrich; 
Gastrointestinal fluids (stomach, small intestinal, caecum, colon and faecal slurry prepared 
from colon fluids) obtained from pig, rat and rabbit.  
Methods 
A solution of 200 µg/mL subtract in acetate buffer was prepared according to the instructions 
described on the kit. A stock solution of α-amylase (400 mM/mL) was prepared in MOPS. 
Different standard solutions (0 - 40 mU/mL) were prepared from this stock solution in order 
to create an enzyme standard curve between 0 and 20 mU/mL. 
For determination of amylase activity, it was use the supernatant obtained after centrifugation 
at 10 000 rpm during 10 minutes. Colon fluids were also prepared as faecal slurry (described 
in Chapter III). Each fluid was diluted with MOPS buffer (4 µL of fluid to 396 µL of MOPS). 
Fluorescence of the digestion products from the substrate was measured by 96 -Plate reader at 
an excitation wavelength of 505 nm and an emission wavelength of 512 nm at room 
temperature. 
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Results and discussion 
Figure 1 shows the activity of α-amylase measured in fluids from different sections of the gut 
of rat, rabbit and pig.  
Figure 1 α-amylase activity (mU/ mL) in fluids from different sections of the 
gastrointestinal tract. The α-amylase was determined in the supernatant of fluids 
(stomach, duodenum, jejunum, ileum, caecum and colon) and in colon fluids prepared 
as faecal slurry.  
The results show that the rat has the higher α-amylase activity in all the sections of the 
gastrointestinal tract when compared with the pig and the rabbit. 
Analysing each section separately, it is observed that stomach of rats has much higher α-
amylase activity than that observed in case of rabbit and pig.  
The higher α- amylase activity is observed at the level of small intestine for all the animal 
models. At the level of the lower intestine the α-amylase activity is comparable between 
caecum and colon. When colon fluids were prepared as faecal slurry is observed a decrease in 
α-amylase activity, which can be associated with the dilution that occurs during the 
preparation of faecal slurry. 
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Not everything that counts can be counted,  
and not everything that can be counted count. 
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